<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80768</article-id><article-id pub-id-type="doi">10.7554/eLife.80768</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Involvement of ILC1-like innate lymphocytes in human autoimmunity, lessons from alopecia areata</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-282372"><name><surname>Laufer Britva</surname><given-names>Rimma</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-282373"><name><surname>Keren</surname><given-names>Aviad</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-282374"><name><surname>Bertolini</surname><given-names>Marta</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-282375"><name><surname>Ullmann</surname><given-names>Yehuda</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-270242"><name><surname>Paus</surname><given-names>Ralf</given-names></name><email>rxp803@med.miami.edu</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-281980"><name><surname>Gilhar</surname><given-names>Amos</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4267-2986</contrib-id><email>doritg2000@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib2">‡</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03qryx823</institution-id><institution>Skin Research Laboratory, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology</institution></institution-wrap><addr-line><named-content content-type="city">Haifa</named-content></addr-line><country>Israel</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01fm87m50</institution-id><institution>Department of Dermatology, Rambam Health Care Campus</institution></institution-wrap><addr-line><named-content content-type="city">Haifa</named-content></addr-line><country>Israel</country></aff><aff id="aff3"><label>3</label><institution>Monasterium Laboratory</institution><addr-line><named-content content-type="city">Münster</named-content></addr-line><country>Germany</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05pp39346</institution-id><institution>Department of Plastic Surgery, Rambam Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Haifa</named-content></addr-line><country>Israel</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02dgjyy92</institution-id><institution>Dr. Phillip Frost Department of Dermatology &amp; Cutaneous Surgery, Miller School of Medicine, University of Miami</institution></institution-wrap><addr-line><named-content content-type="city">Miami</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>CUTANEON</institution><addr-line><named-content content-type="city">Hamburg</named-content></addr-line><country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Horsley</surname><given-names>Valerie</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Diamond</surname><given-names>Betty</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dnene97</institution-id><institution>The Feinstein Institute for Medical Research</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="con" id="equal-contrib2"><label>‡</label><p>These authors also contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>17</day><month>03</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e80768</elocation-id><history><date date-type="received" iso-8601-date="2022-06-03"><day>03</day><month>06</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-02-22"><day>22</day><month>02</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-06-26"><day>26</day><month>06</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.06.22.497177"/></event></pub-history><permissions><copyright-statement>© 2023, Laufer Britva, Keren et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Laufer Britva, Keren et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80768-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-80768-figures-v1.pdf"/><abstract><p>Here, we have explored the involvement of innate lymphoid cells-type 1 (ILC1) in the pathogenesis of alopecia areata (AA), because we found them to be significantly increased around lesional and non-lesional HFs of AA patients. To further explore these unexpected findings, we first co-cultured autologous circulating ILC1-like cells (ILC1lc) with healthy, but stressed, organ-cultured human scalp hair follicles (HFs). ILClc induced all hallmarks of AA ex vivo: they significantly promoted premature, apoptosis-driven HF regression (catagen), HF cytotoxicity/dystrophy, and most important for AA pathogenesis, the collapse of the HFs physiological immune privilege. NKG2D-blocking or IFNγ-neutralizing antibodies antagonized this. In vivo, intradermal injection of autologous activated, NKG2D+/IFNγ-secreting ILC1lc into healthy human scalp skin xenotransplanted onto SCID/beige mice sufficed to rapidly induce characteristic AA lesions. This provides the first evidence that ILC1lc, which are positive for the ILC1 phenotype and negative for the classical NK markers, suffice to induce AA in previously healthy human HFs ex vivo and in vivo, and further questions the conventional wisdom that AA is always an autoantigen-dependent, CD8 +T cell-driven autoimmune disease.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>SCID/beige mice</kwd><kwd>xenotransplants</kwd><kwd>innate immunity</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Technion research and development foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Gilhar</surname><given-names>Amos</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Frost Endowed Scholarship from the university of Miami</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Paus</surname><given-names>Ralf</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Innate lymphoid cells type 1 suffice to induce hallmarks of alopecia areata phenotype in organ-cultured human scalp hair follicles ex vivo and in human scalp skin xenotransplants in vivo<italic>,</italic> suggesting that these cells play a role in early AA pathogenesis.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Alopecia areata (AA) is both the most common inflammatory hair loss disorder and one of the most common human autoimmune diseases and exerts a major negative impact on quality of life (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>; <xref ref-type="bibr" rid="bib42">Gilhar et al., 2019a</xref>; <xref ref-type="bibr" rid="bib68">Korta et al., 2018</xref>; <xref ref-type="bibr" rid="bib105">Pratt et al., 2017</xref>). Despite major recent advances in AA therapy, a causal therapy does not yet exist, and disease relapse after therapy discontinuation is the rule, not the exception in long-standing AA (<xref ref-type="bibr" rid="bib83">Meah et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Gilhar et al., 2019a</xref>). Thus, the currently available, purely symptomatic AA therapy, including JAK inhibitors (<xref ref-type="bibr" rid="bib43">Gilhar et al., 2019b</xref>), remains unsatisfactory. Since the exact pathobiology of AA and its clinical variants remains to be fully characterized, the – likely diverse – disease-initiating factors that ultimately result in the characteristic AA hair loss pattern shared by all AA variants, require more comprehensive dissection for optimal, personalized therapeutic targeting (<xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>; <xref ref-type="bibr" rid="bib97">Paus et al., 2018</xref>).</p><p>Specifically, there is increasing awareness that a classical, autoantigen- and CD8 +T cell-dependent autoimmune variant of AA (AAA) and a possibly autoantigen-independent non-autoimmune variant (NAIAA) may have to be distinguished from each other (<xref ref-type="bibr" rid="bib42">Gilhar et al., 2019a</xref>; <xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>; <xref ref-type="bibr" rid="bib97">Paus et al., 2018</xref>; <xref ref-type="bibr" rid="bib98">Paus, 2020</xref>). This is in line with the long-standing, but often under-appreciated clinical recognition that AA shows a wide spectrum of phenotypes and sub-forms (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>; <xref ref-type="bibr" rid="bib53">Ikeda, 1965</xref>; <xref ref-type="bibr" rid="bib84">Meah et al., 2021</xref>; <xref ref-type="bibr" rid="bib65">King et al., 2022</xref>).</p><p>One reason why the currently available AA therapy is not entirely satisfactory may be related to as yet insufficient therapeutic targeting of innate immunocytes in the immunopathogenesis of human AA, namely in NAIAA, even though these are now recognized as major players in AA pathobiology (<xref ref-type="bibr" rid="bib36">Ghraieb et al., 2018</xref>; <xref ref-type="bibr" rid="bib57">Ito et al., 2008</xref>; <xref ref-type="bibr" rid="bib75">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib125">Uchida et al., 2020</xref>; <xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>).</p><p>Previously, we had demonstrated that AA lesions are associated with a massive increase in the number of perifollicular NKG2D+NK cells (<xref ref-type="bibr" rid="bib39">Gilhar et al., 2013a</xref>), which recognize the activating NKG2D ligand MICA, a ‘danger’ signal that is greatly overexpressed by the epithelium of lesional AA HFs (<xref ref-type="bibr" rid="bib57">Ito et al., 2008</xref>; <xref ref-type="bibr" rid="bib75">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Connell and Jabbari, 2022</xref>). Subsequent work has confirmed the key role of NKG2D and its activating ligands in human and murine AA (<xref ref-type="bibr" rid="bib134">Xing et al., 2014</xref>; <xref ref-type="bibr" rid="bib102">Petukhova et al., 2010</xref>). In fact, AA lesions can be induced experimentally in healthy human scalp skin in vivo by the transfer of interleukin 2 (IL-2)-activated NKG2D+ cells (<xref ref-type="bibr" rid="bib39">Gilhar et al., 2013a</xref>), most of which had NK cell characteristics, with only a small minority of CD8 +T cells being present, that is the best-recognized pathogenic lymphocyte population in AA (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">Gilhar et al., 2013a</xref>; <xref ref-type="bibr" rid="bib105">Pratt et al., 2017</xref>; <xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">de Jong et al., 2018</xref>). Moreover, pro-inflammatory mast cells (<xref ref-type="bibr" rid="bib8">Bertolini et al., 2014</xref>) and (likely autoantigen-non-specific) γδ T-cells are also increased around/in lesional human AA HFs (<xref ref-type="bibr" rid="bib125">Uchida et al., 2020</xref>). Finally, these ‘intermediate immunity’ protagonists suffice to induce the hallmarks of AA ex vivo (<xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>).</p><p>Taken together, this questions whether pathogenic, autoreactive CD8 +T cells are the only drivers of disease, and that all cases of AA, represent a genuine, autoantigen-dependent autoimmune disease (<xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>; <xref ref-type="bibr" rid="bib97">Paus et al., 2018</xref>) in the strictly defined sense of this term (<xref ref-type="bibr" rid="bib110">Rose and Bona, 1993</xref>).</p><p>In our ongoing exploration of the role of innate/transitional immunity in the pathobiology of AA (<xref ref-type="bibr" rid="bib98">Paus, 2020</xref>; <xref ref-type="bibr" rid="bib125">Uchida et al., 2020</xref>; <xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>; <xref ref-type="bibr" rid="bib42">Gilhar et al., 2019a</xref>; <xref ref-type="bibr" rid="bib8">Bertolini et al., 2014</xref>), we, therefore, have asked in the current study whether innate lymphoid cells type 1 (ILC1 cells) (<xref ref-type="bibr" rid="bib138">Zhou et al., 2020</xref>; <xref ref-type="bibr" rid="bib88">Nabekura and Shibuya, 2021a</xref>; <xref ref-type="bibr" rid="bib18">Colonna, 2018</xref>) can initiate human AA lesions.</p><p>We were interested in these immunocytes since human ILC1 cells secrete large amounts of interferon-γ (IFN-γ) (<xref ref-type="bibr" rid="bib27">Ebbo et al., 2017</xref>), the crucial AA pathogenesis-promoting cytokine (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>; <xref ref-type="bibr" rid="bib42">Gilhar et al., 2019a</xref>; <xref ref-type="bibr" rid="bib97">Paus et al., 2018</xref>), and this notably independent of classical autoantigen-specific CD8 +T cell activities. These ‘unconventional’ T-cells are placed in strategic tissue locations (<xref ref-type="bibr" rid="bib17">Collins et al., 2017</xref>; <xref ref-type="bibr" rid="bib59">Jiao et al., 2016</xref>; <xref ref-type="bibr" rid="bib64">Kim et al., 2021</xref>) and represent an important link between innate and adaptive immunity (<xref ref-type="bibr" rid="bib130">Vivier et al., 2018</xref>). While ILC1s play an essential role in human inflammatory bowel disease (IBD) (<xref ref-type="bibr" rid="bib27">Ebbo et al., 2017</xref>; <xref ref-type="bibr" rid="bib79">Luo et al., 2022</xref>; <xref ref-type="bibr" rid="bib16">Clottu et al., 2021</xref>), their role in the pathophysiology of autoimmune hepatitis and rheumatoid arthritis requires further investigation (<xref ref-type="bibr" rid="bib27">Ebbo et al., 2017</xref>; <xref ref-type="bibr" rid="bib30">Fang et al., 2020</xref>; <xref ref-type="bibr" rid="bib135">Yang et al., 2015</xref>), and their role in human autoimmune diseases overall remains insufficiently understood. We hypothesized that AA might offer a good model disease for interrogating this role.</p><p>ILC1 cells are classified as a component of type 1 immunity (<xref ref-type="bibr" rid="bib114">Shannon et al., 2021</xref>), express NKG2D, recognize conserved phosphoantigens (<xref ref-type="bibr" rid="bib88">Nabekura and Shibuya, 2021a</xref>), and contribute to immunity against tumor cells, for example through NKG2D activation (<xref ref-type="bibr" rid="bib24">Dadi et al., 2016</xref>). The activating receptor NKG2D and its ligands (MICA, ULBP3) play an important role in innate (NK, ILC1), ‘translational’ (γδ T-cells) and CD8 T-cell-mediated immune responses to tumors and in several autoimmune diseases (<xref ref-type="bibr" rid="bib33">Frazao et al., 2019</xref>; <xref ref-type="bibr" rid="bib4">Babic and Romagnani, 2018</xref>).</p><p>Given that ILC1 cells produce TH1-type cytokines (such as IFN-γ) and share several phenotypic markers with NK cells, namely NKG2D (<xref ref-type="bibr" rid="bib117">Spits et al., 2016</xref>), it is challenging to distinguish NKs and ILC1 cells (<xref ref-type="bibr" rid="bib124">Tulic et al., 2019</xref>; <xref ref-type="bibr" rid="bib136">Zhang et al., 2018</xref>; <xref ref-type="bibr" rid="bib113">Seillet et al., 2021</xref>; <xref ref-type="bibr" rid="bib19">Conlon et al., 2021</xref>). In fact, how to reliably discriminate between NK cells and ILC1s and unraveling the shared and distinct functions of these cell populations remains an important open quest (<xref ref-type="bibr" rid="bib113">Seillet et al., 2021</xref>; <xref ref-type="bibr" rid="bib76">Lopes et al., 2023</xref>; <xref ref-type="bibr" rid="bib14">Cheng et al., 2023</xref>; <xref ref-type="bibr" rid="bib119">Taggenbrock and van Gisbergen, 2023</xref>). For example, Eomes<sup>hi</sup> T-bet<sup>lo</sup> liver-resident NK cells have been described in humans and mice (<xref ref-type="bibr" rid="bib93">Park et al., 2019</xref>; <xref ref-type="bibr" rid="bib47">Harmon et al., 2016</xref>), while ILC1s from human tonsil and blood was also found to be Eomes+ (<xref ref-type="bibr" rid="bib13">Cella et al., 2019</xref>). Therefore, the distinction between NK cells and ILC1s remains provisional – which is exactly why we have cautiously labeled the latter as ‘ILC1lc.’. The transcriptional and functional identity of ILC1 cells in humans is still a matter of debate, given that in contrast to other ILC subsets ILC1 cells seem to lack robust markers that enable their unequivocal identification and isolation (<xref ref-type="bibr" rid="bib5">Bennstein et al., 2020</xref>).</p><p>However, although integrin α1 (CD49a) is upregulated on activated NK cells (<xref ref-type="bibr" rid="bib1">Albini et al., 2021</xref>; <xref ref-type="bibr" rid="bib137">Zheng et al., 2016</xref>), CD49a and integrin α2 (CD49b) are used as two mutually exclusive markers for distinguishing between NK and ILC1 cells, with NK cells being defined as CD49b+CD49a- and ILC1 as CD49b-CD49a+ (<xref ref-type="bibr" rid="bib35">Gao et al., 2017</xref>; <xref ref-type="bibr" rid="bib129">Vienne et al., 2021</xref>; <xref ref-type="bibr" rid="bib32">Flommersfeld et al., 2021</xref>; <xref ref-type="bibr" rid="bib72">Krzywinska et al., 2022</xref>) In the current study, we have accepted and employed this consensus. Also, in contrast to ILC1 and ILC1lc, classical NK cells demonstrate high T-bet and Eomes expression (T-bet<sup>hi</sup> /Eomes<sup>hi</sup>) (<xref ref-type="bibr" rid="bib128">Verma et al., 2020</xref>). Therefore, for the purpose of this study, we define ILC1lc as CD49a+CD49b- (<xref ref-type="bibr" rid="bib128">Verma et al., 2020</xref>) and as lin-/CD127+/CD117-/CRTH2-phenotype, which are typical to classical ILC1 cells (<xref ref-type="bibr" rid="bib5">Bennstein et al., 2020</xref>; <xref ref-type="bibr" rid="bib69">Krabbendam et al., 2021</xref>), and also as T-bet<sup>lo</sup>/ Eomes<sup>hi</sup> (<xref ref-type="bibr" rid="bib5">Bennstein et al., 2020</xref>) (in contrast to classical T-bet<sup>hi</sup> /Eomes<sup>lo</sup> ILC1 cells <xref ref-type="bibr" rid="bib128">Verma et al., 2020</xref>).</p><p>Specifically, we have asked whether (a) their number is increased in lesional AA skin, (b) they can damage human HFs ex vivo in a manner that mimics the AA phenotype, and finally (c) whether ILC1lc alone suffice to induce AA in previously healthy human scalp skin in vivo. To address these questions, we first analyzed the abundance, distribution, and phenotype of ILC1lc in human AA skin lesions compared to healthy human control skin. We then co-cultured autologous ILC1lc with freshly organ-cultured scalp HFs from the same patient, that is under conditions where the epithelium of these HFs transiently undergo an acute stress response and overexpresses MICA (<xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>), to check whether these innate lymphocytes exert any HFs cytotoxicity and/or impact on the physiological immune privilege (IP) of HFs (<xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>; <xref ref-type="bibr" rid="bib96">Paus et al., 2005</xref>; <xref ref-type="bibr" rid="bib54">Ito et al., 2004</xref>; <xref ref-type="bibr" rid="bib101">Peters et al., 2007</xref>; <xref ref-type="bibr" rid="bib9">Bertolini et al., 2016</xref>). Finally, we injected autologous ILC1lc intradermally into healthy human scalp skin xenotransplants from the same human volunteers on SCID/beige mice to probe whether this suffices to induce classical AA hair loss lesions in vivo.</p><p>Taken together, our data show that ILC1lc is increased in AA lesions and suffice to induce an AA phenotype in healthy human HFs ex vivo and in vivo. This provides the first functional evidence of a key role of ILC1lc innate lymphocytes in a model human autoimmune disease (<xref ref-type="bibr" rid="bib18">Colonna, 2018</xref>; <xref ref-type="bibr" rid="bib113">Seillet et al., 2021</xref>; <xref ref-type="bibr" rid="bib19">Conlon et al., 2021</xref>; <xref ref-type="bibr" rid="bib32">Flommersfeld et al., 2021</xref>; <xref ref-type="bibr" rid="bib25">Daussy et al., 2014</xref>; <xref ref-type="bibr" rid="bib93">Park et al., 2019</xref>) - but also questions whether AA always a classical autoimmune disease is and underscore the role of innate immune cells in AA pathobiology.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Peri- and intrafollicular infiltrates of ILC1lc are seen in both lesional and non-lesional AA skin</title><p>First, we investigated whether healthy and AA-affected human skin differs in their content and/or distribution of ILC1lc, using a comprehensive set of triple-immunofluorescence (IF) staining best suited to identify these immunocytes (<xref ref-type="bibr" rid="bib113">Seillet et al., 2021</xref>; <xref ref-type="bibr" rid="bib5">Bennstein et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Gao et al., 2017</xref>). This revealed the presence of only extremely few ILC1lc in healthy control skin with all three staining settings employed (Eomes+, CD49a+, NKG2D+ [<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>], Eomes+, c-KIT-, CD49a+ [<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>], or NKp44+, CD103+, T-bet- cells [<xref ref-type="fig" rid="fig1">Figure 1C and D</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>; <xref ref-type="bibr" rid="bib63">Kim, 2015</xref>; <xref ref-type="bibr" rid="bib34">Fuchs et al., 2013</xref>; <xref ref-type="bibr" rid="bib112">Salimi and Ogg, 2014</xref>]). These cells appeared to be preferentially scattered along the papillary dermis of healthy scalp skin biopsies and around the HFs (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). This is reminiscent of the few Vδ1+T cells detectable in healthy human skin that also have a preferential perifollicular location and may ‘police’ the skin for molecular indications of tissue stress, namely of HFs (<xref ref-type="bibr" rid="bib125">Uchida et al., 2020</xref>; <xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Immunofluorescence microscopy analyses of ILC1lc and CD8+/NKG2D+ cells in alopecia areata (AA) scalp skin.</title><p>(<bold>A</bold>) ILC1lc (EOMES+, CD49a+, and NKG2D+) around HF in normal scalp skin, intrafollicular and perifollicular ILC1lc infiltrates in lesional and in non-lesional AA scalp patient. (<bold>B</bold>) EOMES+, c-KIT-,CD49a+, and (<bold>C</bold>) NKp44+, CD103+, T-bet- ILC1lc. For each panel, yellow staining indicates double staining A-EOMES+, NKG2D+; B- EOMES+, CD49a+; C- NKp44+,CD103+ (<bold>D</bold>) Quantitative immunohistomorphometry (qIHM) shows an increased number of ILC1lc in AA patients as compared to normal volunteers and increased number of the cells in lesional versus non-lesional areas of the patients. There is a significant increased perifollicular than intrafollicular ILC1lc in the lesional and non lesional areas. (<bold>E</bold>) CD8+/NKG2D+ cells around HF in AA scalp patient and absence of these cells in normal scalp skin of normal scalp skin. (<bold>F</bold>) There is an increased number of CD8+/NKG2D+ cells in HFs of AA patients compared to normal scalp skin and a significant lower number of ILC1lc versus CD8+/NKG2D+ cells in AA scalp skin. N=6 biopsies /AA patients and six biopsies /healthy donors from six independent donors, three areas were evaluated per section, and three sections per biopsy. Following Shapiro-Wilk test, Student’s <italic>t</italic>-test: *p&lt;0.05, **p&lt;0.01 or Mann Whitney <italic>U</italic> test: <sup>#</sup>p&lt;0.05. Scale bars, 50 µm. CTS- connective tissue sheath, DP - dermal papilla, HM - hair matrix, White arrow- c-KIT stained melanocyte.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Quantitative data for immunofluorescence microscopy analyses of ILC1lc and CD8+/NKG2D+ cells in AA scalp skin.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80768-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80768-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Single channels immunofluorescence microscopy analyses of various markers in AA scalp skin and in AA-induced xenotransplants.</title><p>(<bold>A</bold>) Single channels of EOMES, T-bet, CD49a+, NKG2D+, c-kit, CD103, and NKp44 expressing cells in alopecia areata (AA) scalp patient and (<bold>B</bold>) in the humanized AA model. N=4 biopsies from AA patients and five biopsies from the humanized AA mouse model. Scale bars, 50 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80768-fig1-figsupp1-v1.tif"/></fig></fig-group><p>Instead, intra and peri-follicular infiltrates of ILC1lc were frequently present in lesional AA HFs (<xref ref-type="fig" rid="fig1">Figure 1A, B, C and D</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), typically in conjunction with a dominant infiltrate of CD8+/NKG2D+ cells around the hair bulb (p&lt;0.05) (<xref ref-type="fig" rid="fig1">Figure 1E and F</xref>). Importantly, the number of ILC1lc was already significantly increased in/around non-lesional AA HFs compared to healthy scalp skin (p&lt;0.01) (<xref ref-type="fig" rid="fig1">Figure 1A, B, C and D</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). This may indicate that ILC1lc may actually have arrived around the HFs before the CD8 cells and may have contributed to attracting the CD8 cells into the perifollicular space.</p><p>This strongly suggested that ILC1lc are not mere bystanders attracted only secondarily to the HFs by CD8 T-cells, similar to, but more pronounced than we have recently observed regarding perifollicular Vδ1+T cells in non-lesional AA skin (<xref ref-type="bibr" rid="bib125">Uchida et al., 2020</xref>). This invited the hypothesis that ILC1lc is actively involved in transforming healthy human scalp HFs into lesional AA HFs.</p></sec><sec id="s2-2"><title>T-bet<sup>lo</sup>/Eomes<sup>hi</sup> ILC1lc can be expanded from human peripheral blood mononuclear cells (PBMCs) in vitro</title><p>To functionally probe this hypothesis, we isolated, purified, and characterized human peripheral blood-derived ILC1lc as the most suitable cell source for the planned HF-immunocyte co-culture studies. The scarcity of ILC1lc in healthy human skin, compared to their relative abundance in peripheral blood (<xref ref-type="bibr" rid="bib18">Colonna, 2018</xref>; <xref ref-type="bibr" rid="bib3">Artis and Spits, 2015</xref>) necessitated to isolate autologous ILC1lc from the latter source rather than from skin (<xref ref-type="bibr" rid="bib122">Teunissen et al., 2014</xref>). To facilitate ILC1lc isolation, PBMCs of healthy volunteers were first cultured with high-dose IL-2 (100 U/mL) in the presence of IL-18 (1 µg/1 ml), IL-33 (1.5 µg/5 ml), and IL-12 (1.5 µg/5 ml), since these cytokines induce ILC1lc expansion (<xref ref-type="bibr" rid="bib112">Salimi and Ogg, 2014</xref>; <xref ref-type="bibr" rid="bib115">Silver et al., 2016</xref>; <xref ref-type="bibr" rid="bib92">Orimo et al., 2020</xref>; <xref ref-type="bibr" rid="bib91">Ohne et al., 2016</xref>). When ILC1lc were sorted by FACS Aria and characterized by FACS analysis on day seven of culture, low T-bet, and high Eomes expression were observed (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), in contrast to classical T-bet<sup>hi</sup> and Eomes<sup>lo</sup> ILC1 cells (<xref ref-type="bibr" rid="bib59">Jiao et al., 2016</xref>; <xref ref-type="bibr" rid="bib130">Vivier et al., 2018</xref>; <xref ref-type="bibr" rid="bib136">Zhang et al., 2018</xref>). In addition, the ILC1lc expressed and shared the following markers with classical ILC1 cells: LIN- CD3/CD1a/D14/CD19/CD34/CD123/CD11c /BDCH2/FcεR1α/TCRαβ/TCRγδ/CD56, CD127+, CD161+, c-KIT-, and CRTH2- (<xref ref-type="bibr" rid="bib139">Zook and Kee, 2016</xref>; <xref ref-type="bibr" rid="bib7">Bernink et al., 2017</xref>; <xref ref-type="bibr" rid="bib116">Simoni and Newell, 2017</xref>; <xref ref-type="fig" rid="fig2">Figure 2A</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Circulating ILC1lc expanded and characterized by FACS analysis.</title><p>(<bold>A</bold>) PBMCs activated by IL-18, IL-33 and IL-12 were sorted by FACS Aria and characterized by FACS analysis. ILC1lc markers were identified by the expression of CD127+, CD161+, c-KIT-, and CRTH2-, high levels of integrin α1 (CD49a) expression, combined with the absence of integrin α2 (CD49b) and transcription factors Eomes<sup>hi</sup> and T-bet<sup>lo</sup> (<bold>B</bold>) unstimulated PBMCs (<bold>C</bold>) isotype controls. N=10 blood donors, 1.5 × 10<sup>6</sup> cells/blood donor, analysis was performed in triplicates from each of the blood donors. Following Shapiro-Wilk test, Student’s t-test, p&lt;0.05.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Quantitative data for circulating ILC1lc expanded and characterized by FACS analysis.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80768-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80768-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Circulating ILC1lc expanded and characterized by FACS analysis.</title><p>(<bold>A</bold>) PBMCs activated by IL-18, IL-33, and IL-12 were sorted by FACS Aria and characterized by FACS analysis. ILC1-like cell markers were identified by the expression of Eomes+, CXCR6+, CD200R+, IRF8-, Perforin-, CD16-, and NKP80 (<bold>B</bold>) IL-2 induced PBMCs (<bold>C</bold>) isotype controls. (<bold>D</bold>) expression of CD127+, CD161 +, and RORγt-. N=4 blood donors, 1.5 × 10<sup>6</sup> cells/blood donor, analysis was performed in triplicates from each of the blood donors. Following Shapiro-Wilk test, Student’s t-test, p&lt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80768-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Scheme demonstrating the isolation of ILC1lc, ILC2s, and ILC3s cells from PBMCs of healthy human volunteers.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80768-fig2-figsupp2-v1.tif"/></fig></fig-group><p>This immune phenotype suggests that the immune cells used in our study are best classified as ILC1lc (<xref ref-type="bibr" rid="bib88">Nabekura and Shibuya, 2021a</xref>), and documents that all experiments reported below were indeed performed with autologous ILC1lc rather than with NK cell subpopulations. Indeed, the FACS analysis (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A,B and C</xref>) revealed that ILC1lc demonstrates the ILC1 phenotype (CD200R, CD127, CXCR6) (<xref ref-type="bibr" rid="bib76">Lopes et al., 2023</xref>; <xref ref-type="bibr" rid="bib23">Curio and Belz, 2022</xref>) but not of the classical NK cell lineage (IRF8, Perforin, NKp80, CD16) (<xref ref-type="bibr" rid="bib111">Sagebiel et al., 2019</xref>; <xref ref-type="bibr" rid="bib12">Brownlie et al., 2021</xref>; <xref ref-type="bibr" rid="bib70">Krämer et al., 2023</xref>), thus further serving as an evidence that EOMES +ILCs represent distinct ILC1 lineage-defining markers. In contrast to NK cells, ILC1lc also expressed the expected high levels of integrin α1 (CD49a), combined with the absence of integrin α2 (CD49b) (<xref ref-type="bibr" rid="bib59">Jiao et al., 2016</xref>; <xref ref-type="fig" rid="fig2">Figure 2A</xref>). All these characteristic markers of ILClc were absent in the control unstimulated PBMCs (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>).</p><p>This immune phenotype suggests that the immune cells used in our study are best classified as ILC1lc (<xref ref-type="bibr" rid="bib88">Nabekura and Shibuya, 2021a</xref>), and documents that all experiments reported below were indeed performed with autologous ILC1lc rather than with NK cell subpopulations. Note that we had previously shown that NKG2D+/CD56 +NK cells suffice to induce AA lesions in human skin in vivo (<xref ref-type="bibr" rid="bib39">Gilhar et al., 2013a</xref>; <xref ref-type="bibr" rid="bib74">Laufer Britva et al., 2020</xref>) while iNKT cells are AA-protective in the humanized AA mouse model (<xref ref-type="bibr" rid="bib36">Ghraieb et al., 2018</xref>). Subsequently, these ILC1lc were either used for HF co-culture assays or injected into healthy human scalp skin xenotransplants on SCID/beige mice (<xref ref-type="bibr" rid="bib39">Gilhar et al., 2013a</xref>; <xref ref-type="bibr" rid="bib56">Ito et al., 2005b</xref>). As controls, we also isolated ILC2 and ILC3 cells, which failed to induce AA phenotype in a sharp contrast to the ILC1lc (see Materials and methods).</p><p>In order to exclude the possibility that contamination from ILC3s during sorting the ILC1lc and thus contributing to the observed results, we generated a new set of FACS data on sorted ILC1lc. Given that ILC1 cells are RORγt negative while ILC3 cells are RORγt positive (<xref ref-type="bibr" rid="bib99">Peng et al., 2022</xref>; <xref ref-type="bibr" rid="bib31">Fiancette et al., 2021</xref>), the data clearly demonstrate that the contamination hypothesis is highly unlikely (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>).</p></sec><sec id="s2-3"><title>ILC1lc induces HF cytotoxicity ex vivo</title><p>Next, we functionally probed the interaction of ILC1lc with HFs that were investigated here as a model human (mini-) organ in which the interactions of a healthy human tissue system with defined, autologous immunocyte populations can be interrogated ex vivo in the absence of any confounding systemic immune or neural inputs (<xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>). For this, microdissected, organ-cultured human scalp HFs (<xref ref-type="bibr" rid="bib73">Langan et al., 2015</xref>) were co-cultured for six days with autologous, peripheral blood-derived, purified, IL-12/IL-18/IL-33-prestimulated ILC1lc, or with autologous human CD8 +NKG2D+ cells (=positive control), ILC2, ILC3 cells, or PBMCs non-speciﬁcally activated with PHA (PBMCs/PHA) (=negative controls).</p><p>Importantly, only scalp HFs in the anagen VI stage of the hair cycle were used (identified as described) (<xref ref-type="bibr" rid="bib67">Kloepper et al., 2010</xref>) that had been freshly placed into HF organ culture for 24 hr, since these HFs are maximally ‘stressed,’ in contrast to non-cultured HFs, that is immediately after isolation, or that had already undergone several days of adjusting to the harsh conditions of serum-free organ culture (<xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>; <xref ref-type="bibr" rid="bib73">Langan et al., 2015</xref>). These ‘stressed’ day 1 HFs temporarily up-regulate MHC class Ia and ß2-microglobulin while the expression of IP guardians, that is αMSH and TGFβ2 remain unchanged (<xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>)<italic>,</italic> indicating a transiently weakened, but partially maintained HF immune privilege (<xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Ito et al., 2004</xref>). The expression of molecules associated with tissue stress, that is the intrafollicular produced neurohormone, CRH (<xref ref-type="bibr" rid="bib55">Ito et al., 2005a</xref>), and the NKG2D ligand MICA/B is also higher in day 1 organ-cultured HFs compared to freshly microdissected HFs or after day 3 of organ culture. Day 1 HFs also show signs of mild HF dystrophy (as evidenced by increased lactate dehydrogenase [LDH] release into the medium), and express chemokines recognized for their relevance in AA pathobiology, that is CXCL10 and CXCL12 (<xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Ito et al., 2020</xref>). Thus, day 1 HFs are ideally suited for interrogating human immunocyte interactions with a transiently ‘stressed,’ but otherwise healthy human (mini-) organ that overexpresses the NKG2D-activating ‘danger’ signal, MICA/B, under physiologically relevant ex vivo conditions (<xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>; <xref ref-type="bibr" rid="bib73">Langan et al., 2015</xref>).</p><p>First, we studied the cytotoxic effects of ILC1lc on healthy human scalp HF ex vivo by measuring the HF release of LDH into the culture medium. This not only showed significantly higher LDH release induced by ILC1lc than by co-culture with all three negative control cell populations (ILC2s, ILC3s, or PBMCs/PHA) but also even higher HF cytotoxicity levels than those induced by CD8+/NKG2D+ cells (p&lt;0.01), namely after three days of co-culture (<xref ref-type="fig" rid="fig3">Figure 3</xref>). These HF cytotoxicity results were fully corroborated by characteristic morphological signs of HF dystrophy following co-culture with ILC1lc; while CD8+/NKG2D+ cells induced similar dystrophy phenomena, these were not seen after co-culture with PBMC/PHA (<xref ref-type="fig" rid="fig4">Figure 4A, B and C</xref>). The induction of significant HF dystrophy by ILC1lc ex vivo was further documented by the presence of pathological melanin clumping and ectopically located intrafollicular melanin granules (<xref ref-type="bibr" rid="bib11">Bodó et al., 2007</xref>; <xref ref-type="bibr" rid="bib52">Hendrix et al., 2005</xref>; <xref ref-type="fig" rid="fig4">Figure 4D, E, F and G</xref>) and by decreased proliferation and increased apoptosis of hair matrix keratinocytes (<xref ref-type="fig" rid="fig4">Figure 4H, I, J and K</xref>). Both were also seen in the CD8+/NKG2D+group (positive control), but not in HFs co-cultured with PBMCs/PHA (negative control) (p&lt;0.001, p&lt;0.01, respectively). Thus, autologous ILC1lc alone suffice to induce substantial HF cytotoxicity ex vivo if co-cultured with transiently ‘stressed,’ but otherwise healthy human scalp HFs.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Cytotoxic effects of CD8+/NKG2D+and ILC1lc on normal human scalp HF ex vivo.</title><p>These cell populations were placed separately into wells with (+Hair) dissected HFs and without (-Hair). Cytotoxic effects of these cell populations on normal human scalp HF ex vivo were studied by measuring the spontaneous release of lactate dehydrogenase (LDH) from the microdissected HFs. Increased cytotoxicity of ILC1lc co-cultured with HFs compared to CD8+/NKG2D+, as well as to ILC2s and ILC3s, and PBMCs/PHA cells. N=20–24 HFs/group derived from three independent donors analyzed in three independent HF organ culture experiments. Following Shapiro-Wilk test and Dunn’s test <sup>§</sup>p&lt;0.05, <sup>§§</sup>p&lt;0.01, <sup>§§§</sup>p&lt;0.001.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Quantitative data for cytotoxic effects of CD8+/NKG2D+ and ILC1lc on normal human scalp HF ex vivo<italic>.</italic></title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80768-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80768-fig3-v1.tif"/></fig><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Hair follicles (HFs) dystrophy, melanin clumping, and apoptosis in normal human scalp HF ex vivo co-cultured with ILC1lc and CD8+/NKG2D+ cells.</title><p>(<bold>A–C</bold>) H&amp;E staining revealed undifferentiated and prominent matrix cells, condensed dermal papilla, and the appearance of apoptotic cells, N=15–19 HFs/group from three independent donors. (<bold>D–G</bold>) Masson-Fontana histochemistry revealed melanin clumping and ectopic location of melanin granules only in HFs co-cultured with CD8+/NKG2D+and ILC1lc, but not in HFs cultured with PBMCs/PHA. N=7–11, HFs/group from three independent donors. Following Shapiro-Wilk test,Student’s <italic>t</italic>-test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. (<bold>H–K</bold>) HFs co-cultured with ILC1lc or CD8+/NKG2D+ cells showed a significantly decreased proliferation (pink, arrowhead) and increased apoptosis (green, wide arrows). N=6 HFs/group from two independent donors, three areas were evaluated per section. Following Shapiro-Wilk test, Student’s <italic>t</italic>-test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 in the anagen hair bulb compared to HFs cultured with PBMCs/PHA. Scale bars, 50 µm. DP - dermal papilla, HM - hair matrix.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Quantitative data for HFs dystrophy, melanin clumping and apoptosis in normal human scalp HF ex vivo co-cultured with ILC1lc and CD8+/NKG2D+ cells.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80768-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80768-fig4-v1.tif"/></fig></sec><sec id="s2-4"><title>ILC1lc induces HF immune privilege collapse ex vivo via NKG2D stimulation</title><p>Given that AA cannot occur without the prior collapse of HF immune privilege [HF-IP] (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>; <xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>), we also investigated the impact of ILC1lc on key HF-IP markers. Indeed, the co-culture of HFs with ILC1lc triggered IP collapse, as evidenced by ectopic and overexpressed HLA-A,B,C, ß2-microglobulin (ß2 MG), and HLA-DR, along with overexpression of the ‘danger’/tissue distress signals, MICA and CD1d, which interact with and stimulate NKG2D (<xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>; <xref ref-type="bibr" rid="bib29">Fan et al., 2022</xref>) as compared to HFs interacting with PBMC/PHA or with ILC3 cells (<xref ref-type="fig" rid="fig5">Figure 5A, B, C, D, E and F</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Characteristic immunopathology features of alopecia areata (AA) hair follicles (HFs).</title><p>(<bold>A</bold>) MICA, (<bold>B</bold>) HLA-A,B,C, (<bold>C</bold>) β2 MG, (<bold>D</bold>) HLA-DR, and (<bold>E</bold>) CD1d, expression by HFs epithelium, which had been co-cultured with either ILC1lc or CD8+/NKG2D+ cells but not in the control HFs, which had been co-cultured with either ILC3s, PBMCs/PHA, ILC1lc /NKG2D neutralization or in the untreated HFs. (<bold>F</bold>) quantitation. (<bold>G</bold>) The immune inhibitory HF immune privilege guardians, α-MSH and (<bold>H</bold>) TGF-β1 almost disappeared in HFs/ ILC1lc and HFs/NKG2D but were prominently present in ILC1lc /NKG2D neutralization and control HFs, N=9–12 HFs/group from three independent donors, three areas were evaluated per section. Following Shapiro-Wilk test,Student’s t-test, *p&lt;0.05. Scale bar, 100 µm. ORS - outer root sheet.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Quantitative data for characteristic immunopathology features of AA HFs.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80768-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80768-fig5-v1.tif"/></fig><p>Notably, quantitative immunohistomorphoemtry (qIHM) also showed that protein expression of the immunoinhibitory HF-IP guardians, TGF-β1 and α-MSH (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>; <xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>; <xref ref-type="bibr" rid="bib97">Paus et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Ito et al., 2004</xref>), almost disappeared in the epithelium of HFs co-cultured with autologous ILC1lc or CD8+/NKG2D+ cells (=positive control) (<xref ref-type="fig" rid="fig5">Figure 5G, H and I</xref>)<bold>,</bold> while these critical HF-IP guardians were still prominently expressed in negative control HFs (<xref ref-type="fig" rid="fig5">Figure 5G, H and I</xref>). Importantly, adding anti-NKG2D blocking antibodies prevented HFs IP collapse and preserved the IP in the ILC1lc /NKG2D treated group (<xref ref-type="fig" rid="fig5">Figure 5G, H and I</xref>).</p><p>This demonstrates that autologous ILC1lc induces human HF-IP collapse ex vivo – incidentally, the first time that the induction of IP collapse by ILC1lc has been documented in an intact human tissue/organ.</p></sec><sec id="s2-5"><title>ILC1lc are activated by ‘stressed’ HFs and induce premature catagen development via IFN-γ secretion</title><p>Next, we examined how autologous ILC1lc impacted on human HF cycling, given that premature induction of apoptosis-driven HF regression (catagen) is one of the hallmarks of AA (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>; <xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>; <xref ref-type="bibr" rid="bib85">Messenger et al., 1986</xref>). This showed that ILC1lc significantly accelerated the transformation of anagen into catagen HFs ex vivo (<xref ref-type="bibr" rid="bib96">Paus et al., 2005</xref>) compared to all three negative controls (ILC2, ILC3, or PBMCs/PHA) – thus eliciting the third hallmark of the AA phenotype besides HF-IP collapse and dystrophy ex vivo (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>; <xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>; <xref ref-type="bibr" rid="bib85">Messenger et al., 1986</xref>; <xref ref-type="fig" rid="fig6">Figure 6A</xref>), just as we had previously shown for Vδ1+ γδT cells (<xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>). As expected (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>; <xref ref-type="bibr" rid="bib105">Pratt et al., 2017</xref>; <xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">de Jong et al., 2018</xref>; <xref ref-type="bibr" rid="bib134">Xing et al., 2014</xref>), premature catagen induction was also seen with CD8+/NKG2D+ cells (=positive control), but not with any of the negative control cell populations (<xref ref-type="fig" rid="fig6">Figure 6A</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Transition of anagen to catagen hair follicles (HFs) following culture with ILC1lc or CD8+/NKG2D+ cells in human scalp HF ex vivo.</title><p>(<bold>A</bold>) These immune cells significantly accelerated the transformation of anagen HFs into catagen HFs ex vivo compared to ILC2, ILC3, PBMCs/PHA, and neutralizing anti- IFN-γ, anti-NKG2D antibodies. N=28–34 HFs/group taken from six independent donors, Student’s <italic>t</italic>-test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. (<bold>B</bold>) ELISA analysis revealed increased IFN-γproduction by ILC1lc /HFs compared to production by CD8+/NKG2D+ cells, ILC2s, ILC3s, and PBMCs/PHA. N=6 healthy donors, 6 × 10<sup>6</sup> cells from each donor. Following Shapiro-Wilk test, Student’s t-test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. (<bold>C</bold>) FACS analysis revealed a significant increased intracellular IFN-γexpression in ILC1lc co-cultured with HFs compared to the effector CD8+/NKG2D+and to ILC2s and ILC3s, N=6 blood donors, 1.5 × 10<sup>6</sup> cells/blood donor. Student’s <italic>t</italic>-test, p&lt;0.05.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Quantitative data for transition of anagen to catagen HFs following culture with ILC1lc or CD8+/NKG2D+ cells in human scalp HF ex vivo.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80768-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80768-fig6-v1.tif"/></fig><p>ILC1lc prominently secrete IFN-γ (<xref ref-type="bibr" rid="bib113">Seillet et al., 2021</xref>), that is the cytokine that we had shown to induce HF damage (dystrophy), premature catagen, and HF-IP collapse most potently (<xref ref-type="bibr" rid="bib54">Ito et al., 2004</xref>; <xref ref-type="bibr" rid="bib55">Ito et al., 2005a</xref>). Therefore, we next investigated IFN-γrelease in these co-culture experiments. ELISA analysis revealed that ILC1lc produced and secreted higher amounts of IFN-γ into the medium than all other cells co-cultured with ‘stressed’ HFs, including CD8+/NKG2D+ cells (p&lt;0.05) (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). This suggests that ILC1lc possesses even stronger HF cytotoxicity-, IP collapse- and dystrophy-inducing properties than CD8 +T cells, the classical effector cells of AAA (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>; <xref ref-type="bibr" rid="bib105">Pratt et al., 2017</xref>; <xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>).</p><p>FACS analysis showed ILC1lc activation when these were co-cultured with ‘stressed,’ autologous HFs (600 cells/HF), as evidenced by significantly increased intracellular IFN-γ expression by ILC1lc (<xref ref-type="bibr" rid="bib7">Bernink et al., 2017</xref>) (93 ± 11%) compared to the positive control (CD8+/NKG2D+, 75 ± 9%, p&lt;0.05) (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) and the negative controls ILC2s, 11 ± 1%, p&lt;0.05; ILC3s, 28 ± 5%, p&lt;0.05; PBMCs/PHA, 2 ± 1.3%, p&lt;0.001 (<xref ref-type="fig" rid="fig6">Figure 6C</xref>).</p><p>When neutralizing anti- IFN-γ antibodies were administered into the medium of the organ culture, premature catagen development of HFs co-cultured with ILC1lc was significantly reduced (<xref ref-type="fig" rid="fig6">Figure 6A</xref>), strongly suggesting that premature catagen induction by ILC1lc depends on their IFN-γsecretion (<xref ref-type="bibr" rid="bib113">Seillet et al., 2021</xref>). Importantly, reduced catagen induction was also seen after adding NKG2D-blocking antibodies to the medium (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). This suggests that ILC1lc activation and IFN-γsecretion are induced by NKG2D-stimulating danger signals overexpressed by stressed HF epithelium, such as MICA. These findings further support the recognized central role of both IFN-γand NKG2D in the initial stages of AA pathobiology (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>; <xref ref-type="bibr" rid="bib97">Paus et al., 2018</xref>; <xref ref-type="bibr" rid="bib57">Ito et al., 2008</xref>; <xref ref-type="bibr" rid="bib26">de Jong et al., 2018</xref>).</p></sec><sec id="s2-6"><title>ILC1lc suffice to induce AA lesions in healthy human scalp skin in vivo</title><p>Taken together, these clinically relevant ex vivo experiments documented that ILC1lc can indeed induce the hallmarks of AA in healthy human scalp HFs ex vivo: HF-IP collapse, HF dystrophy, and premature catagen development (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>; <xref ref-type="bibr" rid="bib97">Paus et al., 2018</xref>). Therefore, we finally probed the hypothesis that ILC1lc may also suffice to induce human AA-like hair loss lesions in vivo using our established humanized AA mouse model (<xref ref-type="bibr" rid="bib39">Gilhar et al., 2013a</xref>; <xref ref-type="bibr" rid="bib36">Ghraieb et al., 2018</xref>; <xref ref-type="bibr" rid="bib41">Gilhar et al., 2016</xref>). We had previously demonstrated that a macroscopic and histological phenocopy of human AA lesions can be rapidly induced experimentally in healthy human scalp skin xenotransplants on SCID/beige mice in vivo by the intradermal injection of enriched CD8/NKG2D are defined as PBMCs that have been cultured for 14 days in high-dose IL-2 (100 U/ml) according to our previously published characterization (<xref ref-type="bibr" rid="bib36">Ghraieb et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Gilhar et al., 2013a</xref>; <xref ref-type="bibr" rid="bib40">Gilhar et al., 2013b</xref>; <xref ref-type="bibr" rid="bib41">Gilhar et al., 2016</xref>; <xref ref-type="bibr" rid="bib8">Bertolini et al., 2014</xref>). These cells are derived from healthy donors, that is in the absence of a specific genetic or autoimmune constellation.</p><p>For this, 10 SCID/beige mice were each xenotransplanted with three full-thickness human scalp skin grafts (3 mm) obtained from parietal skin regions of four healthy donors without a prior history of AA (males aged 37±6). Eighty-nine days after transplantation, that is when hair regrowth had occurred in all xenotransplants, the mice were randomly divided into three groups, and each mouse from each group received one intradermal injection of either autologous IL-12/IL-18/IL-33-preactivated ILC1lc (test), PBMCs co-cultured with a nonspecific mitogen (PHA; negative control), or enriched CD8/NKG2D cells (positive control). When measured 45 days later, significant AA-like hair loss was observed macroscopically in the xenotransplants injected with ILC1lc compared to the negative control, at about the same level as positive control xenotransplants (<xref ref-type="fig" rid="fig7">Figure 7A</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Development of alopecia areata (AA) in the humanized mouse model treated with ILC1lc.</title><p>(<bold>A</bold>) Significant hair loss is observed following the injection of ILC1lc and enriched CD8/NKG2D cells, while in the PBMCs/PHA treated group, hair number remains almost constant. N=7–9 xenotransplants/group from three independent donors, Following Shapiro-Wilk test, Mann-Whitney <italic>U</italic> test: <sup>#</sup>p&lt;0.05, <sup>##</sup>p&lt;0.01. (<bold>B</bold>) HF dystrophy and perifollicular lymphocytic infiltrates around anagen hair follicles (HFs) (H&amp;E staining) combined with strong expression of (<bold>C</bold>) HLA-A,B,C, β2 MG, HLA-DR, and downregulation of α-MSH and TGF-β1 in the ILC1lc and in (<bold>D</bold>) enriched CD8/NKG2D cells versus xenotransplants treated with (<bold>E</bold>) PBMCs/PHA (IHC staining) (<bold>F</bold>) quantitative data. N=5–9 xenotransplats/group from three independent donors. 4–5 defined reference areas were evaluated per section, and three sections per xenotransplants. Following Shapiro-Wilk test, Student’s <italic>t</italic>-test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. Scale bar, 50 µm. DP - dermal papilla, HM - hair matrix.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Quantitative data for development of AA in the humanized mouse model treated with ILC1lc.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80768-fig7-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80768-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Anti-CD3 antibodies prevent the development of alopecia areata (AA) in scalp skin xenotransplants treated with enriched CD8/NKG2D but not with ILC1lc.</title><p>(<bold>A</bold>) Significant hair loss was observed following the injection of ILC1lc, ILC1lc /OKT3, or enriched CD8/NKG2D cells into normal scalp skin on SCID/beige mice, but not in those treated with enriched CD8+/NKG2D+/anti-CD3 (OKT3), N=5 xenotransplants/group from two independent donors. Following Shapiro-Wilk test, Mann-Whitney <italic>U</italic> test: <sup>#</sup>p&lt;0.05, <sup>##</sup>p&lt;0.01. Hair follicle (HF) dystrophy combined with perifollicular lymphocytic infiltrate around anagen HFs (H&amp;E staining) in xenotransplants treated with (<bold>B</bold>) ILC1lc, ILC1lc /OKT3, or enriched CD8/NKG2D. Normal HF in anagen in xenotransplant treated with enriched CD8/NKG2D/OKT3. Induction of HLA-A,B,C and of HLA-DR, downregulation of α-MSH and TGF-β1 by the follicular epithelium and increased dermal IFN-γ cells (IHC staining) in xenotransplants treated with (<bold>C</bold>) ILC1lc and similarly in (<bold>D</bold>) ILC1lc /OKT3 and (<bold>E</bold>) enriched CD8/NKG2D treated groups. Reduced expression of HLA-A,B,C, HLA-DR, and upregulation of α-MSH and TGF-β1 combined with decreased number of dermal IFN-γ cells were observed in xenotransplants treated with (<bold>F</bold>) enriched CD8/NKG2D/OKT3 cells. (<bold>G</bold>) Quantitative data, N=5–6 xenotransplants/group from two independent donors. 3–4 areas were evaluated per section, and three sections per xenotransplant. Following Shapiro-Wilk test, Student’s <italic>t</italic>-test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. Scale bar, 50 µm. HM - hair matrix.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Quantitative data for anti-CD3 antibodies prevent the development of AA in scalp skin xenotransplants treated with enriched CD8/NKG2D but not with ILC1lc.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80768-fig7-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80768-fig7-figsupp1-v1.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Dermal infiltrates of the various treated xenotransplants.</title><p>Several CD8 and CD4 in xenotransplants treated with (<bold>A</bold>) ILC1lc and similarly in xenotransplants treated with (<bold>B</bold>) ILC1lc /OKT3, and (<bold>C</bold>) enriched CD8/NKG2D/OKT3 cells versus increased CD8 and CD4 in xenotransplants treated with (<bold>D</bold>) enriched CD8/NKG2D cells. (<bold>E</bold>) Quantitative data,N=5–6 xenotransplants/group from two independent donors, 3–four areas were evaluated per section, and three sections per xenotransplant. Following Shapiro-Wilk test, Student’s <italic>t</italic>-test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. Scale bar, 50 µm. DP - dermal papilla,HM - hair matrix.</p><p><supplementary-material id="fig7s2sdata1"><label>Figure 7—figure supplement 2—source data 1.</label><caption><title>Quantitative data for dermal infiltrates of the various treated xenotransplants.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80768-fig7-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80768-fig7-figsupp2-v1.tif"/></fig><fig id="fig7s3" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 3.</label><caption><title>Development of alopecia areata (AA) in normal human scalp skin xenotransplants treated with (<bold>A</bold>) ILC1lc.</title><p>Infiltrates of IFN-γ +, CD8, and CD4 cells in group treated with (<bold>B</bold>) enriched CD8/NKG2D cells. Decreased number of IFN-γ +, CD8, and CD4 cells in the (<bold>C</bold>) PBMCs/PHA treated one. (<bold>D</bold>) Quantitative data (<bold>E</bold>) presence of ILC1lc in transplants injected with ILC1lc compared to the virtual absence of these cells in enriched CD8/NKG2D and PBMCs/PHA treated mice.(<bold>F</bold>) Quantitative data N=5–9 xenotransplats/group from three donors. 4–5 areas were evaluated per section, and three sections per xenotransplant. Following Shapiro-Wilk test, Student’s <italic>t</italic>-test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. Scale bar, 50 µm. DP - dermal papilla,HM - hair matrix.</p><p><supplementary-material id="fig7s3sdata1"><label>Figure 7—figure supplement 3—source data 1.</label><caption><title>Quantitative data for development of AA in normal human scalp skin xenotransplants treated with ILC1lc, enriched CD8/NKG2D and PBMCs/PHA.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80768-fig7-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80768-fig7-figsupp3-v1.tif"/></fig></fig-group><p>To exclude that the above phenomena were not caused by residual human T-cells present in the transplants, an additional eight xenotransplanted mice were also injected intradermally once daily for 45 days with anti-CD3 antibodies (OKT3), in addition to injecting either ILC1lc or enriched CD8/NKG2D cells as described above (four mice each). This showed that anti-CD3 failed to abrogate hair loss induction in the mice treated with ILC1lc alone, but suppressed hair loss in the group treated with enriched CD8/NKG2D cells, as expected (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). These findings invalidate the residual T-cell hypothesis.</p></sec><sec id="s2-7"><title>ILC1lc induce the characteristic immunopathology of human AA lesions in vivo</title><p>Immunohistology revealed that ILC1lc, just like autologous enriched CD8/NKG2D cells, induced a phenocopy of AA immunopathology in previously healthy human scalp skin in vivo, in sharp contrast to the negative control PBMCs/PHA group: HFs dystrophy, miniaturization and perifollicular lymphocytic infiltrate around anagen HFs (<xref ref-type="fig" rid="fig7">Figure 7B</xref>) as well as induction of HF-IP collapse (significantly increased expression of HLA-A,B,C, β2 MG, and HLA-DR of the HF epithelium, along with downregulation of the immune privilege guardians, α-MSH and TGF-β1) (<xref ref-type="fig" rid="fig7">Figure 7C and D</xref>). In contrast, negative control xenotransplants injected with PBMCs/PHA showed normal anagen HFs and a significantly lower expression of HLA-A,B,C, β2 MG, and HLA-DR, paired with the expected normal expression levels α-MSH and TGF-β1 protein (<xref ref-type="fig" rid="fig7">Figure 7E</xref>) as assessed by qIHM (<xref ref-type="fig" rid="fig7">Figure 7F</xref>).</p><p>In addition, histology and quantitative immunohistomorphometry confirmed the preventive effect of anti-CD3 antibodies in inducing an AA-like phenotype in xenotransplants treated with enriched CD8/NKG2D cells, but not in those treated with ILC1lc (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B,C,D,E,F and G</xref> and <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>).</p><p>In line with the key role of IFN-γ in the development of AA (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>; <xref ref-type="bibr" rid="bib42">Gilhar et al., 2019a</xref>), IFN-γ+ cells were found to be increased around the bulb of xenotransplants injected with ILC1lc, even in the presence of the anti-CD3 antibody (OKT3), or with enriched CD8/NKG2D cells, but not with PHA-treated PBMCs or enriched CD8/NKG2D cells in the presence of OKT3 (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A,B,C,D,E,F and G</xref> and <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A,B,C and D</xref>).</p></sec><sec id="s2-8"><title>ILC1lc in the experimentally induced AA lesions</title><p>Given that both, enriched CD8/NKG2D cells, and ILC1lc produce high amounts of IFN-γ, we then investigated the subtype of these cells around the bulb of control and treated xenotransplants, along with the frequencies of CD4 +T cells. In enriched CD8/NKG2D cells injected xenotransplants, the number of CD8 + cells and CD4 +T cells was significantly increased as compared to ILC1lc (p&lt;0.001, p&lt;0.001) (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3A,B,C and D</xref>) while dense infiltration of ILC1lc was found only in xenotransplants treated with the purified ILC1lc (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3E and F</xref>).</p><p>Interestingly, qIHM also showed that the peri- and intrafollicular distribution and mean number of ILC1lc in human skin xenotransplants injected with enriched CD8/NKG2D cells imitated that of ILC1lc seen in spontaneously developed hair loss lesions of AA patients, further supporting the role of ILC1lc in human AA (<xref ref-type="fig" rid="fig1">Figure 1A, B, C and D</xref>, <xref ref-type="fig" rid="fig8">Figure 8A, B, C and D</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Yet, CD8+/NKG2D+lymphocytes significantly outnumbered ILC1lc in the experimentally induced AA lesions (p&lt;0.01) (<xref ref-type="fig" rid="fig8">Figure 8E and F</xref>), just as they do in human AA patients (<xref ref-type="fig" rid="fig1">Figure 1E and F</xref>).</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Immunofluorescence microscopy analysis of ILC1lc and enriched CD8/NKG2D cells in AA-induced xenotransplant.</title><p>(<bold>A</bold>) EOMES+, CD49a+, and NKG2D+ around hair follicle (HF) in normal scalp skin, intrafollicular and perifollicular ILC1lc infiltrates in AA-induced xenotransplants (<bold>B</bold>) EOMES+,c-KIT-,CD49a+, and (<bold>C</bold>) NKp44+, CD103+, T-bet- ILC1lc. Absence of these cells in normal scalp xenotransplant. For each panel, yellow staining indicates double staining A-EOMES+, NKG2D+; B- EOMES+,CD49a+; C- NKp44+, CD103+. (<bold>D</bold>) Quantitation. (<bold>E</bold>) CD8+/NKG2D+ cells around HF in AA-induced xenotransplant versus absence of the cells in normal xenotransplant. (<bold>F</bold>) The quantitative data demonstrate the significant increased CD8+/NKG2D+ cells in HFs of alopecia areata (AA) humanized mice compared to normal scalp xenotransplants. N=6 xenotransplants/ group from three independent donors, three areas were evaluated per section. Following Shapiro-Wilk test, Student’s <italic>t</italic>-test: *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. Mann Whitney <italic>U</italic> test: <sup>#</sup>p&lt;0.05, <sup>##</sup>p&lt;0.01.Scale bar, 50 µm. DP - dermal papilla, HM - hair matrix, White arrow- c-KIT stained melanocyte.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Quantitative data for immunofluorescence microscopy analysis of ILC1lc and enriched CD8/NKG2D cells in AA-induced xenotransplant.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80768-fig8-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80768-fig8-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The current study is the first to phenotypically and functionally explore the role of Eomes +ILC1 lc in human AA in vivo and ex vivo. Eomes +ILCs may represent the NK cell lineage and therefore the ILC1 phenotype in our study, more closely resembles a tissue-resident or activated NK cell rather than an ILC1, based on recent single-cell RNAseq studies in mice and human tissues (<xref ref-type="bibr" rid="bib76">Lopes et al., 2023</xref>). However, Eomes expression by ILCs was observed differently depending on the tissue localization (<xref ref-type="bibr" rid="bib82">McFarland et al., 2021</xref>). For example, a recent single-cell RNA-sequencing study reveals that ILC1lc both in blood and tonsil are Eomes positive (<xref ref-type="bibr" rid="bib80">Mazzurana et al., 2021</xref>). Other study demonstrated that intraepithelial ILC1s from human tonsils were found to be heterogeneous, encompassing Eomes− and Eomes +subsets (<xref ref-type="bibr" rid="bib13">Cella et al., 2019</xref>). It is indeed very important to obtain greater clarity on how ILC1lc and NKs differ from each other, namely in the context of human AA. Our new data demonstrate that ILC1lc are positive for CD49a, CD200R, CD127, CXCR6 (<xref ref-type="bibr" rid="bib76">Lopes et al., 2023</xref>) but negative for IRF8, Perforin, NKp80, CD16 (<xref ref-type="bibr" rid="bib111">Sagebiel et al., 2019</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A,B and C</xref>), strongly support that ILC1lc and NK cells have distinct lineages. This claim remains limited by the set of biomarkers that is currently available (and can reasonably be expected to be applied) to ‘definitively’ distinguish between ILC1 and NK lineages, namely in human skin, and that our data may eventually have to be re-evaluated in the context of research progress in this fast-moving field. It would be desirable to further complement these results in future studies with unbiased scRNAseq data, which can then be compared with published human ILC1 and NK cell gene signatures so as to gain deeper insights into the – still controversial and unclear - transcriptional similarities and differences between ILC1lc and NK cells and their lineage relationship to each other.</p><p>Here, we show that ILC1lc are increased in AA lesions provide the first functional evidence that expanded circulating autologous human ILC1lc suffice to induce all hallmarks of the AA hair loss phenotype (premature catagen, HF dystrophy, and HF-IP collapse) in previously healthy, organ-cultured human scalp HFs ex vivo and in human scalp skin xenotransplants in vivo, where they also cause the characteristic clinical hair loss phenomenon. This also provides the first unequivocal functional evidence of a key role of ILC1lc innate lymphocytes in a model human autoimmune disease, and thus identifies these lymphocytes as important novel targets in future AA therapy.</p><p>Mechanistically, we demonstrate that IFN-γsecretion and NKG2D signaling are both required for this AA-pattern HF damage to occur (<xref ref-type="fig" rid="fig9">Figure 9</xref>). That ILC1lc alone can induce all hallmarks of AA in a healthy human (mini-) organ ex vivo and in vivo, presumably in an autoantigen-independent manner, also demonstrates that these innate/transitional lymphocytes interact directly with human HFs, rather than affecting them only indirectly. We also show that resident T-cells in human scalp skin transplants are not responsible for the AA-inducing effects of ILC1lc in vivo (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref> and <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>).</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Pathobiology scenario: How ILC1lc can induce alopecia areata (AA).</title><p>(<bold>A</bold>) ILC1lc are rarely detected around the bulb of healthy human scalp hair follicles (HFs), which exhibit relative immune privilege and low or absent expression of MICA and MHC class I, and CD1d. (<bold>B</bold>) Various tissue stressors (in the current study: hair follicle microdissection and organ culture), can transiently weaken the hair follicle’s physiological immune privilege by upregulating the expression of MHC class I, MICA (a key activating NKG2D ligand), and of CD1d, along with the secretion of chemoattractants such as CXCL12. (<bold>C</bold>) This recruits and activates ILC1lc, which migrates towards the ‘stressed’ hair follicle and secretes IFN-γ, thus ultimately inducing HF-IP collapse. (<bold>D</bold>) Either alone or in conjunction with other recognized AA-inducing immune cells (i.e. CD8 +T cells which recognize hair follicle autoantigens now exposed by ectopically expressed MHC class I; NK cells, and <italic>γδ</italic>TCs), ILC1lc can then induce the full AA phenotype, characterized by HF-IP collapse, premature hair follicle regression (catagen), and hair follicle dystrophy.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80768-fig9-v1.tif"/></fig><p>Our study demonstrates that CD8<sup>+</sup> T cells, which have long been thought to represent the central players in AA pathobiology (<xref ref-type="bibr" rid="bib105">Pratt et al., 2017</xref>; <xref ref-type="bibr" rid="bib134">Xing et al., 2014</xref>; <xref ref-type="bibr" rid="bib26">de Jong et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Gilhar et al., 1998</xref>; <xref ref-type="bibr" rid="bib132">Wang et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Paus et al., 1993</xref>), are not the only drivers of disease (<xref ref-type="bibr" rid="bib42">Gilhar et al., 2019a</xref>; <xref ref-type="bibr" rid="bib105">Pratt et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">de Jong et al., 2018</xref>; <xref ref-type="bibr" rid="bib94">Paus et al., 1993</xref>), and are no joined not only by NK cells (<xref ref-type="bibr" rid="bib57">Ito et al., 2008</xref>; <xref ref-type="bibr" rid="bib39">Gilhar et al., 2013a</xref>) and γδT cells (<xref ref-type="bibr" rid="bib125">Uchida et al., 2020</xref>; <xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>), but also by ILC1lc lymphocytes. The study further supports the concept that the characteristic hair loss pattern we diagnose as AA phenotype, does not always represent a classical, autoantigen- and autoreactive CD8+/NKGD2 +T-cell-dependent autoimmune disease (‘autoimmune AA’ [AAA]), but can also reflect non-autoimmune pathomechanisms that may perhaps best be defined as non-autoimmune AA subtype (NAIAA) (<xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>; <xref ref-type="bibr" rid="bib97">Paus et al., 2018</xref>; <xref ref-type="fig" rid="fig9">Figure 9</xref>). In a state of prolonged HF-IP collapse and thus chronic exposure of HF-associated autoantigens to (pre-existent?) autoreactive CD8 +T cells, it is well conceivable that an AA-subtype that began as NAIAA can over time transform into the AAA-variant, thus explaining the chronic-intermittent course that is seen in so many autoimmune diseases.</p><p>The novel concept of ILC1-induced NAIAA mandates a differential, personalized management approach to future AA therapy, which tailors treatment to the specific pathobiology at hand in any given AA patient. This must now include the targeting of pathogenic, potently IFN-γ -secreting ILC1lc, at least when these are seen to be increased in lesional AA biopsies.</p><p>Although the number of ILC1lc in lesional AA skin was significantly lower than that of CD8 + cells (<xref ref-type="fig" rid="fig1">Figure 1</xref>) this does not rule out a crucial role of the cells in spontaneous AA development in patients. In fact, we demonstrate here that ILC1lc are even more potent IFN-γproducers than CD8 +T cells. Also, despite the relatively low numbers of ILC1lc, their selective tissue distribution makes them ideally localized to provide an early source of cytokines to initiate/trigger pro-inflammatory immune responses directed against distressed tissues (<xref ref-type="bibr" rid="bib131">Vivier, 2021</xref>), as documented here in our co-culture assay with ‘stressed’ human scalp HFs ex vivo.</p><p>That IL-12 and IL-18 were among the cytokines used here to facilitate ILC1lc isolation from human PBMCs is also interesting in the context of our most recent observation that local IL-12 signaling, supported by IL-18, may be involved in the early stages of AA development by stimulating IFN-γ production from resident IL-12Rß2+immune cells, eventually leading to HF-IP collapse (<xref ref-type="bibr" rid="bib28">Edelkamp, 2021</xref>). In fact, treatment with IL-12 +IL-18 of healthy HFs selectively enriches IFN-γ -inducible genes and promotes the release of IFN-γ into the medium and thus HF-IP collapse. These responses were abrogated by the co-administration of a selective TYK2 inhibitor (<xref ref-type="bibr" rid="bib28">Edelkamp, 2021</xref>), which confirms a key role of IL-12, whose receptor utilizes a TYK2 and Janus kinase 2 pair for downstream signal transduction (<xref ref-type="bibr" rid="bib127">Ullrich et al., 2020</xref>; <xref ref-type="bibr" rid="bib71">Krueger et al., 2022</xref>), These preliminary findings suggest that IL-12 is a key effector cytokine in promoting pathogenic IFN-γ secretion and HF-IP collapse. Given that ILC1 are IFN-γ producing cells (<xref ref-type="bibr" rid="bib89">Nabekura and Shibuya, 2021b</xref>; <xref ref-type="bibr" rid="bib109">Resende et al., 2017</xref>; <xref ref-type="bibr" rid="bib108">Quintino-de-Carvalho et al., 2022</xref>), our data, therefore, encourage one to dissect, next, the exact role of IL-12/IL-12R-mediated signaling in activating, attracting and/or expanding ILC1lc and in stimulating their IFN-γ secretion in the early stages of human AA pathogenesis.</p><p>An immunopathology-initiating role of ILC1lc is not unique to AA and has also been proposed in other inflammatory conditions (<xref ref-type="bibr" rid="bib64">Kim et al., 2021</xref>), including vitiligo (<xref ref-type="bibr" rid="bib124">Tulic et al., 2019</xref>), which shares some pathogenesis features with AA (<xref ref-type="bibr" rid="bib49">Harris, 2013</xref>; <xref ref-type="bibr" rid="bib123">Tomaszewska et al., 2020</xref>), inflammatory bowel disease (<xref ref-type="bibr" rid="bib81">McDonald et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Bernink et al., 2013</xref>; <xref ref-type="bibr" rid="bib121">Tang et al., 2019</xref>), lupus erythematosus (<xref ref-type="bibr" rid="bib45">Guo et al., 2019</xref>), and the aggravation of atherosclerosis (<xref ref-type="bibr" rid="bib133">Wu et al., 2018</xref>). Yet, to the best of our knowledge, the current study is the first to demonstrate that these innate immunocytes can indeed induce the full disease-mimicking immunopathology phenotype in a previously healthy human (mini-) organ. Also, abnormalities in the crosstalk between ILC1lc and gut microbiota have been observed in various diseases (<xref ref-type="bibr" rid="bib60">Jiao et al., 2020</xref>). Therefore, it is interesting to ask whether the microbial dysbiosis that has been reported in the scalp skin of AA patients (<xref ref-type="bibr" rid="bib103">Pinto et al., 2020</xref>) may activate the very few, strategically positioned perifollicular ILC1lc present in healthy human scalp skin through abnormal crosstalk with HF microbiota (<xref ref-type="bibr" rid="bib77">Lousada et al., 2021</xref>). This hypothesis can now be explored using our ex vivo and humanized AA mouse model.</p><p>Collectively, our study introduces IFN-γ -secreting ILC1lc lymphocytes as important novel players in human AA pathobiology and identifies them as new therapeutic intervention targets. Their strategic location, their capability to recognize and respond to HF distress signals such as MICA and selected chemokines, the excessive production of IFN-γ by ILC1lc, and their direct, pathogenic effects on human HFs ex vivo documented here, all support that these cells play a hitherto unappreciated role in early AA pathogenesis. Moreover, our study demonstrates that autoreactive CD8 +T cells are not indispensable for AA induction and further supports that non-autoimmune AA variants (NAIAA) (<xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>) exist and that innate/transitional immune cells play an important role in AA pathobiology.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Patients, tissue, and blood samples</title><p>For the in situ analyses we used archival paraffin-embedded biopsy specimens of human AA scalp skin lesions from the Department of Pathology, Rambam Medical Center ( fourfemales, 12–35 years, mean age 20.5±9.5; sixmales, 6–38 years, mean age 18±12). Three of these AA patients showed active hair loss of the AA universalis phenotype while the other patients showed stable hair loss patches of the multifocal AA phenotype (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>). One ten-year-old male patient had a positive family history of allergic rhinitis. AA was diagnosed both clinically and by histopathology, and none of the enrolled patients showed clinical evidence or had a personal history of other AA-associated autoimmune diseases (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>; <xref ref-type="bibr" rid="bib84">Meah et al., 2021</xref>).</p><p>Clinically healthy human skin scalp specimens were obtained from healthy volunteers undergoing cosmetic facelift surgery ( three females, 43–72 years, mean age 58±15; 5 males, 31–44 years, mean age 36±8).</p><p>The ex vivo experiments utilized scalp HFs from 20 healthy donors (13 males and seven females) without a history of AA (31–63 years, mean age 49±12).</p><p>The in vivo experiments in the humanized AA mouse model <xref ref-type="bibr" rid="bib36">Ghraieb et al., 2018</xref> used scalp skin pieces obtained from five healthy donors ( four males and one female, 34–45 years, mean age 38±5). For the ex vivo and in vivo experiments, frontotemporal human scalp skin specimens were obtained during elective cosmetic facelift procedures performed under general anesthesia, and 20 ml of autologous venous blood was drawn, both with informed written patient consent.</p><p>The study for both ex vivo and in vivo experiments was approved by the Institutional Ethics Committee of the Rambam Health Care Campus, Haifa, Israel (RMB-0182–14).</p><p>For the ex vivo experiments, frozen HFs sections were dehydrated for 40 min and incubated with acetone for 10 min at –20 °C for fixation. Slides were dehydrated for 20 min and transferred to double-distilled water following three times wash with 1xphosphate buffered saline (PBS) (pH = 7.4). Sections were blocked with suitable serum (horse/goat) for 30 min to prevent nonspecific binding and incubated at 4 °C with primary Ab overnight. Slides were incubated with an appropriate biotinylated secondary Ab (FITC-conjugated goat anti-mouse Ab, Rhodamine-conjugated goat anti-mouse IgG Ab or Alexa Fluor 488-conjugated goat anti-rabbit IgG Ab) for 30 min, following three times wash with PBS.</p><p>For the in vivo experiment, five-micrometer paraffin sections were used. Antigen <ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/topics/immunology-and-microbiology/information-retrieval">retrieval</ext-link> was for 20  min at 90 °C in a microwave. Specimens were blocked for 30  min to prevent nonspecific binding and incubated with the first antibody (Ab) overnight, followed by a wash and incubation with biotinylated 2<sup>nd</sup> Ab (Jackson ImmunoResearch, West Grove, PA), and subsequent binding with <ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/topics/medicine-and-dentistry/horseradish-peroxidase">horseradish peroxidase</ext-link>-conjugated <ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/topics/medicine-and-dentistry/streptavidin">streptavidin</ext-link>. Markers were revealed with AEC (red) (Aminoethyl <ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/topics/medicine-and-dentistry/carbazole-derivative">Carbazole</ext-link> Substrate kit). Sections were then mounted and analyzed under a light microscope.</p></sec><sec id="s4-2"><title>Histochemistry, immunohistology, and quantitative immunohistomorphometry (qIHM)</title><p>Five-micrometer paraffin sections of lesional AA biopsies and human scalp skin xenotransplants were processed for histochemistry or immunohistology. The following primary antibodies were used: anti-CD8 (Cell Marque-108M-95), anti-CD4 (DAKO-M7310), anti-HLA-A,B,C (Abcam-70328), anti-HLA-DR (Abcam-20281), anti- IFN-γ (Abcam-25101), anti- α-MSH (LSBio-C25584), anti-beta2 microglobulin (Abcam-218230), and anti-TGF-β1 (Santa Cruz-52893) (<xref ref-type="bibr" rid="bib36">Ghraieb et al., 2018</xref>; <xref ref-type="bibr" rid="bib74">Laufer Britva et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Keren et al., 2018</xref>).</p><p>Since there is no single, highly specific surface marker for ILC1 cells, triple immunostaining was performed with three sets of antibodies that are routinely used for the identification of human ILC1lc (<xref ref-type="bibr" rid="bib120">Talayero et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Hawke et al., 2020a</xref>; <xref ref-type="bibr" rid="bib51">Hawke et al., 2020b</xref>; <xref ref-type="bibr" rid="bib22">Cruz-Zárate et al., 2018</xref>): (a) NKp44+ (Bioss-YEYS3W) (<xref ref-type="bibr" rid="bib120">Talayero et al., 2016</xref>), CD103+ (eBioscience 1401038–82) (<xref ref-type="bibr" rid="bib51">Hawke et al., 2020b</xref>) and T-bet- (Santa Cruz-H3112) <xref ref-type="bibr" rid="bib22">Cruz-Zárate et al., 2018</xref>; (b) c-KIT- (DAKO-MA512944) (<xref ref-type="bibr" rid="bib90">Nagasawa et al., 2019</xref>), CD49a+ (R&amp;D systems-AF5676) (<xref ref-type="bibr" rid="bib18">Colonna, 2018</xref>) and EOMES+ (ThermoFisher-14-4877-82); and (c) CD49a+ (R&amp;D systems), EOMES+ (ThermoFisher-14-4877-82) and NKG2D+ (Novus-5c6) (<xref ref-type="bibr" rid="bib26">de Jong et al., 2018</xref>). Skin-infiltrating CD8 +NKG2D+T cells were double-immunostained by NKG2D (Novus-5c6)/CD8 (Cell Marque-108M-95) (<xref ref-type="bibr" rid="bib26">de Jong et al., 2018</xref>). For negative control, the primary antibody was replaced with non-specific IgG1 and IgG2 isotype control.</p><p>Hematoxylin and eosin (H&amp;E) staining was performed on cryo- or paraffin sections as previously described (<xref ref-type="bibr" rid="bib62">Keren et al., 2018</xref>). For the ex vivo experiments, HFs cryosections were dehydrated for 40 min and fixed with acetone for 10 min at –20 °C (<xref ref-type="bibr" rid="bib36">Ghraieb et al., 2018</xref>; <xref ref-type="bibr" rid="bib74">Laufer Britva et al., 2020</xref>; <xref ref-type="bibr" rid="bib61">Keren et al., 2015</xref>).</p><p>The following primary antibodies were used for immunohistochemistry (IHC) or immunofluorescence microscopy (IF) of key HF immune privilege markers (<xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>; <xref ref-type="bibr" rid="bib96">Paus et al., 2005</xref>) anti-HLA-A,B,C (Abcam-70328)/ anti-HLA-DR (Abcam-20281)/anti-MICA(Santa Cruz- 20931)/anti-CD1d (Abcam-11076)/anti- α-MSH (LSBio-C25584)/anti-beta2 microglobulin (Abcam-218230) and anti-TGF-β1(Santa Cruz-52893).</p><p>The immunoreactivity patterns were assessed in standardized, well-defined reference areas by quantitative immunohistomorphoemtry (qIHM) by experienced, blinded observers, following our standard protocols for evaluating human HF immunology read-outs (<xref ref-type="bibr" rid="bib8">Bertolini et al., 2014</xref>; <xref ref-type="bibr" rid="bib9">Bertolini et al., 2016</xref>; <xref ref-type="bibr" rid="bib15">Christoph et al., 2000</xref>; <xref ref-type="bibr" rid="bib48">Harries et al., 2013</xref>; <xref ref-type="bibr" rid="bib46">Hardman-Smart et al., 2020</xref>), counting at least three reference areas each on three non-consecutive sections, presented randomly to the blinded observer(s). Specifically, immunoreactive cells around and within the <ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/topics/immunology-and-microbiology/hair-follicle">HFs</ext-link> were counted in an area of 0.66  mm<sup>2</sup>.</p><p>For HLA-A,B,C, HLA-DR, MICA, CD1d, α-MSH, beta2 microglobulin, and TGF-β1 image analysis was performed using Image J software. Protein expression was measured by calculating the percentage of staining coverage within the analyzed area.</p><p>Masson-Fontana staining (Abcam) was performed as described by us (<xref ref-type="bibr" rid="bib74">Laufer Britva et al., 2020</xref>; <xref ref-type="bibr" rid="bib107">Purba et al., 2016</xref>). Briefly, five-micrometer paraffin sections were deparaffinized and hydrated in distilled water. Slides were placed in mixed ammoniacal silver solution in a 58–60°C water bath and allowed adequate time for the temperature to equilibrate. Slides were then placed in the warmed ammoniacal silver solution for 30–60 min or until the tissue section became yellowish/brown in color. Counterstaining was performed with Nuclear Fast Red Solution for 5 min.</p></sec><sec id="s4-3"><title>TUNEL analysis</title><p>Apoptotic cells were evaluated using a commercial TUNEL kit (Roche) with anti-digoxigenin fluorescein labeling and according to the manufacturer’s protocol. Ki-67 (Invitrogen) was visualized using Alexa Flour 594-conjugated goat anti-mouse (Jackson, 115-585-062). Sections were counterstained by DAPI (Thermo Fisher Scientific). Staining was visualized using a confocal Microscope - Zeiss LSM 700. Quantification was performed as previously described (<xref ref-type="bibr" rid="bib100">Peters et al., 2006</xref>).</p></sec><sec id="s4-4"><title>Immunohistology</title><p>Slides were photographed using immunofluorescence confocal microscopy and compared systematically by qIHM in standardized, defined tissue compartments. Mouse skin served as a negative control. Three non-consecutive sections were analyzed per patient.</p></sec><sec id="s4-5"><title>Isolation, characterization, and culture of circulating ILC1lc, ILC2, ILC3, and CD8+/NKG2D+ cells</title><p>ILC2 and ILC3 cells were used as negative controls, while CD8+/NKG2D+ cells were used as a positive control to evaluate the ILC1lc cytotoxic effects on HFs.</p><p>The cells were cultured and induced to expand, as we have previously described (<xref ref-type="bibr" rid="bib62">Keren et al., 2018</xref>). The isolation and characterization of ILC1lc, ILC2, and ILC3 cells by FACS cell sorting or MACS were performed as we previously described (<xref ref-type="bibr" rid="bib62">Keren et al., 2018</xref>; <xref ref-type="bibr" rid="bib86">Mjösberg et al., 2011</xref>; <xref ref-type="bibr" rid="bib87">Mora-Velandia et al., 2017</xref>; <xref ref-type="bibr" rid="bib21">Creyns et al., 2020</xref>).</p><p>Autologous human PBMCs were isolated from heparinized whole blood from healthy donors by Lymphoprep density gradient centrifugation (Alere Technologies, Norway). Cells were frozen for further assays (70% FBS, 20% RPMI1640, and 10% DMSO) or cultured at a seeding density of 3 × 10<sup>6</sup> cells/ml in 24 wells plate with medium (RPMI 1640, 10% human AB serum, 1% penicillin-streptomycin antibiotics, 2 mML glutamine) in the presence of different cytokines for cells expansion.</p><p>The following components are required for the expansion of various immune cell populations:</p><list list-type="simple"><list-item><p>ILC1lc (<xref ref-type="bibr" rid="bib115">Silver et al., 2016</xref>): IL-18(1 µg/1 ml) (CYT-269(A), IL-33) (1.5 µg/5 ml) (BLG-581802), IL-12 (1.5 µg/5 ml) (BLG-573002).</p></list-item><list-item><p>ILC2 (<xref ref-type="bibr" rid="bib21">Creyns et al., 2020</xref>): IL-7 (10 ng/ ml) (BLG-581904), IL-25 (100 ng/ml) (C792-50), IL-2 (50 ng/m) (Prospec-Cyt-209-b).</p></list-item><list-item><p>ILC3 (<xref ref-type="bibr" rid="bib62">Keren et al., 2018</xref>): AHR (200 nM) (BML-GR2060100), IL-2 (100 U/mL).</p></list-item><list-item><p>CD8 +NKG2D+ (<xref ref-type="bibr" rid="bib39">Gilhar et al., 2013a</xref>): IL-2 (100 U/ml).</p></list-item><list-item><p>PHA (<xref ref-type="bibr" rid="bib39">Gilhar et al., 2013a</xref>): PHA (10 µg/ml) (Sigma-C1668).</p></list-item></list><p>On days three and five, half of the medium was either frozen for further analysis or discarded and replaced with fresh medium containing cytokines. After seven days, cells were sorted by FACS Aria (FACSAria III Cell Sorter, BD Biosciences, USA) and in the case of ILC3 further enriched by MACS for negative selection of CD3 + cells (see <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p></sec><sec id="s4-6"><title>Flow cytometry sorting for ILC1lc, ILC2, and CD8+/NKG2D+ cells</title><p>Cells were cultured for one week, collected, and washed with PBS containing 1% BSA and 2% PSN. Surface cells were stained with antibodies to the PE-conjugated lineage cocktail that includes antibodies against CD1a (BLG-300105), CD3 (BLG-300–307), CD14 (BLG-367103), CD19 (BLG-302207), CD34 (BLG-343605), CD123 (BLG-306005), CD11c (BLG-301605), BDCA2 (BLG-354203), FcεR1α (BLG-334609), TCRαβ (BLG-306707), TCRγδ (BLG-331209), CD56 (BLG- 362565) (<xref ref-type="bibr" rid="bib51">Hawke et al., 2020b</xref>).</p><p>Following gating on lineage, cell population cells were sorted as follows:</p><p>ILC1lc – APC-conjugated-CD127+ (BLG-351315), PE/CY7-conjugated-CD161+ (BLG-339917), and FITC-conjugated-NKp44 + (SC-53597), Brilliant Violet 421TM anti-human CD117- (c-KIT) (BLG-313215) and APC/CY7-conjugated-CRTH2- (BLG-350113). (Santa Cruz H3112) (<xref ref-type="bibr" rid="bib120">Talayero et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Hawke et al., 2020a</xref>).</p><p>ILC2 cells – APC-conjugated-CD127+ (BLG-351315), PE/CY7-conjugated-CD161+ (BLG-339917), Brilliant Violet 421TM anti-human CD117+ (c-KIT) (BLG-313215) and APC/CY7-conjugated-CRTH2+ (BLG-350113) (<xref ref-type="bibr" rid="bib22">Cruz-Zárate et al., 2018</xref>; <xref ref-type="bibr" rid="bib90">Nagasawa et al., 2019</xref>).</p><p>CD8+/NKG2D+ cells – CD8 (Cell Marque-108M-95)/NKG2D(Novus-5c6) (<xref ref-type="bibr" rid="bib57">Ito et al., 2008</xref>). The cells were sorted using a FACS Aria instrument with software (BD Biosciences). The sorted cells were collected in a tube with a medium enriched with 20% human serum. Afterward, the cells were centrifuged, suspended, counted, and co-cultured with HFs or used for ELISA assay.</p><p>Compensation was done using Comp-Beads (BDTM Biosciences) and data were analyzed using FlowJo software.</p></sec><sec id="s4-7"><title>Magnetic isolation of ILC3 subsets</title><p>Separation was performed using anti-CD3 antibodies conjugated to ferromagnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and directed through a cell separation column containing a magnetic field (Miltenyi Biotec). For the purification of ILC3s, CD3−sorted cells were collected and stained with anti-NKp44-PE conjugated to ferromagnetic microbeads (Miltenyi Biotec) and directed through a cell separation column containing a magnetic field (<xref ref-type="bibr" rid="bib62">Keren et al., 2018</xref>).</p><p>Finally, cells were co-cultured with autologous HFs ex vivo (see below) or used for different assays (<xref ref-type="bibr" rid="bib62">Keren et al., 2018</xref>).</p></sec><sec id="s4-8"><title>Co-culture of autologous ILC1lc with ‘stressed’ human scalp hair follicles ex vivo</title><p>Experimental induction of HF-IP collapse by IFN-γ is the standard ex vivo-assay system for interrogating key elements of AA-related human HF immunopathology (<xref ref-type="bibr" rid="bib54">Ito et al., 2004</xref>; <xref ref-type="bibr" rid="bib9">Bertolini et al., 2016</xref>; <xref ref-type="bibr" rid="bib66">Kinori et al., 2012</xref>). We have recently complemented this assay by co-culturing key immunocytes in AA pathogenesis (CD8 +T cells, γδTCs) directly with organ-cultured human scalp HFs ex vivo (<xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>).</p><p>For this, healthy human anagen scalp HFs were collected and microdissected as described (<xref ref-type="bibr" rid="bib54">Ito et al., 2004</xref>), and HFs were placed individually into a 96-well plate slot with 100 µl supplemented medium (William’s E plus 1% penicillin-streptomycin antibiotics, 1% L-glutamine (Invitrogen-Gibco)), 0.01% hydrocortisone (Sigma-Aldrich) and 0.01% insulin (Sigma-Aldrich) (<xref ref-type="bibr" rid="bib73">Langan et al., 2015</xref>).</p><p>As we have documented in detail elsewhere (<xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>), on day 1 after initiation of organ culture, the HFs are markedly, but transiently stressed by the trauma of microdissection and the transfer to a harsh, hyperoxygenated ex vivo culture environment. This results in significantly increased LDH activity release and up-regulation of CXCL12 and CXCL10 expression as well as in a transient, partial weakening of the HFs physiological immune privilege. The latter was evidenced by increased protein expression of MHC class Ia, β2-microglobulin, and MICA/B but no change in the expression of IP guardians such as αMSH and TGFβ2. As reported before, all these ‘HF stress’ indicators normalize on day 3 of organ culture (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) (Taken from: <xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>). Thus, due to their expression of NKG2D ligands (MICA/B) CXCL12 and CXCL10 secretion, and transiently weakened HF immune privilege, the stressed (day 1) HFs can attract and interact with immune cells expressing NKG2D receptors and are primed to elicit anti-HF immune responses ex vivo (<xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>).</p><p>Therefore, organ culture-stressed day 1 HFs (1HF/well) were co-cultured in supplemented William’s E medium from day 1 until day 6 with one of five different immune cell populations: (1) ILC1lc (100 µl/600 cells per well), either alone or in combination with anti- IFN-γ antibody (10 µg/ml, R&amp;D Systems, MAB285) or NKG2D neutralizing antibody (5 µg/ml, R&amp;D Systems, MAB139-100); ILC1lc demonstrated cytotoxic effect on HFs with 600 cells per well, while (2) CD8/NKG2D cells demonstrated similar effect only with 100 µl/3500 cells per well. Therefore, 100 µl/3500 per well was used for the following control groups: (3) ILC2s cells; (4) ILC3s, or (5) PHA cultured PBMCs.</p><p>The medium was not replaced in order to avoid losing any immunocytes. Basic HF biology read-out parameters were assessed by evaluating the Ki-67/TUNEL ratio, values of LDH release, HF pigmentation, and hair shaft production in situ, all of which indicated that the HFs did not suffer major damage after 6 days of organ culture. At the end of the experimentation, the HFs were photo-documented and cryopreserved in optimal cutting temperature (OCT) blocks. Cytokine release into the culture medium by ELISA was analyzed as previously described (<xref ref-type="bibr" rid="bib139">Zook and Kee, 2016</xref>).</p></sec><sec id="s4-9"><title>Flow cytometry analysis for characterization of ILC1lc</title><p>PBMCs were isolated from healthy blood via centrifugation on ficol/Hypaque and cultured for seven days in a medium composed of RPMI 1640, 10% human AB serum, 1% L-glutamine, and 1% PSN. The medium was changed as needed.</p><p>Seven days later, 6 hr prior to FACS staining, cells were then collected (1–1.5 × 10<sup>6</sup> cells/tube), centrifuged at 1200 RPM for 5 min, and washed twice in staining buffer (1 ml of 1% Bovine Serum Albumin [BSA] in 1 x sterile PBS). First antibodies (as described above, flow cytometry sorting) were used at a concentration of 2.5 μl per 1 × 10<sup>6</sup> cells.</p><p>Cells were incubated for 25 min at room temperature in the dark. All tubes were washed once with 1 ml staining buffer, then Fixation/Permeabilization solution (250 μl) was added and cells were incubated for 20 min at 4 °C. Cell permeability was performed using 1 × BD Perm/Wash buffer, intra-cellular antibody mixtures (50 μl/Brilliant Violet 605TM anti-T-bet BLG 644817), Eomes-conjugated-PerCP-eFluor 710 (Dan11mag), IRF8 (sc-365042), Perforin (BLG-308119), and INF-γ-conjugated- PE/VIO-770 (Miltenyi Biotec 130-109-313), CD49a-APC-Vio770 (Miltenyi Biotec 130-101-324),FITC anti-human CD49b (BLG 359305), APC anti-human NKp80 (BLG 346707), BV421 anti-human CXCR6 (BLG 356013) and APC/Fire 810 anti-human CD16 (BLG 302073) and BV421 anti-human RORγt were added and incubated for 30 min at room temperature in the dark, cells were then washed twice with 1xBD Perm/Wash buffer (BD Cytofix/CytopermTM Fixation/Permeabilization Kit).</p><p>All cell samples were detected by FACS Calibur Flow Cytometer (Benton Dickinson) using Cell Quest software, and the acquired data were further analyzed using FlowJo 5.7.2 (Tree Star).</p></sec><sec id="s4-10"><title>Cytokine analyses in culture medium by ELISA</title><p>Production of IFN-γ by ILC1lc from healthy volunteers was analyzed using <ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/topics/medicine-and-dentistry/enzyme-linked-immunosorbent-assay">ELISA</ext-link>. ILC2, ILC3, and PBMCs/PHA were analyzed as negative controls. CD8+/NKG2D+ cells were analyzed as a positive control.</p><p>The concentration of IFN-γ was determined in the supernatant of 6 × 10<sup>6</sup> cells from each donor (six healthy donors) using the Human IFN-γ ELISA deluxe set (BioLegend) according to the manufacturer’s protocol.</p></sec><sec id="s4-11"><title>Analysis of HF cytotoxicity, catagen induction, and immune privilege collapse</title><p>As an indication of HF cytotoxicity, LDH release into the supernatants was quantified by colorimetric assay using the Cytotoxicity Detection kit Plus (Roche), which measures the conversion of tetrazolium salt in formazan, a water-soluble dye with a broad absorption maximum at approximately 500 nm (<xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref>; <xref ref-type="bibr" rid="bib78">Lu et al., 2007</xref>; <xref ref-type="bibr" rid="bib104">Poeggeler et al., 2010</xref>). Medium with/without HFs was cultured with PBMCs/PHA, CD8+/NKG2D+, ILC1lc, ILC2, or ILC3 cells for three days. Formazan absorbance was measured for each condition that correlates with cell cytotoxicity. Anagen and catagen HFs were visualized and differentiated under Nikon Diaphot inverted binocular and thereafter qualitative morphological and quantitative morphometric assessments were analyzed as previously described (<xref ref-type="bibr" rid="bib67">Kloepper et al., 2010</xref>). IHC staining was performed to test all hallmarks of AA in order to probe whether co-culture with ILC1lc induced abnormal HLA-DR, HLA-ABC, CD1d, ß2-microglobulin, and MICA protein expression in the proximal HF epithelium and/or downregulated the key guardians of HF immune privilege, TGF-β1, and α-MSH (<xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Ito et al., 2004</xref>), using the qIHM method described above.</p><p>In order to check whether ILC1lc affects HFs via IFN-γoverproduction or via activation of the NKG2D-NKG2DL axis following excessive MICA expression by stressed HFs, neutralizing anti- IFN-γ (10 µg/ml, R&amp;D Systems, MAB285) or function-blocking NKG2D (5 µg/ml, R&amp;D Systems, MAB139-100) antibodies, were added to the HFs co-cultured with ILC1lc (defined as CD49a+CD49b- <xref ref-type="bibr" rid="bib128">Verma et al., 2020</xref>), lin-/CD127+/CD117-/CRTH2-, and T-bet<sup>lo</sup>/ Eomes<sup>hi</sup> (<xref ref-type="bibr" rid="bib5">Bennstein et al., 2020</xref>; <xref ref-type="bibr" rid="bib69">Krabbendam et al., 2021</xref>).</p></sec><sec id="s4-12"><title>Humanized AA mouse model</title><p>For the humanized AA mouse model (<xref ref-type="bibr" rid="bib39">Gilhar et al., 2013a</xref>; <xref ref-type="bibr" rid="bib36">Ghraieb et al., 2018</xref>; <xref ref-type="bibr" rid="bib41">Gilhar et al., 2016</xref>), full-thickness biopsies were taken from healthy donors undergoing plastic surgery on the scalp. Biopsies from each donor were dissected horizontally to generate pieces with a diameter of 3  mm. Three 3  mm pieces were grafted orthotopically into the subcutaneous layer of each SCID/beige mice as previously described (<xref ref-type="bibr" rid="bib39">Gilhar et al., 2013a</xref>; <xref ref-type="bibr" rid="bib36">Ghraieb et al., 2018</xref>; <xref ref-type="bibr" rid="bib40">Gilhar et al., 2013b</xref>). Seven days after surgery, mice were treated with Minoxi-5 (hair regrowth treatment for men containing 5% Minoxidil active ingredient) by spreading it on the grafts twice a day until we received optimal expedited hair growth (period of two months). The topical minoxidil application is not required for hair regrowth induction after the initial post-transplantion hair shaft shedding, but only accelerates it. This application is discontinued before the ILC1lc injection (<xref ref-type="bibr" rid="bib39">Gilhar et al., 2013a</xref>). Since the immune cell infiltrate in AA attacks only hair follicles in anagen (<xref ref-type="bibr" rid="bib38">Gilhar et al., 2012</xref>), it is critical that the majority of xenotransplant HFs are in anagen at the time the immune cells are injected. Topical minoxidil pretreatment increases the likelihood that this is the case (<xref ref-type="bibr" rid="bib106">Price et al., 1999</xref>; <xref ref-type="bibr" rid="bib118">Suchonwanit et al., 2019</xref>). Moreover, we have recently demonstrated that 5% minoxidil does indeed significantly stimulate hair regrowth in human androgenetic alopecia scalp skin transplanted onto SCID/beige mice (<xref ref-type="bibr" rid="bib44">Gilhar et al., 2022</xref>). It also deserves mentioning that topical minoxidil reduces the degranulation of – hair growth-modulatory! (<xref ref-type="bibr" rid="bib95">Paus et al., 1994</xref>) - perifollicular mast cells in the skin of mice, namely under conditions of perceived stress (<xref ref-type="bibr" rid="bib2">Arck et al., 2003</xref>), while excessive degranulation of perifollicular mast cells is an important feature of lesional human AA skin (<xref ref-type="bibr" rid="bib8">Bertolini et al., 2014</xref>). Therefore, this pretreatment likely also helps to reestablish perifollicular mast cell homeostasis after the stress of xenotransplantation. In the current study, 18 female SCID/beige mice (C.B-17/IcrHsd-scid-bg) (Harlan Laboratories Ltd., Jerusalem, Israel) were used at 2–3 months of age and were housed in the pathogen-free animal facility of the Rappaport Faculty of Medicine, Technion – Israel Institute of Technology. Animal care and research protocols were in accordance with institutional guidelines and were approved by the Institutional Committee on Animal Use (17-08-115-IL).</p></sec><sec id="s4-13"><title>Culture of Peripheral blood mononuclear cells</title><p>PBMCs were isolated from healthy donors without any history of AA or other autoimmune diseases by centrifugation on Ficoll/Hypaque (Pharmacia, Amersham Pharmacia Biotech, Uppsala, Sweden) (<xref ref-type="bibr" rid="bib36">Ghraieb et al., 2018</xref>). The PBMCs were then cultured for 14 days with 100 U IL-2 per ml (Pepro Tech Inc, Rocky Hill, NJ) in a medium composed of RPMI 1640, 10% human AB serum (Sigma, St. Louis, MO), 1% glutamine, 1% antibiotics (media components; Biological Industries, Kibbutz Beit Haemeck, Israel). Medium was changed as needed. The cultured cells defined as enriched CD8/NKG2D according to our previous publication (<xref ref-type="bibr" rid="bib36">Ghraieb et al., 2018</xref>), were injected intradermally into human explants on beige-SCID mice.</p></sec><sec id="s4-14"><title>Study design</title><p>Two sets of experiments were performed: In the first set, the mice were divided randomly into three groups on day 89 after scalp skin transplantation and treated as described in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p><p>The second set of experiments was performed to eliminate the confounding influence of resident human T-cells present in the human scalp skin xenotransplants. To this end, anti-CD3/OKT3 antibodies (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) were injected into xenotransplants treated with either autologous ILC1lc or autologous enriched CD8+/NKG2D+ cells. For both sets of experiments, the mice were sacrificed and skin biopsies were taken for analysis on day 45 after immunocyte injection.</p></sec><sec id="s4-15"><title>Statistical analysis</title><p>Data are presented as the mean ± standard error of mean (SEM) or fold change of mean ± SEM; p values of &lt;0.05 were regarded as significant.</p><p>Gaussian distribution of the data was analyzed using Shapiro-Wilk test. Significant differences were analyzed using either unpaired Student′s t-test (comparison between one set of data), or One Way ANOVA (comparison between multiple sets of data) for parametric data, or Mann–Whitney test (comparison between one set of data and sham or vehicle) for nonparametric data or Kruskal–Wallis test, and Dunn’s test (comparison between multiple sets of data). The n (e.g. number of donors, tissue sections, or microscopic fields) used for each individual data reported here is listed in corresponding figure legend.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>is affiliated with CUTANEON. The author has no financial interests regarding the research presented here to declare</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con2"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con4"><p>Methodology</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Supervision, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The informed consent was obtained. The study for both ex vivo and in vivo experiments was approved by the Institutional Ethics Committee of the Rambam Health Care Campus, Haifa, Israel (RMB-0182-14).</p></fn><fn fn-type="other"><p>This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Technion - Israel Institute of Technology. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#17-08-115-IL) of the Technion - Israel Institute of Technology. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Technion - Israel Institute of Technology (Permit Number: 17-08-115-IL). All surgery was performed under isoflurane anesthesia, and every effort was made to minimize suffering.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Microdissected, organ-cultured HFs are ‘stressed’ on day 1, but become equilibrated on day 3, as assessed by the listed objective read-out parameters that indicate a temporarily weakened HF immune privilege and HF damage as well as MICA overexpression on day 1.</title><p>Instead, the expression of HF immune privilege guardians (αMSH, TGFß2) (<xref ref-type="bibr" rid="bib10">Bertolini et al., 2020</xref>) is preserved. This makes freshly microdissected healthy human scalp HFs one day after initiation of HF organ culture optimally suited as ‘stressed’ human (mini-) organs that strongly express the NKG2D-activating ‘danger’ ‘signal,’ MICA, which also is overexpressed by human AA HFs (<xref ref-type="bibr" rid="bib75">Li et al., 2016</xref>) (these data are repeated from <xref ref-type="bibr" rid="bib126">Uchida et al., 2021</xref> to illustrate the HF distress/partial IP collapse of microdissected human scalp HFs one day 1 after initiation of organ culture).</p></caption><media xlink:href="elife-80768-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Route of injections, volume, and the number of immune cells injected into the normal healthy human xenotransplants.</title></caption><media xlink:href="elife-80768-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-80768-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Source Data files have been provided for Figures 1-8 and figures supplement 2,3,4.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The study was supported in part by the Technion Research &amp; Development Foundation (to AG), a Frost Endowed Scholarship from the University of Miami Dermatology Department (to RP), and a basic research grant from Monasterium Laboratory GmbH, Münster (to AG &amp; CR).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albini</surname><given-names>A</given-names></name><name><surname>Gallazzi</surname><given-names>M</given-names></name><name><surname>Palano</surname><given-names>MT</given-names></name><name><surname>Carlini</surname><given-names>V</given-names></name><name><surname>Ricotta</surname><given-names>R</given-names></name><name><surname>Bruno</surname><given-names>A</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>WG</given-names></name><name><surname>Noonan</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TIMP1 and TIMP2 downregulate TGFβ induced decidual-like phenotype in natural killer cells</article-title><source>Cancers</source><volume>13</volume><elocation-id>4955</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13194955</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arck</surname><given-names>PC</given-names></name><name><surname>Handjiski</surname><given-names>B</given-names></name><name><surname>Peters</surname><given-names>EMJ</given-names></name><name><surname>Hagen</surname><given-names>E</given-names></name><name><surname>Klapp</surname><given-names>BF</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Topical minoxidil counteracts stress-induced hair growth inhibition in mice</article-title><source>Experimental Dermatology</source><volume>12</volume><fpage>580</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0625.2003.00028.x</pub-id><pub-id pub-id-type="pmid">14705798</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artis</surname><given-names>D</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The biology of innate lymphoid cells</article-title><source>Nature</source><volume>517</volume><fpage>293</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1038/nature14189</pub-id><pub-id pub-id-type="pmid">25592534</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babic</surname><given-names>M</given-names></name><name><surname>Romagnani</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The role of natural killer group 2, member D in chronic inflammation and autoimmunity</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>1219</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.01219</pub-id><pub-id pub-id-type="pmid">29910814</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennstein</surname><given-names>SB</given-names></name><name><surname>Weinhold</surname><given-names>S</given-names></name><name><surname>Manser</surname><given-names>AR</given-names></name><name><surname>Scherenschlich</surname><given-names>N</given-names></name><name><surname>Noll</surname><given-names>A</given-names></name><name><surname>Raba</surname><given-names>K</given-names></name><name><surname>Kögler</surname><given-names>G</given-names></name><name><surname>Walter</surname><given-names>L</given-names></name><name><surname>Uhrberg</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Umbilical cord blood-derived ILC1-like cells constitute a novel precursor for mature KIR+NKG2A- NK cells</article-title><source>eLife</source><volume>9</volume><elocation-id>e55232</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.55232</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernink</surname><given-names>JH</given-names></name><name><surname>Peters</surname><given-names>CP</given-names></name><name><surname>Munneke</surname><given-names>M</given-names></name><name><surname>te Velde</surname><given-names>AA</given-names></name><name><surname>Meijer</surname><given-names>SL</given-names></name><name><surname>Weijer</surname><given-names>K</given-names></name><name><surname>Hreggvidsdottir</surname><given-names>HS</given-names></name><name><surname>Heinsbroek</surname><given-names>SE</given-names></name><name><surname>Legrand</surname><given-names>N</given-names></name><name><surname>Buskens</surname><given-names>CJ</given-names></name><name><surname>Bemelman</surname><given-names>WA</given-names></name><name><surname>Mjösberg</surname><given-names>JM</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues</article-title><source>Nature Immunology</source><volume>14</volume><fpage>221</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1038/ni.2534</pub-id><pub-id pub-id-type="pmid">23334791</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernink</surname><given-names>JH</given-names></name><name><surname>Mjösberg</surname><given-names>J</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Human ILC1: to be or not to be</article-title><source>Immunity</source><volume>46</volume><fpage>756</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.05.001</pub-id><pub-id pub-id-type="pmid">28514676</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolini</surname><given-names>M</given-names></name><name><surname>Zilio</surname><given-names>F</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Kleditzsch</surname><given-names>P</given-names></name><name><surname>Emelianov</surname><given-names>VE</given-names></name><name><surname>Gilhar</surname><given-names>A</given-names></name><name><surname>Keren</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>KC</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Funk</surname><given-names>W</given-names></name><name><surname>McElwee</surname><given-names>K</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e94260</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0094260</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolini</surname><given-names>M</given-names></name><name><surname>Pretzlaff</surname><given-names>M</given-names></name><name><surname>Sulk</surname><given-names>M</given-names></name><name><surname>Bähr</surname><given-names>M</given-names></name><name><surname>Gherardini</surname><given-names>J</given-names></name><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Reibelt</surname><given-names>M</given-names></name><name><surname>Kinori</surname><given-names>M</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Bíró</surname><given-names>T</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Vasoactive intestinal peptide, whose receptor-mediated signalling may be defective in alopecia areata, provides protection from hair follicle immune privilege collapse</article-title><source>The British Journal of Dermatology</source><volume>175</volume><fpage>531</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1111/bjd.14645</pub-id><pub-id pub-id-type="pmid">27059672</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolini</surname><given-names>M</given-names></name><name><surname>McElwee</surname><given-names>K</given-names></name><name><surname>Gilhar</surname><given-names>A</given-names></name><name><surname>Bulfone-Paus</surname><given-names>S</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hair follicle immune privilege and its collapse in alopecia areata</article-title><source>Experimental Dermatology</source><volume>29</volume><fpage>703</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1111/exd.14155</pub-id><pub-id pub-id-type="pmid">32682334</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodó</surname><given-names>E</given-names></name><name><surname>Tobin</surname><given-names>DJ</given-names></name><name><surname>Kamenisch</surname><given-names>Y</given-names></name><name><surname>Bíró</surname><given-names>T</given-names></name><name><surname>Berneburg</surname><given-names>M</given-names></name><name><surname>Funk</surname><given-names>W</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Dissecting the impact of chemotherapy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy</article-title><source>Am J Pathol</source><volume>171</volume><fpage>1153</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2007.061164</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brownlie</surname><given-names>D</given-names></name><name><surname>Scharenberg</surname><given-names>M</given-names></name><name><surname>Mold</surname><given-names>JE</given-names></name><name><surname>Hård</surname><given-names>J</given-names></name><name><surname>Kekäläinen</surname><given-names>E</given-names></name><name><surname>Buggert</surname><given-names>M</given-names></name><name><surname>Nguyen</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>JN</given-names></name><name><surname>Al-Ameri</surname><given-names>M</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name><name><surname>Marquardt</surname><given-names>N</given-names></name><name><surname>Michaëlsson</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Expansions of adaptive-like NK cells with a tissue-resident phenotype in human lung and blood</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2016580118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2016580118</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Gamini</surname><given-names>R</given-names></name><name><surname>Sécca</surname><given-names>C</given-names></name><name><surname>Collins</surname><given-names>PL</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Peng</surname><given-names>V</given-names></name><name><surname>Robinette</surname><given-names>ML</given-names></name><name><surname>Schettini</surname><given-names>J</given-names></name><name><surname>Zaitsev</surname><given-names>K</given-names></name><name><surname>Gordon</surname><given-names>W</given-names></name><name><surname>Bando</surname><given-names>JK</given-names></name><name><surname>Yomogida</surname><given-names>K</given-names></name><name><surname>Cortez</surname><given-names>V</given-names></name><name><surname>Fronick</surname><given-names>C</given-names></name><name><surname>Fulton</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>LL</given-names></name><name><surname>Gilfillan</surname><given-names>S</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Shan</surname><given-names>L</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name><name><surname>Bowman</surname><given-names>M</given-names></name><name><surname>Oltz</surname><given-names>EM</given-names></name><name><surname>Jelinsky</surname><given-names>SA</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Subsets of ILC3-ILC1-like cells generate a diversity spectrum of innate lymphoid cells in human mucosal tissues</article-title><source>Nature Immunology</source><volume>20</volume><fpage>980</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0425-y</pub-id><pub-id pub-id-type="pmid">31209406</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gui</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Ju</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Yin</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Interplay between liver type 1 innate lymphoid cells and NK cells drives the development of alcoholic steatohepatitis</article-title><source>Cell Mol Gastroenterol Hepatol</source><volume>15</volume><fpage>261</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2022.09.010</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christoph</surname><given-names>T</given-names></name><name><surname>Müller-Röver</surname><given-names>S</given-names></name><name><surname>Audring</surname><given-names>H</given-names></name><name><surname>Tobin</surname><given-names>DJ</given-names></name><name><surname>Hermes</surname><given-names>B</given-names></name><name><surname>Cotsarelis</surname><given-names>G</given-names></name><name><surname>Rückert</surname><given-names>R</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The human hair follicle immune system: cellular composition and immune privilege</article-title><source>The British Journal of Dermatology</source><volume>142</volume><fpage>862</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2133.2000.03464.x</pub-id><pub-id pub-id-type="pmid">10809841</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clottu</surname><given-names>AS</given-names></name><name><surname>Humbel</surname><given-names>M</given-names></name><name><surname>Fluder</surname><given-names>N</given-names></name><name><surname>Karampetsou</surname><given-names>MP</given-names></name><name><surname>Comte</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Innate lymphoid cells in autoimmune diseases</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>789788</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.789788</pub-id><pub-id pub-id-type="pmid">35069567</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>A</given-names></name><name><surname>Rothman</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Reiner</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Eomesodermin and T-bet mark developmentally distinct human natural killer cells</article-title><source>JCI Insight</source><volume>2</volume><elocation-id>e90063</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.90063</pub-id><pub-id pub-id-type="pmid">28289707</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Innate lymphoid cells: diversity, plasticity, and unique functions in immunity</article-title><source>Immunity</source><volume>48</volume><fpage>1104</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.05.013</pub-id><pub-id pub-id-type="pmid">29924976</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conlon</surname><given-names>TM</given-names></name><name><surname>Knolle</surname><given-names>PA</given-names></name><name><surname>Yildirim</surname><given-names>AÖ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Local tissue development of type 1 innate lymphoid cells: guided by interferon-gamma</article-title><source>Signal Transduction and Targeted Therapy</source><volume>6</volume><elocation-id>287</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-021-00705-1</pub-id><pub-id pub-id-type="pmid">34326313</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connell</surname><given-names>SJ</given-names></name><name><surname>Jabbari</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The current state of knowledge of the immune ecosystem in alopecia areata</article-title><source>Autoimmunity Reviews</source><volume>21</volume><elocation-id>103061</elocation-id><pub-id pub-id-type="doi">10.1016/j.autrev.2022.103061</pub-id><pub-id pub-id-type="pmid">35151885</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creyns</surname><given-names>B</given-names></name><name><surname>Jacobs</surname><given-names>I</given-names></name><name><surname>Verstockt</surname><given-names>B</given-names></name><name><surname>Cremer</surname><given-names>J</given-names></name><name><surname>Ballet</surname><given-names>V</given-names></name><name><surname>Vandecasteele</surname><given-names>R</given-names></name><name><surname>Vanuytsel</surname><given-names>T</given-names></name><name><surname>Ferrante</surname><given-names>M</given-names></name><name><surname>Vermeire</surname><given-names>S</given-names></name><name><surname>Van Assche</surname><given-names>G</given-names></name><name><surname>Ceuppens</surname><given-names>JL</given-names></name><name><surname>Breynaert</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Biological therapy in inflammatory bowel disease patients partly restores intestinal innate lymphoid cell subtype equilibrium</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>1847</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01847</pub-id><pub-id pub-id-type="pmid">32983101</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruz-Zárate</surname><given-names>D</given-names></name><name><surname>Cabrera-Rivera</surname><given-names>GL</given-names></name><name><surname>Ruiz-Sánchez</surname><given-names>BP</given-names></name><name><surname>Serafín-López</surname><given-names>J</given-names></name><name><surname>Chacón-Salinas</surname><given-names>R</given-names></name><name><surname>López-Macías</surname><given-names>C</given-names></name><name><surname>Isibasi</surname><given-names>A</given-names></name><name><surname>Gallegos-Pérez</surname><given-names>H</given-names></name><name><surname>León-Gutiérrez</surname><given-names>MA</given-names></name><name><surname>Ferat-Osorio</surname><given-names>E</given-names></name><name><surname>Arriaga-Pizano</surname><given-names>L</given-names></name><name><surname>Estrada-García</surname><given-names>I</given-names></name><name><surname>Wong-Baeza</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Innate lymphoid cells have decreased HLA-DR expression but retain their responsiveness to TLR ligands during sepsis</article-title><source>Journal of Immunology</source><volume>201</volume><fpage>3401</fpage><lpage>3410</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1800735</pub-id><pub-id pub-id-type="pmid">30373848</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curio</surname><given-names>S</given-names></name><name><surname>Belz</surname><given-names>GT</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The unique role of innate lymphoid cells in cancer and the hepatic microenvironment</article-title><source>Cellular &amp; Molecular Immunology</source><volume>19</volume><fpage>1012</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1038/s41423-022-00901-1</pub-id><pub-id pub-id-type="pmid">35962192</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dadi</surname><given-names>S</given-names></name><name><surname>Chhangawala</surname><given-names>S</given-names></name><name><surname>Whitlock</surname><given-names>BM</given-names></name><name><surname>Franklin</surname><given-names>RA</given-names></name><name><surname>Luo</surname><given-names>CT</given-names></name><name><surname>Oh</surname><given-names>SA</given-names></name><name><surname>Toure</surname><given-names>A</given-names></name><name><surname>Pritykin</surname><given-names>Y</given-names></name><name><surname>Huse</surname><given-names>M</given-names></name><name><surname>Leslie</surname><given-names>CS</given-names></name><name><surname>Li</surname><given-names>MO</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells</article-title><source>Cell</source><volume>164</volume><fpage>365</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.01.002</pub-id><pub-id pub-id-type="pmid">26806130</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daussy</surname><given-names>C</given-names></name><name><surname>Faure</surname><given-names>F</given-names></name><name><surname>Mayol</surname><given-names>K</given-names></name><name><surname>Viel</surname><given-names>S</given-names></name><name><surname>Gasteiger</surname><given-names>G</given-names></name><name><surname>Charrier</surname><given-names>E</given-names></name><name><surname>Bienvenu</surname><given-names>J</given-names></name><name><surname>Henry</surname><given-names>T</given-names></name><name><surname>Debien</surname><given-names>E</given-names></name><name><surname>Hasan</surname><given-names>UA</given-names></name><name><surname>Marvel</surname><given-names>J</given-names></name><name><surname>Yoh</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Prinz</surname><given-names>I</given-names></name><name><surname>de Bernard</surname><given-names>S</given-names></name><name><surname>Buffat</surname><given-names>L</given-names></name><name><surname>Walzer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>T-Bet and eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow</article-title><source>The Journal of Experimental Medicine</source><volume>211</volume><fpage>563</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1084/jem.20131560</pub-id><pub-id pub-id-type="pmid">24516120</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>A</given-names></name><name><surname>Jabbari</surname><given-names>A</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Xing</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>MM</given-names></name><name><surname>Duvic</surname><given-names>M</given-names></name><name><surname>Hordinsky</surname><given-names>M</given-names></name><name><surname>Norris</surname><given-names>DA</given-names></name><name><surname>Price</surname><given-names>V</given-names></name><name><surname>Mackay-Wiggan</surname><given-names>J</given-names></name><name><surname>Clynes</surname><given-names>R</given-names></name><name><surname>Christiano</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>High-Throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata</article-title><source>JCI Insight</source><volume>3</volume><elocation-id>e121949</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.121949</pub-id><pub-id pub-id-type="pmid">30282836</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebbo</surname><given-names>M</given-names></name><name><surname>Crinier</surname><given-names>A</given-names></name><name><surname>Vély</surname><given-names>F</given-names></name><name><surname>Vivier</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Innate lymphoid cells: major players in inflammatory diseases</article-title><source>Nature Reviews. Immunology</source><volume>17</volume><fpage>665</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.86</pub-id><pub-id pub-id-type="pmid">28804130</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Edelkamp</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><source>Selective Inhibition of Tyrosine Kinase 2 (TYK2) Protects Hair Follicles from Immune Privilege Collapse Induced by Interleukin (IL)-12 Stimulation</source><publisher-name>EADV’s 30th Anniversary Congress</publisher-name></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>An</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Qin</surname><given-names>R</given-names></name><name><surname>Yao</surname><given-names>D</given-names></name><name><surname>Shou</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Tong</surname><given-names>Z</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>W</given-names></name><name><surname>Lou</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Nkg2D discriminates diverse ligands through selectively mechano-regulated ligand conformational changes</article-title><source>The EMBO Journal</source><volume>41</volume><elocation-id>e107739</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2021107739</pub-id><pub-id pub-id-type="pmid">34913508</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Innate lymphoid cells in inflammatory arthritis</article-title><source>Arthritis Research &amp; Therapy</source><volume>22</volume><elocation-id>25</elocation-id><pub-id pub-id-type="doi">10.1186/s13075-020-2115-4</pub-id><pub-id pub-id-type="pmid">32051038</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiancette</surname><given-names>R</given-names></name><name><surname>Finlay</surname><given-names>CM</given-names></name><name><surname>Willis</surname><given-names>C</given-names></name><name><surname>Bevington</surname><given-names>SL</given-names></name><name><surname>Soley</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>STH</given-names></name><name><surname>Baker</surname><given-names>SM</given-names></name><name><surname>Andrews</surname><given-names>S</given-names></name><name><surname>Hepworth</surname><given-names>MR</given-names></name><name><surname>Withers</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Reciprocal transcription factor networks govern tissue-resident ILC3 subset function and identity</article-title><source>Nature Immunology</source><volume>22</volume><fpage>1245</fpage><lpage>1255</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-01024-x</pub-id><pub-id pub-id-type="pmid">34556884</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flommersfeld</surname><given-names>S</given-names></name><name><surname>Böttcher</surname><given-names>JP</given-names></name><name><surname>Ersching</surname><given-names>J</given-names></name><name><surname>Flossdorf</surname><given-names>M</given-names></name><name><surname>Meiser</surname><given-names>P</given-names></name><name><surname>Pachmayr</surname><given-names>LO</given-names></name><name><surname>Leube</surname><given-names>J</given-names></name><name><surname>Hensel</surname><given-names>I</given-names></name><name><surname>Jarosch</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Chaudhry</surname><given-names>MZ</given-names></name><name><surname>Andrae</surname><given-names>I</given-names></name><name><surname>Schiemann</surname><given-names>M</given-names></name><name><surname>Busch</surname><given-names>DH</given-names></name><name><surname>Cicin-Sain</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>JC</given-names></name><name><surname>Gasteiger</surname><given-names>G</given-names></name><name><surname>Victora</surname><given-names>GD</given-names></name><name><surname>Höfer</surname><given-names>T</given-names></name><name><surname>Buchholz</surname><given-names>VR</given-names></name><name><surname>Grassmann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Fate mapping of single NK cells identifies a type 1 innate lymphoid-like lineage that bridges innate and adaptive recognition of viral infection</article-title><source>Immunity</source><volume>54</volume><fpage>2288</fpage><lpage>2304</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.08.002</pub-id><pub-id pub-id-type="pmid">34437840</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frazao</surname><given-names>A</given-names></name><name><surname>Rethacker</surname><given-names>L</given-names></name><name><surname>Messaoudene</surname><given-names>M</given-names></name><name><surname>Avril</surname><given-names>MF</given-names></name><name><surname>Toubert</surname><given-names>A</given-names></name><name><surname>Dulphy</surname><given-names>N</given-names></name><name><surname>Caignard</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>NKG2D/NKG2-ligand pathway offers new opportunities in cancer treatment</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>661</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00661</pub-id><pub-id pub-id-type="pmid">30984204</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>A</given-names></name><name><surname>Vermi</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Lonardi</surname><given-names>S</given-names></name><name><surname>Gilfillan</surname><given-names>S</given-names></name><name><surname>Newberry</surname><given-names>RD</given-names></name><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells</article-title><source>Immunity</source><volume>38</volume><fpage>769</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.02.010</pub-id><pub-id pub-id-type="pmid">23453631</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Souza-Fonseca-Guimaraes</surname><given-names>F</given-names></name><name><surname>Bald</surname><given-names>T</given-names></name><name><surname>Ng</surname><given-names>SS</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Ngiow</surname><given-names>SF</given-names></name><name><surname>Rautela</surname><given-names>J</given-names></name><name><surname>Straube</surname><given-names>J</given-names></name><name><surname>Waddell</surname><given-names>N</given-names></name><name><surname>Blake</surname><given-names>SJ</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Bartholin</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Vivier</surname><given-names>E</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Messaoudene</surname><given-names>M</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Teng</surname><given-names>MWL</given-names></name><name><surname>Belz</surname><given-names>GT</given-names></name><name><surname>Engwerda</surname><given-names>CR</given-names></name><name><surname>Huntington</surname><given-names>ND</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Hölzel</surname><given-names>M</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells</article-title><source>Nature Immunology</source><volume>18</volume><fpage>1004</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1038/ni.3800</pub-id><pub-id pub-id-type="pmid">28759001</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghraieb</surname><given-names>A</given-names></name><name><surname>Keren</surname><given-names>A</given-names></name><name><surname>Ginzburg</surname><given-names>A</given-names></name><name><surname>Ullmann</surname><given-names>Y</given-names></name><name><surname>Schrum</surname><given-names>AG</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name><name><surname>Gilhar</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>INKT cells ameliorate human autoimmunity: lessons from alopecia areata</article-title><source>Journal of Autoimmunity</source><volume>91</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2018.04.001</pub-id><pub-id pub-id-type="pmid">29680372</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilhar</surname><given-names>A</given-names></name><name><surname>Ullmann</surname><given-names>Y</given-names></name><name><surname>Berkutzki</surname><given-names>T</given-names></name><name><surname>Assy</surname><given-names>B</given-names></name><name><surname>Kalish</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice</article-title><source>J Clin Invest</source><volume>101</volume><fpage>62</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1172/JCI551</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilhar</surname><given-names>A</given-names></name><name><surname>Etzioni</surname><given-names>A</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Alopecia areata</article-title><source>The New England Journal of Medicine</source><volume>366</volume><fpage>1515</fpage><lpage>1525</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1103442</pub-id><pub-id pub-id-type="pmid">22512484</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilhar</surname><given-names>A</given-names></name><name><surname>Keren</surname><given-names>A</given-names></name><name><surname>Shemer</surname><given-names>A</given-names></name><name><surname>d’Ovidio</surname><given-names>R</given-names></name><name><surname>Ullmann</surname><given-names>Y</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013a</year><article-title>Autoimmune disease induction in a healthy human organ: a humanized mouse model of alopecia areata</article-title><source>The Journal of Investigative Dermatology</source><volume>133</volume><fpage>844</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1038/jid.2012.365</pub-id><pub-id pub-id-type="pmid">23096715</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilhar</surname><given-names>A</given-names></name><name><surname>Keren</surname><given-names>A</given-names></name><name><surname>Shemer</surname><given-names>A</given-names></name><name><surname>Ullmann</surname><given-names>Y</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013b</year><article-title>Blocking potassium channels (kv1.3): a new treatment option for alopecia areata?</article-title><source>The Journal of Investigative Dermatology</source><volume>133</volume><fpage>2088</fpage><lpage>2091</lpage><pub-id pub-id-type="doi">10.1038/jid.2013.141</pub-id><pub-id pub-id-type="pmid">23636064</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilhar</surname><given-names>A</given-names></name><name><surname>Schrum</surname><given-names>AG</given-names></name><name><surname>Etzioni</surname><given-names>A</given-names></name><name><surname>Waldmann</surname><given-names>H</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Alopecia areata: animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies</article-title><source>Autoimmunity Reviews</source><volume>15</volume><fpage>726</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2016.03.008</pub-id><pub-id pub-id-type="pmid">26971464</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilhar</surname><given-names>A</given-names></name><name><surname>Keren</surname><given-names>A</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Jak inhibitors and alopecia areata</article-title><source>Lancet</source><volume>393</volume><fpage>318</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)32987-8</pub-id><pub-id pub-id-type="pmid">30696569</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilhar</surname><given-names>A</given-names></name><name><surname>Laufer-Britva</surname><given-names>R</given-names></name><name><surname>Keren</surname><given-names>A</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>Frontiers in alopecia areata pathobiology research</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>144</volume><fpage>1478</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2019.08.035</pub-id><pub-id pub-id-type="pmid">31606262</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilhar</surname><given-names>A</given-names></name><name><surname>Keren</surname><given-names>A</given-names></name><name><surname>Ullmann</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Effect of minoxidil formulations on human scalp skin xenotransplants on SCID mice: A novel pre-clinical in vivo assay for androgenetic alopecia research</article-title><source>Experimental Dermatology</source><volume>31</volume><fpage>980</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1111/exd.14523</pub-id><pub-id pub-id-type="pmid">35000229</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Gaskin</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>N</given-names></name><name><surname>Fu</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Innate lymphoid cell disturbance with increase in ILC1 in systemic lupus erythematosus</article-title><source>Clinical Immunology</source><volume>202</volume><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2019.03.008</pub-id><pub-id pub-id-type="pmid">30926441</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardman-Smart</surname><given-names>JA</given-names></name><name><surname>Purba</surname><given-names>TS</given-names></name><name><surname>Panicker</surname><given-names>S</given-names></name><name><surname>Farjo</surname><given-names>B</given-names></name><name><surname>Farjo</surname><given-names>N</given-names></name><name><surname>Harries</surname><given-names>MJ</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Does mitochondrial dysfunction of hair follicle epithelial stem cells play a role in the pathobiology of lichen planopilaris?</article-title><source>The British Journal of Dermatology</source><volume>183</volume><fpage>964</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1111/bjd.19259</pub-id><pub-id pub-id-type="pmid">32471007</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmon</surname><given-names>C</given-names></name><name><surname>Robinson</surname><given-names>MW</given-names></name><name><surname>Fahey</surname><given-names>R</given-names></name><name><surname>Whelan</surname><given-names>S</given-names></name><name><surname>Houlihan</surname><given-names>DD</given-names></name><name><surname>Geoghegan</surname><given-names>J</given-names></name><name><surname>O’Farrelly</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tissue-resident eomes(hi) T-bet(lo) CD56(bright) NK cells with reduced proinflammatory potential are enriched in the adult human liver</article-title><source>European Journal of Immunology</source><volume>46</volume><fpage>2111</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1002/eji.201646559</pub-id><pub-id pub-id-type="pmid">27485474</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harries</surname><given-names>MJ</given-names></name><name><surname>Meyer</surname><given-names>K</given-names></name><name><surname>Chaudhry</surname><given-names>I</given-names></name><name><surname>E Kloepper</surname><given-names>J</given-names></name><name><surname>Poblet</surname><given-names>E</given-names></name><name><surname>Griffiths</surname><given-names>CE</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Lichen planopilaris is characterized by immune privilege collapse of the hair follicle’s epithelial stem cell niche</article-title><source>The Journal of Pathology</source><volume>231</volume><fpage>236</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1002/path.4233</pub-id><pub-id pub-id-type="pmid">23788005</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Vitiligo and alopecia areata: apples and oranges?</article-title><source>Experimental Dermatology</source><volume>22</volume><fpage>785</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1111/exd.12264</pub-id><pub-id pub-id-type="pmid">24131336</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawke</surname><given-names>LG</given-names></name><name><surname>Mitchell</surname><given-names>BZ</given-names></name><name><surname>Ormiston</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>TGF-β and IL-15 synergize through MAPK pathways to drive the conversion of human NK cells to an innate lymphoid cell 1-like phenotype</article-title><source>Journal of Immunology</source><volume>204</volume><fpage>3171</fpage><lpage>3181</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1900866</pub-id><pub-id pub-id-type="pmid">32332109</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawke</surname><given-names>LG</given-names></name><name><surname>Whitford</surname><given-names>MKM</given-names></name><name><surname>Ormiston</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>The production of pro-angiogenic VEGF-A isoforms by hypoxic human NK cells is independent of their TGF-β-mediated conversion to an ILC1-like phenotype</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>1903</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01903</pub-id><pub-id pub-id-type="pmid">32983113</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrix</surname><given-names>S</given-names></name><name><surname>Handjiski</surname><given-names>B</given-names></name><name><surname>Peters</surname><given-names>EMJ</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A guide to assessing damage response pathways of the hair follicle: lessons from cyclophosphamide-induced alopecia in mice</article-title><source>The Journal of Investigative Dermatology</source><volume>125</volume><fpage>42</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1111/j.0022-202X.2005.23787.x</pub-id><pub-id pub-id-type="pmid">15982301</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1965">1965</year><article-title>A new classification of alopecia areata</article-title><source>Dermatologica</source><volume>131</volume><fpage>421</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1159/000254503</pub-id><pub-id pub-id-type="pmid">5864736</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>N</given-names></name><name><surname>Bettermann</surname><given-names>A</given-names></name><name><surname>Tokura</surname><given-names>Y</given-names></name><name><surname>Takigawa</surname><given-names>M</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model</article-title><source>The American Journal of Pathology</source><volume>164</volume><fpage>623</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)63151-3</pub-id><pub-id pub-id-type="pmid">14742267</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>N</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Kromminga</surname><given-names>A</given-names></name><name><surname>Bettermann</surname><given-names>A</given-names></name><name><surname>Takigawa</surname><given-names>M</given-names></name><name><surname>Kees</surname><given-names>F</given-names></name><name><surname>Straub</surname><given-names>RH</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2005">2005a</year><article-title>Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol</article-title><source>FASEB Journal</source><volume>19</volume><fpage>1332</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1096/fj.04-1968fje</pub-id><pub-id pub-id-type="pmid">15946990</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>N</given-names></name><name><surname>Saathoff</surname><given-names>M</given-names></name><name><surname>Bettermann</surname><given-names>A</given-names></name><name><surname>Takigawa</surname><given-names>M</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2005">2005b</year><article-title>Interferon-gamma is a potent inducer of catagen-like changes in cultured human anagen hair follicles</article-title><source>The British Journal of Dermatology</source><volume>152</volume><fpage>623</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2005.06453.x</pub-id><pub-id pub-id-type="pmid">15840090</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>N</given-names></name><name><surname>Saatoff</surname><given-names>M</given-names></name><name><surname>Hashizume</surname><given-names>H</given-names></name><name><surname>Fukamizu</surname><given-names>H</given-names></name><name><surname>Nickoloff</surname><given-names>BJ</given-names></name><name><surname>Takigawa</surname><given-names>M</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack</article-title><source>The Journal of Investigative Dermatology</source><volume>128</volume><fpage>1196</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1038/sj.jid.5701183</pub-id><pub-id pub-id-type="pmid">18160967</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Kageyama</surname><given-names>R</given-names></name><name><surname>Nakazawa</surname><given-names>S</given-names></name><name><surname>Honda</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata</article-title><source>Experimental Dermatology</source><volume>29</volume><fpage>726</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1111/exd.14129</pub-id><pub-id pub-id-type="pmid">32533873</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>Y</given-names></name><name><surname>Huntington</surname><given-names>ND</given-names></name><name><surname>Belz</surname><given-names>GT</given-names></name><name><surname>Seillet</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Type 1 innate lymphoid cell biology: lessons learnt from natural killer cells</article-title><source>Frontiers in Immunology</source><volume>7</volume><elocation-id>426</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2016.00426</pub-id><pub-id pub-id-type="pmid">27785129</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Huntington</surname><given-names>ND</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Crosstalk between gut microbiota and innate immunity and its implication in autoimmune diseases</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>282</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.00282</pub-id><pub-id pub-id-type="pmid">32153586</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keren</surname><given-names>A</given-names></name><name><surname>Shemer</surname><given-names>A</given-names></name><name><surname>Ullmann</surname><given-names>Y</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name><name><surname>Gilhar</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo</article-title><source>Journal of Dermatological Science</source><volume>77</volume><fpage>74</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2014.11.009</pub-id><pub-id pub-id-type="pmid">25530115</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keren</surname><given-names>A</given-names></name><name><surname>Shemer</surname><given-names>A</given-names></name><name><surname>Ginzburg</surname><given-names>A</given-names></name><name><surname>Ullmann</surname><given-names>Y</given-names></name><name><surname>Schrum</surname><given-names>AG</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name><name><surname>Gilhar</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Innate lymphoid cells 3 induce psoriasis in xenotransplanted healthy human skin</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>142</volume><fpage>305</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2018.02.015</pub-id><pub-id pub-id-type="pmid">29501801</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>BS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Innate lymphoid cells in the skin</article-title><source>The Journal of Investigative Dermatology</source><volume>135</volume><fpage>673</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1038/jid.2014.401</pub-id><pub-id pub-id-type="pmid">25339380</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Ryu</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>HY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Innate lymphoid cells in tissue homeostasis and disease pathogenesis</article-title><source>Molecules and Cells</source><volume>44</volume><fpage>301</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.14348/molcells.2021.0053</pub-id><pub-id pub-id-type="pmid">33972473</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>BA</given-names></name><name><surname>Mesinkovska</surname><given-names>NA</given-names></name><name><surname>Craiglow</surname><given-names>B</given-names></name><name><surname>Kindred</surname><given-names>C</given-names></name><name><surname>Ko</surname><given-names>J</given-names></name><name><surname>McMichael</surname><given-names>A</given-names></name><name><surname>Shapiro</surname><given-names>J</given-names></name><name><surname>Goh</surname><given-names>C</given-names></name><name><surname>Mirmirani</surname><given-names>P</given-names></name><name><surname>Tosti</surname><given-names>A</given-names></name><name><surname>Hordinsky</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>KP</given-names></name><name><surname>Castelo-Soccio</surname><given-names>L</given-names></name><name><surname>Bergfeld</surname><given-names>W</given-names></name><name><surname>Paller</surname><given-names>AS</given-names></name><name><surname>Mackay-Wiggan</surname><given-names>J</given-names></name><name><surname>Glashofer</surname><given-names>M</given-names></name><name><surname>Aguh</surname><given-names>C</given-names></name><name><surname>Piliang</surname><given-names>M</given-names></name><name><surname>Yazdan</surname><given-names>P</given-names></name><name><surname>Lo Sicco</surname><given-names>K</given-names></name><name><surname>Cassella</surname><given-names>JV</given-names></name><name><surname>Koenigsberg</surname><given-names>J</given-names></name><name><surname>Ahluwalia</surname><given-names>G</given-names></name><name><surname>Ghorayeb</surname><given-names>E</given-names></name><name><surname>Fakharzadeh</surname><given-names>S</given-names></name><name><surname>Napatalung</surname><given-names>L</given-names></name><name><surname>Gandhi</surname><given-names>K</given-names></name><name><surname>DeLozier</surname><given-names>AM</given-names></name><name><surname>Nunes</surname><given-names>FP</given-names></name><name><surname>Senna</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort</article-title><source>Journal of the American Academy of Dermatology</source><volume>86</volume><fpage>359</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2021.08.043</pub-id><pub-id pub-id-type="pmid">34474079</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinori</surname><given-names>M</given-names></name><name><surname>Bertolini</surname><given-names>M</given-names></name><name><surname>Funk</surname><given-names>W</given-names></name><name><surname>Samuelov</surname><given-names>L</given-names></name><name><surname>Meyer</surname><given-names>KC</given-names></name><name><surname>Emelianov</surname><given-names>VU</given-names></name><name><surname>Hasse</surname><given-names>S</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Calcitonin gene-related peptide (CGRP) may award relative protection from interferon-γ-induced collapse of human hair follicle immune privilege</article-title><source>Experimental Dermatology</source><volume>21</volume><fpage>223</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0625.2011.01432.x</pub-id><pub-id pub-id-type="pmid">22379970</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kloepper</surname><given-names>JE</given-names></name><name><surname>Sugawara</surname><given-names>K</given-names></name><name><surname>Al-Nuaimi</surname><given-names>Y</given-names></name><name><surname>Gáspár</surname><given-names>E</given-names></name><name><surname>van Beek</surname><given-names>N</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Methods in hair research: how to objectively distinguish between anagen and catagen in human hair follicle organ culture</article-title><source>Experimental Dermatology</source><volume>19</volume><fpage>305</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0625.2009.00939.x</pub-id><pub-id pub-id-type="pmid">19725870</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korta</surname><given-names>DZ</given-names></name><name><surname>Christiano</surname><given-names>AM</given-names></name><name><surname>Bergfeld</surname><given-names>W</given-names></name><name><surname>Duvic</surname><given-names>M</given-names></name><name><surname>Ellison</surname><given-names>A</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Harris</surname><given-names>JE</given-names></name><name><surname>Hordinsky</surname><given-names>MK</given-names></name><name><surname>King</surname><given-names>B</given-names></name><name><surname>Kranz</surname><given-names>D</given-names></name><name><surname>Mackay-Wiggan</surname><given-names>J</given-names></name><name><surname>McMichael</surname><given-names>A</given-names></name><name><surname>Norris</surname><given-names>DA</given-names></name><name><surname>Price</surname><given-names>V</given-names></name><name><surname>Shapiro</surname><given-names>J</given-names></name><name><surname>Atanaskova Mesinkovska</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Alopecia areata is a medical disease</article-title><source>Journal of the American Academy of Dermatology</source><volume>78</volume><fpage>832</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2017.09.011</pub-id><pub-id pub-id-type="pmid">29548423</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krabbendam</surname><given-names>L</given-names></name><name><surname>Bernink</surname><given-names>JH</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Innate lymphoid cells: from helper to killer</article-title><source>Current Opinion in Immunology</source><volume>68</volume><fpage>28</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2020.08.007</pub-id><pub-id pub-id-type="pmid">32971468</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krämer</surname><given-names>B</given-names></name><name><surname>Nalin</surname><given-names>AP</given-names></name><name><surname>Ma</surname><given-names>F</given-names></name><name><surname>Eickhoff</surname><given-names>S</given-names></name><name><surname>Lutz</surname><given-names>P</given-names></name><name><surname>Leonardelli</surname><given-names>S</given-names></name><name><surname>Goeser</surname><given-names>F</given-names></name><name><surname>Finnemann</surname><given-names>C</given-names></name><name><surname>Hack</surname><given-names>G</given-names></name><name><surname>Raabe</surname><given-names>J</given-names></name><name><surname>ToVinh</surname><given-names>M</given-names></name><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Hoffmeister</surname><given-names>C</given-names></name><name><surname>Kaiser</surname><given-names>KM</given-names></name><name><surname>Manekeller</surname><given-names>S</given-names></name><name><surname>Branchi</surname><given-names>V</given-names></name><name><surname>Bald</surname><given-names>T</given-names></name><name><surname>Hölzel</surname><given-names>M</given-names></name><name><surname>Hüneburg</surname><given-names>R</given-names></name><name><surname>Nischalke</surname><given-names>HD</given-names></name><name><surname>Semaan</surname><given-names>A</given-names></name><name><surname>Langhans</surname><given-names>B</given-names></name><name><surname>Kaczmarek</surname><given-names>DJ</given-names></name><name><surname>Benner</surname><given-names>B</given-names></name><name><surname>Lordo</surname><given-names>MR</given-names></name><name><surname>Kowalski</surname><given-names>J</given-names></name><name><surname>Gerhardt</surname><given-names>A</given-names></name><name><surname>Timm</surname><given-names>J</given-names></name><name><surname>Toma</surname><given-names>M</given-names></name><name><surname>Mohr</surname><given-names>R</given-names></name><name><surname>Türler</surname><given-names>A</given-names></name><name><surname>Charpentier</surname><given-names>A</given-names></name><name><surname>van Bremen</surname><given-names>T</given-names></name><name><surname>Feldmann</surname><given-names>G</given-names></name><name><surname>Sattler</surname><given-names>A</given-names></name><name><surname>Kotsch</surname><given-names>K</given-names></name><name><surname>Abdallah</surname><given-names>AT</given-names></name><name><surname>Strassburg</surname><given-names>CP</given-names></name><name><surname>Spengler</surname><given-names>U</given-names></name><name><surname>Carson</surname><given-names>WE</given-names></name><name><surname>Mundy-Bosse</surname><given-names>BL</given-names></name><name><surname>Pellegrini</surname><given-names>M</given-names></name><name><surname>O’Sullivan</surname><given-names>TE</given-names></name><name><surname>Freud</surname><given-names>AG</given-names></name><name><surname>Nattermann</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Single-cell RNA sequencing identifies a population of human liver-type ilc1s</article-title><source>Cell Reports</source><volume>42</volume><elocation-id>111937</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.111937</pub-id><pub-id pub-id-type="pmid">36640314</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>JG</given-names></name><name><surname>McInnes</surname><given-names>IB</given-names></name><name><surname>Blauvelt</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis</article-title><source>Journal of the American Academy of Dermatology</source><volume>86</volume><fpage>148</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2021.06.869</pub-id><pub-id pub-id-type="pmid">34224773</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krzywinska</surname><given-names>E</given-names></name><name><surname>Sobecki</surname><given-names>M</given-names></name><name><surname>Nagarajan</surname><given-names>S</given-names></name><name><surname>Zacharjasz</surname><given-names>J</given-names></name><name><surname>Tambuwala</surname><given-names>MM</given-names></name><name><surname>Pelletier</surname><given-names>A</given-names></name><name><surname>Cummins</surname><given-names>E</given-names></name><name><surname>Gotthardt</surname><given-names>D</given-names></name><name><surname>Fandrey</surname><given-names>J</given-names></name><name><surname>Kerdiles</surname><given-names>YM</given-names></name><name><surname>Peyssonnaux</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>CT</given-names></name><name><surname>Sexl</surname><given-names>V</given-names></name><name><surname>Stockmann</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The transcription factor HIF-1α mediates plasticity of nkp46+ innate lymphoid cells in the gut</article-title><source>The Journal of Experimental Medicine</source><volume>219</volume><elocation-id>e20210909</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20210909</pub-id><pub-id pub-id-type="pmid">35024767</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langan</surname><given-names>EA</given-names></name><name><surname>Philpott</surname><given-names>MP</given-names></name><name><surname>Kloepper</surname><given-names>JE</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Human hair follicle organ culture: theory, application and perspectives</article-title><source>Experimental Dermatology</source><volume>24</volume><fpage>903</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1111/exd.12836</pub-id><pub-id pub-id-type="pmid">26284830</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laufer Britva</surname><given-names>R</given-names></name><name><surname>Keren</surname><given-names>A</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name><name><surname>Gilhar</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata</article-title><source>The British Journal of Dermatology</source><volume>182</volume><fpage>227</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1111/bjd.18264</pub-id><pub-id pub-id-type="pmid">31254391</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>van Vliet</surname><given-names>C</given-names></name><name><surname>Rufaut</surname><given-names>NW</given-names></name><name><surname>Jones</surname><given-names>LN</given-names></name><name><surname>Sinclair</surname><given-names>RD</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Laser capture microdissection reveals transcriptional abnormalities in alopecia areata before, during, and after active hair loss</article-title><source>The Journal of Investigative Dermatology</source><volume>136</volume><fpage>715</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2015.12.003</pub-id><pub-id pub-id-type="pmid">27015457</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopes</surname><given-names>N</given-names></name><name><surname>Vivier</surname><given-names>E</given-names></name><name><surname>Narni-Mancinelli</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Natural killer cells and type 1 innate lymphoid cells in cancer</article-title><source>Seminars in Immunology</source><volume>66</volume><elocation-id>101709</elocation-id><pub-id pub-id-type="doi">10.1016/j.smim.2022.101709</pub-id><pub-id pub-id-type="pmid">36621291</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lousada</surname><given-names>MB</given-names></name><name><surname>Lachnit</surname><given-names>T</given-names></name><name><surname>Edelkamp</surname><given-names>J</given-names></name><name><surname>Rouillé</surname><given-names>T</given-names></name><name><surname>Ajdic</surname><given-names>D</given-names></name><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Di Nardo</surname><given-names>A</given-names></name><name><surname>Bosch</surname><given-names>TCG</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Exploring the human hair follicle microbiome</article-title><source>The British Journal of Dermatology</source><volume>184</volume><fpage>802</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1111/bjd.19461</pub-id><pub-id pub-id-type="pmid">32762039</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Hasse</surname><given-names>S</given-names></name><name><surname>Bodo</surname><given-names>E</given-names></name><name><surname>Rose</surname><given-names>C</given-names></name><name><surname>Funk</surname><given-names>W</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Towards the development of a simplified long-term organ culture method for human scalp skin and its appendages under serum-free conditions</article-title><source>Experimental Dermatology</source><volume>16</volume><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0625.2006.00510.x</pub-id><pub-id pub-id-type="pmid">17181635</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>B</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Xiao</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Update: innate lymphoid cells in inflammatory bowel disease</article-title><source>Digestive Diseases and Sciences</source><volume>67</volume><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/s10620-021-06831-8</pub-id><pub-id pub-id-type="pmid">33609209</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzurana</surname><given-names>L</given-names></name><name><surname>Czarnewski</surname><given-names>P</given-names></name><name><surname>Jonsson</surname><given-names>V</given-names></name><name><surname>Wigge</surname><given-names>L</given-names></name><name><surname>Ringnér</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>TC</given-names></name><name><surname>Ravindran</surname><given-names>A</given-names></name><name><surname>Björklund</surname><given-names>ÅK</given-names></name><name><surname>Säfholm</surname><given-names>J</given-names></name><name><surname>Nilsson</surname><given-names>G</given-names></name><name><surname>Dahlén</surname><given-names>SE</given-names></name><name><surname>Orre</surname><given-names>AC</given-names></name><name><surname>Al-Ameri</surname><given-names>M</given-names></name><name><surname>Höög</surname><given-names>C</given-names></name><name><surname>Hedin</surname><given-names>C</given-names></name><name><surname>Szczegielniak</surname><given-names>S</given-names></name><name><surname>Almer</surname><given-names>S</given-names></name><name><surname>Mjösberg</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Tissue-specific transcriptional imprinting and heterogeneity in human innate lymphoid cells revealed by full-length single-cell RNA-sequencing</article-title><source>Cell Research</source><volume>31</volume><fpage>554</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-00445-x</pub-id><pub-id pub-id-type="pmid">33420427</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>BD</given-names></name><name><surname>Jabri</surname><given-names>B</given-names></name><name><surname>Bendelac</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Diverse developmental pathways of intestinal intraepithelial lymphocytes</article-title><source>Nature Reviews. Immunology</source><volume>18</volume><fpage>514</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1038/s41577-018-0013-7</pub-id><pub-id pub-id-type="pmid">29717233</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFarland</surname><given-names>AP</given-names></name><name><surname>Yalin</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>SY</given-names></name><name><surname>Cortez</surname><given-names>VS</given-names></name><name><surname>Landsberger</surname><given-names>T</given-names></name><name><surname>Sudan</surname><given-names>R</given-names></name><name><surname>Peng</surname><given-names>V</given-names></name><name><surname>Miller</surname><given-names>HL</given-names></name><name><surname>Ricci</surname><given-names>B</given-names></name><name><surname>David</surname><given-names>E</given-names></name><name><surname>Faccio</surname><given-names>R</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Multi-Tissue single-cell analysis deconstructs the complex programs of mouse natural killer and type 1 innate lymphoid cells in tissues and circulation</article-title><source>Immunity</source><volume>54</volume><fpage>1320</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.03.024</pub-id><pub-id pub-id-type="pmid">33945787</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meah</surname><given-names>N</given-names></name><name><surname>Wall</surname><given-names>D</given-names></name><name><surname>York</surname><given-names>K</given-names></name><name><surname>Bhoyrul</surname><given-names>B</given-names></name><name><surname>Bokhari</surname><given-names>L</given-names></name><name><surname>Sigall</surname><given-names>DA</given-names></name><name><surname>Bergfeld</surname><given-names>WF</given-names></name><name><surname>Betz</surname><given-names>RC</given-names></name><name><surname>Blume-Peytavi</surname><given-names>U</given-names></name><name><surname>Callender</surname><given-names>V</given-names></name><name><surname>Chitreddy</surname><given-names>V</given-names></name><name><surname>Combalia</surname><given-names>A</given-names></name><name><surname>Cotsarelis</surname><given-names>G</given-names></name><name><surname>Craiglow</surname><given-names>B</given-names></name><name><surname>Donovan</surname><given-names>J</given-names></name><name><surname>Eisman</surname><given-names>S</given-names></name><name><surname>Farrant</surname><given-names>P</given-names></name><name><surname>Green</surname><given-names>J</given-names></name><name><surname>Grimalt</surname><given-names>R</given-names></name><name><surname>Harries</surname><given-names>M</given-names></name><name><surname>Hordinsky</surname><given-names>M</given-names></name><name><surname>Irvine</surname><given-names>AD</given-names></name><name><surname>Itami</surname><given-names>S</given-names></name><name><surname>Jolliffe</surname><given-names>V</given-names></name><name><surname>King</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>W-S</given-names></name><name><surname>McMichael</surname><given-names>A</given-names></name><name><surname>Messenger</surname><given-names>A</given-names></name><name><surname>Mirmirani</surname><given-names>P</given-names></name><name><surname>Olsen</surname><given-names>E</given-names></name><name><surname>Orlow</surname><given-names>SJ</given-names></name><name><surname>Piraccini</surname><given-names>BM</given-names></name><name><surname>Rakowska</surname><given-names>A</given-names></name><name><surname>Reygagne</surname><given-names>P</given-names></name><name><surname>Roberts</surname><given-names>JL</given-names></name><name><surname>Rudnicka</surname><given-names>L</given-names></name><name><surname>Shapiro</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Tosti</surname><given-names>A</given-names></name><name><surname>Vogt</surname><given-names>A</given-names></name><name><surname>Wade</surname><given-names>M</given-names></name><name><surname>Yip</surname><given-names>L</given-names></name><name><surname>Zlotogorski</surname><given-names>A</given-names></name><name><surname>Sinclair</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The alopecia areata consensus of experts (ACE) study: results of an international expert opinion on treatments for alopecia areata</article-title><source>Journal of the American Academy of Dermatology</source><volume>83</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2020.03.004</pub-id><pub-id pub-id-type="pmid">32165196</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meah</surname><given-names>N</given-names></name><name><surname>Wall</surname><given-names>D</given-names></name><name><surname>York</surname><given-names>K</given-names></name><name><surname>Bhoyrul</surname><given-names>B</given-names></name><name><surname>Bokhari</surname><given-names>L</given-names></name><name><surname>Asz-Sigall</surname><given-names>D</given-names></name><name><surname>Bergfeld</surname><given-names>WF</given-names></name><name><surname>Betz</surname><given-names>RC</given-names></name><name><surname>Blume-Peytavi</surname><given-names>U</given-names></name><name><surname>Callender</surname><given-names>V</given-names></name><name><surname>Chitreddy</surname><given-names>V</given-names></name><name><surname>Combalia</surname><given-names>A</given-names></name><name><surname>Cotsarelis</surname><given-names>G</given-names></name><name><surname>Craiglow</surname><given-names>B</given-names></name><name><surname>Donovan</surname><given-names>J</given-names></name><name><surname>Eisman</surname><given-names>S</given-names></name><name><surname>Farrant</surname><given-names>P</given-names></name><name><surname>Green</surname><given-names>J</given-names></name><name><surname>Grimalt</surname><given-names>R</given-names></name><name><surname>Harries</surname><given-names>M</given-names></name><name><surname>Hordinsky</surname><given-names>M</given-names></name><name><surname>Irvine</surname><given-names>AD</given-names></name><name><surname>Itami</surname><given-names>S</given-names></name><name><surname>Jolliffe</surname><given-names>V</given-names></name><name><surname>King</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>W-S</given-names></name><name><surname>McMichael</surname><given-names>A</given-names></name><name><surname>Messenger</surname><given-names>A</given-names></name><name><surname>Mirmirani</surname><given-names>P</given-names></name><name><surname>Olsen</surname><given-names>E</given-names></name><name><surname>Orlow</surname><given-names>SJ</given-names></name><name><surname>Piraccini</surname><given-names>BM</given-names></name><name><surname>Rakowska</surname><given-names>A</given-names></name><name><surname>Reygagne</surname><given-names>P</given-names></name><name><surname>Roberts</surname><given-names>JL</given-names></name><name><surname>Rudnicka</surname><given-names>L</given-names></name><name><surname>Shapiro</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Tosti</surname><given-names>A</given-names></name><name><surname>Vogt</surname><given-names>A</given-names></name><name><surname>Wade</surname><given-names>M</given-names></name><name><surname>Yip</surname><given-names>L</given-names></name><name><surname>Zlotogorski</surname><given-names>A</given-names></name><name><surname>Sinclair</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The alopecia areata consensus of experts (ACE) study part II: results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata</article-title><source>Journal of the American Academy of Dermatology</source><volume>84</volume><fpage>1594</fpage><lpage>1601</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2020.09.028</pub-id><pub-id pub-id-type="pmid">32926985</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messenger</surname><given-names>AG</given-names></name><name><surname>Slater</surname><given-names>DN</given-names></name><name><surname>Bleehen</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Alopecia areata: alterations in the hair growth cycle and correlation with the follicular pathology</article-title><source>The British Journal of Dermatology</source><volume>114</volume><fpage>337</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.1986.tb02825.x</pub-id><pub-id pub-id-type="pmid">3954954</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mjösberg</surname><given-names>JM</given-names></name><name><surname>Trifari</surname><given-names>S</given-names></name><name><surname>Crellin</surname><given-names>NK</given-names></name><name><surname>Peters</surname><given-names>CP</given-names></name><name><surname>Drunen</surname><given-names>CM</given-names></name><name><surname>Piet</surname><given-names>B</given-names></name><name><surname>Fokkens</surname><given-names>WJ</given-names></name><name><surname>Cupedo</surname><given-names>T</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161</article-title><source>Nat Immunol</source><volume>12</volume><fpage>1055</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1038/ni.2104</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mora-Velandia</surname><given-names>LM</given-names></name><name><surname>Castro-Escamilla</surname><given-names>O</given-names></name><name><surname>Méndez</surname><given-names>AG</given-names></name><name><surname>Aguilar-Flores</surname><given-names>C</given-names></name><name><surname>Velázquez-Avila</surname><given-names>M</given-names></name><name><surname>Tussié-Luna</surname><given-names>MI</given-names></name><name><surname>Téllez-Sosa</surname><given-names>J</given-names></name><name><surname>Maldonado-García</surname><given-names>C</given-names></name><name><surname>Jurado-Santacruz</surname><given-names>F</given-names></name><name><surname>Ferat-Osorio</surname><given-names>E</given-names></name><name><surname>Martínez-Barnetche</surname><given-names>J</given-names></name><name><surname>Pelayo</surname><given-names>R</given-names></name><name><surname>Bonifaz</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A human lin- CD123+ cd127low population endowed with ILC features and migratory capabilities contributes to immunopathological hallmarks of psoriasis</article-title><source>Front Immunol</source><volume>8</volume><elocation-id>176</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.00176</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabekura</surname><given-names>T</given-names></name><name><surname>Shibuya</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Type 1 innate lymphoid cells: soldiers at the front line of immunity</article-title><source>Biomedical Journal</source><volume>44</volume><fpage>115</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.bj.2020.10.001</pub-id><pub-id pub-id-type="pmid">33839081</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabekura</surname><given-names>T</given-names></name><name><surname>Shibuya</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>ILC1: guardians of the oral mucosa against enemy viruses</article-title><source>Immunity</source><volume>54</volume><fpage>196</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.01.002</pub-id><pub-id pub-id-type="pmid">33567258</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagasawa</surname><given-names>M</given-names></name><name><surname>Heesters</surname><given-names>BA</given-names></name><name><surname>Kradolfer</surname><given-names>CMA</given-names></name><name><surname>Krabbendam</surname><given-names>L</given-names></name><name><surname>Martinez-Gonzalez</surname><given-names>I</given-names></name><name><surname>de Bruijn</surname><given-names>MJW</given-names></name><name><surname>Golebski</surname><given-names>K</given-names></name><name><surname>Hendriks</surname><given-names>RW</given-names></name><name><surname>Stadhouders</surname><given-names>R</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name><name><surname>Bal</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>KLRG1 and nkp46 discriminate subpopulations of human CD117+CRTH2− ilcs biased toward ILC2 or ILC3</article-title><source>Journal of Experimental Medicine</source><volume>216</volume><fpage>1762</fpage><lpage>1776</lpage><pub-id pub-id-type="doi">10.1084/jem.20190490</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohne</surname><given-names>Y</given-names></name><name><surname>Silver</surname><given-names>JS</given-names></name><name><surname>Thompson-Snipes</surname><given-names>L</given-names></name><name><surname>Collet</surname><given-names>MA</given-names></name><name><surname>Blanck</surname><given-names>JP</given-names></name><name><surname>Cantarel</surname><given-names>BL</given-names></name><name><surname>Copenhaver</surname><given-names>AM</given-names></name><name><surname>Humbles</surname><given-names>AA</given-names></name><name><surname>Liu</surname><given-names>YJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>IL-1 is a critical regulator of group 2 innate lymphoid cell function and plasticity</article-title><source>Nature Immunology</source><volume>17</volume><fpage>646</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1038/ni.3447</pub-id><pub-id pub-id-type="pmid">27111142</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orimo</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Morita</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Innate lymphoid cells in the airways: their functions and regulators</article-title><source>Allergy, Asthma &amp; Immunology Research</source><volume>12</volume><fpage>381</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.4168/aair.2020.12.3.381</pub-id><pub-id pub-id-type="pmid">32141254</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>E</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Andhey</surname><given-names>P</given-names></name><name><surname>Zaitsev</surname><given-names>K</given-names></name><name><surname>Porter</surname><given-names>S</given-names></name><name><surname>Hershey</surname><given-names>M</given-names></name><name><surname>Bern</surname><given-names>M</given-names></name><name><surname>Plougastel-Douglas</surname><given-names>B</given-names></name><name><surname>Collins</surname><given-names>P</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name><name><surname>Oltz</surname><given-names>E</given-names></name><name><surname>Artyomov</surname><given-names>M</given-names></name><name><surname>Sibley</surname><given-names>LD</given-names></name><name><surname>Yokoyama</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title><italic>Toxoplasma gondii</italic> infection drives conversion of NK cells into ILC1-like cells</article-title><source>eLife</source><volume>8</volume><elocation-id>e47605</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.47605</pub-id><pub-id pub-id-type="pmid">31393266</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paus</surname><given-names>R</given-names></name><name><surname>Slominski</surname><given-names>A</given-names></name><name><surname>Czarnetzki</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb?</article-title><source>The Yale Journal of Biology and Medicine</source><volume>66</volume><fpage>541</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">7716973</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paus</surname><given-names>R</given-names></name><name><surname>Maurer</surname><given-names>M</given-names></name><name><surname>Slominski</surname><given-names>A</given-names></name><name><surname>Czarnetzki</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Mast cell involvement in murine hair growth</article-title><source>Developmental Biology</source><volume>163</volume><fpage>230</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1006/dbio.1994.1139</pub-id><pub-id pub-id-type="pmid">8174779</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paus</surname><given-names>R</given-names></name><name><surname>Nickoloff</surname><given-names>BJ</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A “ hairy ” privilege</article-title><source>Trends in Immunology</source><volume>26</volume><fpage>32</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.it.2004.09.014</pub-id><pub-id pub-id-type="pmid">15629407</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paus</surname><given-names>R</given-names></name><name><surname>Bulfone-Paus</surname><given-names>S</given-names></name><name><surname>Bertolini</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hair follicle immune privilege revisited: the key to alopecia areata management</article-title><source>The Journal of Investigative Dermatology. Symposium Proceedings</source><volume>19</volume><fpage>S12</fpage><lpage>S17</lpage><pub-id pub-id-type="doi">10.1016/j.jisp.2017.10.014</pub-id><pub-id pub-id-type="pmid">29273098</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The evolving pathogenesis of alopecia areata: major open questions</article-title><source>The Journal of Investigative Dermatology. Symposium Proceedings</source><volume>20</volume><fpage>S6</fpage><lpage>S10</lpage><pub-id pub-id-type="doi">10.1016/j.jisp.2020.04.002</pub-id><pub-id pub-id-type="pmid">33099388</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>V</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Trsan</surname><given-names>T</given-names></name><name><surname>Bando</surname><given-names>JK</given-names></name><name><surname>Avila-Pacheco</surname><given-names>J</given-names></name><name><surname>Cleveland</surname><given-names>JL</given-names></name><name><surname>Clish</surname><given-names>C</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Ornithine decarboxylase supports ILC3 responses in infectious and autoimmune colitis through positive regulation of IL-22 transcription</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2214900119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2214900119</pub-id><pub-id pub-id-type="pmid">36279426</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>EMJ</given-names></name><name><surname>Stieglitz</surname><given-names>MG</given-names></name><name><surname>Liezman</surname><given-names>C</given-names></name><name><surname>Overall</surname><given-names>RW</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Hagen</surname><given-names>E</given-names></name><name><surname>Klapp</surname><given-names>BF</given-names></name><name><surname>Arck</surname><given-names>P</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>P75 neurotrophin receptor-mediated signaling promotes human hair follicle regression (catagen)</article-title><source>The American Journal of Pathology</source><volume>168</volume><fpage>221</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2006.050163</pub-id><pub-id pub-id-type="pmid">16400025</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>EMJ</given-names></name><name><surname>Liotiri</surname><given-names>S</given-names></name><name><surname>Bodó</surname><given-names>E</given-names></name><name><surname>Hagen</surname><given-names>E</given-names></name><name><surname>Bíró</surname><given-names>T</given-names></name><name><surname>Arck</surname><given-names>PC</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Probing the effects of stress mediators on the human hair follicle: substance P holds central position</article-title><source>The American Journal of Pathology</source><volume>171</volume><fpage>1872</fpage><lpage>1886</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2007.061206</pub-id><pub-id pub-id-type="pmid">18055548</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petukhova</surname><given-names>L</given-names></name><name><surname>Duvic</surname><given-names>M</given-names></name><name><surname>Hordinsky</surname><given-names>M</given-names></name><name><surname>Norris</surname><given-names>D</given-names></name><name><surname>Price</surname><given-names>V</given-names></name><name><surname>Shimomura</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>WV</given-names></name><name><surname>Meyer</surname><given-names>KC</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name><name><surname>Jahoda</surname><given-names>CAB</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Gregersen</surname><given-names>PK</given-names></name><name><surname>Christiano</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Genome-wide association study in alopecia areata implicates both innate and adaptive immunity</article-title><source>Nature</source><volume>466</volume><fpage>113</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1038/nature09114</pub-id><pub-id pub-id-type="pmid">20596022</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>D</given-names></name><name><surname>Calabrese</surname><given-names>FM</given-names></name><name><surname>De Angelis</surname><given-names>M</given-names></name><name><surname>Celano</surname><given-names>G</given-names></name><name><surname>Giuliani</surname><given-names>G</given-names></name><name><surname>Gobbetti</surname><given-names>M</given-names></name><name><surname>Rinaldi</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Predictive metagenomic profiling, urine metabolomics, and human marker gene expression as an integrated approach to study alopecia areata</article-title><source>Front Cell Infect Microbiol</source><volume>10</volume><elocation-id>146</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.00146</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poeggeler</surname><given-names>B</given-names></name><name><surname>Bodó</surname><given-names>E</given-names></name><name><surname>Nadrowitz</surname><given-names>R</given-names></name><name><surname>Dunst</surname><given-names>J</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A simple assay for the study of human hair follicle damage induced by ionizing irradiation</article-title><source>Experimental Dermatology</source><volume>19</volume><elocation-id>e306-9</elocation-id><pub-id pub-id-type="doi">10.1111/j.1600-0625.2009.01009.x</pub-id><pub-id pub-id-type="pmid">19925637</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pratt</surname><given-names>CH</given-names></name><name><surname>King</surname><given-names>LE</given-names></name><name><surname>Messenger</surname><given-names>AG</given-names></name><name><surname>Christiano</surname><given-names>AM</given-names></name><name><surname>Sundberg</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Alopecia areata</article-title><source>Nature Reviews. Disease Primers</source><volume>3</volume><elocation-id>17011</elocation-id><pub-id pub-id-type="doi">10.1038/nrdp.2017.11</pub-id><pub-id pub-id-type="pmid">28300084</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>VH</given-names></name><name><surname>Menefee</surname><given-names>E</given-names></name><name><surname>Strauss</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment</article-title><source>Journal of the American Academy of Dermatology</source><volume>41</volume><fpage>717</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1016/s0190-9622(99)70006-x</pub-id><pub-id pub-id-type="pmid">10534633</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purba</surname><given-names>TS</given-names></name><name><surname>Brunken</surname><given-names>L</given-names></name><name><surname>Hawkshaw</surname><given-names>NJ</given-names></name><name><surname>Peake</surname><given-names>M</given-names></name><name><surname>Hardman</surname><given-names>J</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A primer for studying cell cycle dynamics of the human hair follicle</article-title><source>Experimental Dermatology</source><volume>25</volume><fpage>663</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1111/exd.13046</pub-id><pub-id pub-id-type="pmid">27094702</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintino-de-Carvalho</surname><given-names>IL</given-names></name><name><surname>Gonçalves-Pereira</surname><given-names>MH</given-names></name><name><surname>Faria Ramos</surname><given-names>M</given-names></name><name><surname>de Aguiar Milhim</surname><given-names>BHG</given-names></name><name><surname>Da Costa</surname><given-names>ÚL</given-names></name><name><surname>Santos</surname><given-names>ÉG</given-names></name><name><surname>Nogueira</surname><given-names>ML</given-names></name><name><surname>Da Costa Santiago</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Type 1 innate lymphoid cell and natural killer cells are sources of interferon-γ and other inflammatory cytokines associated with distinct clinical presentation in early dengue infection</article-title><source>The Journal of Infectious Diseases</source><volume>225</volume><fpage>84</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab312</pub-id><pub-id pub-id-type="pmid">34125227</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Resende</surname><given-names>M</given-names></name><name><surname>Cardoso</surname><given-names>MS</given-names></name><name><surname>Ribeiro</surname><given-names>AR</given-names></name><name><surname>Flórido</surname><given-names>M</given-names></name><name><surname>Borges</surname><given-names>M</given-names></name><name><surname>Castro</surname><given-names>AG</given-names></name><name><surname>Alves</surname><given-names>NL</given-names></name><name><surname>Cooper</surname><given-names>AM</given-names></name><name><surname>Appelberg</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Innate IFN-γ-producing cells developing in the absence of IL-2 receptor common γ-chain</article-title><source>Journal of Immunology</source><volume>199</volume><fpage>1429</fpage><lpage>1439</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601701</pub-id><pub-id pub-id-type="pmid">28687660</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>NR</given-names></name><name><surname>Bona</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Defining criteria for autoimmune diseases (witebsky’s postulates revisited)</article-title><source>Immunology Today</source><volume>14</volume><fpage>426</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/0167-5699(93)90244-F</pub-id><pub-id pub-id-type="pmid">8216719</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sagebiel</surname><given-names>AF</given-names></name><name><surname>Steinert</surname><given-names>F</given-names></name><name><surname>Lunemann</surname><given-names>S</given-names></name><name><surname>Körner</surname><given-names>C</given-names></name><name><surname>Schreurs</surname><given-names>R</given-names></name><name><surname>Altfeld</surname><given-names>M</given-names></name><name><surname>Perez</surname><given-names>D</given-names></name><name><surname>Reinshagen</surname><given-names>K</given-names></name><name><surname>Bunders</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tissue-resident eomes+ NK cells are the major innate lymphoid cell population in human infant intestine</article-title><source>Nat Commun</source><volume>10</volume><elocation-id>975</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-08267-7</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salimi</surname><given-names>M</given-names></name><name><surname>Ogg</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Innate lymphoid cells and the skin</article-title><source>BMC Dermatology</source><volume>14</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.1186/1471-5945-14-18</pub-id><pub-id pub-id-type="pmid">25427661</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seillet</surname><given-names>C</given-names></name><name><surname>Brossay</surname><given-names>L</given-names></name><name><surname>Vivier</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Natural killers or ilc1s? that is the question</article-title><source>Current Opinion in Immunology</source><volume>68</volume><fpage>48</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2020.08.009</pub-id><pub-id pub-id-type="pmid">33069142</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>JP</given-names></name><name><surname>Vrba</surname><given-names>SM</given-names></name><name><surname>Reynoso</surname><given-names>GV</given-names></name><name><surname>Wynne-Jones</surname><given-names>E</given-names></name><name><surname>Kamenyeva</surname><given-names>O</given-names></name><name><surname>Malo</surname><given-names>CS</given-names></name><name><surname>Cherry</surname><given-names>CR</given-names></name><name><surname>McManus</surname><given-names>DT</given-names></name><name><surname>Hickman</surname><given-names>HD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Group 1 innate lymphoid-cell-derived interferon-γ maintains anti-viral vigilance in the mucosal epithelium</article-title><source>Immunity</source><volume>54</volume><fpage>276</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.12.004</pub-id><pub-id pub-id-type="pmid">33434494</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>JS</given-names></name><name><surname>Kearley</surname><given-names>J</given-names></name><name><surname>Copenhaver</surname><given-names>AM</given-names></name><name><surname>Sanden</surname><given-names>C</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Pritchard</surname><given-names>GH</given-names></name><name><surname>Berlin</surname><given-names>AA</given-names></name><name><surname>Hunter</surname><given-names>CA</given-names></name><name><surname>Bowler</surname><given-names>R</given-names></name><name><surname>Erjefalt</surname><given-names>JS</given-names></name><name><surname>Kolbeck</surname><given-names>R</given-names></name><name><surname>Humbles</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs</article-title><source>Nature Immunology</source><volume>17</volume><fpage>626</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1038/ni.3443</pub-id><pub-id pub-id-type="pmid">27111143</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simoni</surname><given-names>Y</given-names></name><name><surname>Newell</surname><given-names>EW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Toward meaningful definitions of innate-lymphoid-cell subsets</article-title><source>Immunity</source><volume>46</volume><fpage>760</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.04.026</pub-id><pub-id pub-id-type="pmid">28514678</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spits</surname><given-names>H</given-names></name><name><surname>Bernink</surname><given-names>JH</given-names></name><name><surname>Lanier</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>NK cells and type 1 innate lymphoid cells: partners in host defense</article-title><source>Nature Immunology</source><volume>17</volume><fpage>758</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1038/ni.3482</pub-id><pub-id pub-id-type="pmid">27328005</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suchonwanit</surname><given-names>P</given-names></name><name><surname>Iamsumang</surname><given-names>W</given-names></name><name><surname>Rojhirunsakool</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: A randomized, double-blind, controlled study</article-title><source>American Journal of Clinical Dermatology</source><volume>20</volume><fpage>147</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1007/s40257-018-0387-0</pub-id><pub-id pub-id-type="pmid">30206824</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taggenbrock</surname><given-names>R</given-names></name><name><surname>van Gisbergen</surname><given-names>KPJM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>ILC1: development, maturation, and transcriptional regulation</article-title><source>European Journal of Immunology</source><volume>53</volume><elocation-id>e2149435</elocation-id><pub-id pub-id-type="doi">10.1002/eji.202149435</pub-id><pub-id pub-id-type="pmid">36408791</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talayero</surname><given-names>P</given-names></name><name><surname>Mancebo</surname><given-names>E</given-names></name><name><surname>Calvo-Pulido</surname><given-names>J</given-names></name><name><surname>Rodríguez-Muñoz</surname><given-names>S</given-names></name><name><surname>Bernardo</surname><given-names>I</given-names></name><name><surname>Laguna-Goya</surname><given-names>R</given-names></name><name><surname>Cano-Romero</surname><given-names>FL</given-names></name><name><surname>García-Sesma</surname><given-names>A</given-names></name><name><surname>Loinaz</surname><given-names>C</given-names></name><name><surname>Jiménez</surname><given-names>C</given-names></name><name><surname>Justo</surname><given-names>I</given-names></name><name><surname>Paz-Artal</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Innate lymphoid cells groups 1 and 3 in the epithelial compartment of functional human intestinal allografts</article-title><source>American Journal of Transplantation</source><volume>16</volume><fpage>72</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1111/ajt.13435</pub-id><pub-id pub-id-type="pmid">26317573</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>SA</given-names></name><name><surname>Iqbal</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Glover</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title><italic>STAT3</italic> genotypic variant <italic>rs744166</italic> and increased tyrosine phosphorylation of STAT3 in IL-23 responsive innate lymphoid cells during pathogenesis of crohn’s disease</article-title><source>Journal of Immunology Research</source><volume>2019</volume><elocation-id>9406146</elocation-id><pub-id pub-id-type="doi">10.1155/2019/9406146</pub-id><pub-id pub-id-type="pmid">31321245</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teunissen</surname><given-names>MBM</given-names></name><name><surname>Munneke</surname><given-names>JM</given-names></name><name><surname>Bernink</surname><given-names>JH</given-names></name><name><surname>Spuls</surname><given-names>PI</given-names></name><name><surname>Res</surname><given-names>PCM</given-names></name><name><surname>Te Velde</surname><given-names>A</given-names></name><name><surname>Cheuk</surname><given-names>S</given-names></name><name><surname>Brouwer</surname><given-names>MWD</given-names></name><name><surname>Menting</surname><given-names>SP</given-names></name><name><surname>Eidsmo</surname><given-names>L</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name><name><surname>Hazenberg</surname><given-names>MD</given-names></name><name><surname>Mjösberg</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR(+) ILC3 in lesional skin and blood of psoriasis patients</article-title><source>The Journal of Investigative Dermatology</source><volume>134</volume><fpage>2351</fpage><lpage>2360</lpage><pub-id pub-id-type="doi">10.1038/jid.2014.146</pub-id><pub-id pub-id-type="pmid">24658504</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomaszewska</surname><given-names>K</given-names></name><name><surname>Kozłowska</surname><given-names>M</given-names></name><name><surname>Kaszuba</surname><given-names>A</given-names></name><name><surname>Lesiak</surname><given-names>A</given-names></name><name><surname>Narbutt</surname><given-names>J</given-names></name><name><surname>Zalewska-Janowska</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Increased serum levels of IFN-γ, IL-1β, and IL-6 in patients with alopecia areata and nonsegmental vitiligo</article-title><source>Oxid Med Cell Longev</source><volume>2020</volume><elocation-id>5693572</elocation-id><pub-id pub-id-type="doi">10.1155/2020/5693572</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tulic</surname><given-names>MK</given-names></name><name><surname>Cavazza</surname><given-names>E</given-names></name><name><surname>Cheli</surname><given-names>Y</given-names></name><name><surname>Jacquel</surname><given-names>A</given-names></name><name><surname>Luci</surname><given-names>C</given-names></name><name><surname>Cardot-Leccia</surname><given-names>N</given-names></name><name><surname>Hadhiri-Bzioueche</surname><given-names>H</given-names></name><name><surname>Abbe</surname><given-names>P</given-names></name><name><surname>Gesson</surname><given-names>M</given-names></name><name><surname>Sormani</surname><given-names>L</given-names></name><name><surname>Regazzetti</surname><given-names>C</given-names></name><name><surname>Beranger</surname><given-names>GE</given-names></name><name><surname>Lereverend</surname><given-names>C</given-names></name><name><surname>Pons</surname><given-names>C</given-names></name><name><surname>Khemis</surname><given-names>A</given-names></name><name><surname>Ballotti</surname><given-names>R</given-names></name><name><surname>Bertolotto</surname><given-names>C</given-names></name><name><surname>Rocchi</surname><given-names>S</given-names></name><name><surname>Passeron</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo</article-title><source>Nat Commun</source><volume>10</volume><elocation-id>2178</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09963-8</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Gherardini</surname><given-names>J</given-names></name><name><surname>Schulte-Mecklenbeck</surname><given-names>A</given-names></name><name><surname>Alam</surname><given-names>M</given-names></name><name><surname>Chéret</surname><given-names>J</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Kanekura</surname><given-names>T</given-names></name><name><surname>Gross</surname><given-names>CC</given-names></name><name><surname>Arakawa</surname><given-names>A</given-names></name><name><surname>Gilhar</surname><given-names>A</given-names></name><name><surname>Bertolini</surname><given-names>M</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pro-inflammatory Vδ1<sup>+</sup>t-cells infiltrates are present in and around the hair bulbs of non-lesional and lesional alopecia areata hair follicles</article-title><source>Journal of Dermatological Science</source><volume>100</volume><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2020.09.001</pub-id><pub-id pub-id-type="pmid">33039243</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Gherardini</surname><given-names>J</given-names></name><name><surname>Pappelbaum</surname><given-names>K</given-names></name><name><surname>Chéret</surname><given-names>J</given-names></name><name><surname>Schulte-Mecklenbeck</surname><given-names>A</given-names></name><name><surname>Gross</surname><given-names>CC</given-names></name><name><surname>Strbo</surname><given-names>N</given-names></name><name><surname>Gilhar</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Funk</surname><given-names>W</given-names></name><name><surname>Kanekura</surname><given-names>T</given-names></name><name><surname>Almeida</surname><given-names>L</given-names></name><name><surname>Bertolini</surname><given-names>M</given-names></name><name><surname>Paus</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Resident human dermal γδT-cells operate as stress-sentinels: lessons from the hair follicle</article-title><source>Journal of Autoimmunity</source><volume>124</volume><elocation-id>102711</elocation-id><pub-id pub-id-type="doi">10.1016/j.jaut.2021.102711</pub-id><pub-id pub-id-type="pmid">34479087</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullrich</surname><given-names>KAM</given-names></name><name><surname>Schulze</surname><given-names>LL</given-names></name><name><surname>Paap</surname><given-names>EM</given-names></name><name><surname>Müller</surname><given-names>TM</given-names></name><name><surname>Neurath</surname><given-names>MF</given-names></name><name><surname>Zundler</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Immunology of IL-12: an update on functional activities and implications for disease</article-title><source>EXCLI Journal</source><volume>19</volume><fpage>1563</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.17179/excli2020-3104</pub-id><pub-id pub-id-type="pmid">33408595</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>R</given-names></name><name><surname>Er</surname><given-names>JZ</given-names></name><name><surname>Pu</surname><given-names>RW</given-names></name><name><surname>Sheik Mohamed</surname><given-names>J</given-names></name><name><surname>Soo</surname><given-names>RA</given-names></name><name><surname>Muthiah</surname><given-names>HM</given-names></name><name><surname>Tam</surname><given-names>JKC</given-names></name><name><surname>Ding</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Eomes expression defines group 1 innate lymphoid cells during metastasis in human and mouse</article-title><source>Front Immunol</source><volume>11</volume><elocation-id>1190</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01190</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vienne</surname><given-names>M</given-names></name><name><surname>Etiennot</surname><given-names>M</given-names></name><name><surname>Escalière</surname><given-names>B</given-names></name><name><surname>Galluso</surname><given-names>J</given-names></name><name><surname>Spinelli</surname><given-names>L</given-names></name><name><surname>Guia</surname><given-names>S</given-names></name><name><surname>Fenis</surname><given-names>A</given-names></name><name><surname>Vivier</surname><given-names>E</given-names></name><name><surname>Kerdiles</surname><given-names>YM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Type 1 innate lymphoid cells limit the antitumoral immune response</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>768989</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.768989</pub-id><pub-id pub-id-type="pmid">34868026</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivier</surname><given-names>E</given-names></name><name><surname>Artis</surname><given-names>D</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Diefenbach</surname><given-names>A</given-names></name><name><surname>Di Santo</surname><given-names>JP</given-names></name><name><surname>Eberl</surname><given-names>G</given-names></name><name><surname>Koyasu</surname><given-names>S</given-names></name><name><surname>Locksley</surname><given-names>RM</given-names></name><name><surname>McKenzie</surname><given-names>ANJ</given-names></name><name><surname>Mebius</surname><given-names>RE</given-names></name><name><surname>Powrie</surname><given-names>F</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Innate lymphoid cells: 10 years on</article-title><source>Cell</source><volume>174</volume><fpage>1054</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.07.017</pub-id><pub-id pub-id-type="pmid">30142344</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivier</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The discovery of innate lymphoid cells</article-title><source>Nature Reviews. Immunology</source><volume>21</volume><elocation-id>616</elocation-id><pub-id pub-id-type="doi">10.1038/s41577-021-00595-y</pub-id><pub-id pub-id-type="pmid">34580448</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>EHC</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Breitkopf</surname><given-names>T</given-names></name><name><surname>Akhoundsadegh</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>FT</given-names></name><name><surname>Leung</surname><given-names>G</given-names></name><name><surname>Dutz</surname><given-names>JP</given-names></name><name><surname>Shapiro</surname><given-names>J</given-names></name><name><surname>McElwee</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification of autoantigen epitopes in alopecia areata</article-title><source>The Journal of Investigative Dermatology</source><volume>136</volume><fpage>1617</fpage><lpage>1626</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2016.04.004</pub-id><pub-id pub-id-type="pmid">27094591</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Type 1 innate lymphoid cell aggravation of atherosclerosis is mediated through TLR4</article-title><source>Scandinavian Journal of Immunology</source><volume>87</volume><elocation-id>e12661</elocation-id><pub-id pub-id-type="doi">10.1111/sji.12661</pub-id><pub-id pub-id-type="pmid">29570822</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>L</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Jabbari</surname><given-names>A</given-names></name><name><surname>Cerise</surname><given-names>JE</given-names></name><name><surname>Higgins</surname><given-names>CA</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>de Jong</surname><given-names>A</given-names></name><name><surname>Harel</surname><given-names>S</given-names></name><name><surname>DeStefano</surname><given-names>GM</given-names></name><name><surname>Rothman</surname><given-names>L</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Petukhova</surname><given-names>L</given-names></name><name><surname>Mackay-Wiggan</surname><given-names>J</given-names></name><name><surname>Christiano</surname><given-names>AM</given-names></name><name><surname>Clynes</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition</article-title><source>Nature Medicine</source><volume>20</volume><fpage>1043</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1038/nm.3645</pub-id><pub-id pub-id-type="pmid">25129481</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Type 1 innate lymphoid cells contribute to the pathogenesis of chronic hepatitis B</article-title><source>Innate Immunity</source><volume>21</volume><fpage>665</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1177/1753425915586074</pub-id><pub-id pub-id-type="pmid">25977358</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Marotel</surname><given-names>M</given-names></name><name><surname>Fauteux-Daniel</surname><given-names>S</given-names></name><name><surname>Mathieu</surname><given-names>AL</given-names></name><name><surname>Viel</surname><given-names>S</given-names></name><name><surname>Marçais</surname><given-names>A</given-names></name><name><surname>Walzer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>T-bet and eomes govern differentiation and function of mouse and human NK cells and ILC1</article-title><source>European Journal of Immunology</source><volume>48</volume><fpage>738</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1002/eji.201747299</pub-id><pub-id pub-id-type="pmid">29424438</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Nk cells help induce anti-hepatitis B virus CD8+ T cell immunity in mice</article-title><source>Journal of Immunology</source><volume>196</volume><fpage>4122</fpage><lpage>4131</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1500846</pub-id><pub-id pub-id-type="pmid">27183639</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The pathogenic role of innate lymphoid cells in autoimmune-related and inflammatory skin diseases</article-title><source>Cellular &amp; Molecular Immunology</source><volume>17</volume><fpage>335</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-0399-6</pub-id><pub-id pub-id-type="pmid">32203190</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zook</surname><given-names>EC</given-names></name><name><surname>Kee</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Development of innate lymphoid cells</article-title><source>Nature Immunology</source><volume>17</volume><fpage>775</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1038/ni.3481</pub-id><pub-id pub-id-type="pmid">27328007</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80768.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Horsley</surname><given-names>Valerie</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>This manuscript provides fundamental data that implicate ILC1-like cells in alopeia areata. The data are solid in the use of cultured human hair follicles co-cultured with ILC-1-like cells and demonstration that alopecia phenotypes emerge. The authors also provide compelling evidence that injection of ILC1-like cells induces alopecia in a mouse model grafted with human hair follicle-containing skin. This work will be of interest to immunologists, skin biologists, and scientists interested in autoimmune disorders.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80768.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Horsley</surname><given-names>Valerie</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Sinclair</surname><given-names>Rodney</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043sz6670</institution-id><institution>Sinclair Dermatology</institution></institution-wrap><country>Australia</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Involvement of ILC1-like innate lymphocytes in human autoimmunity, lessons from alopecia areata&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Betty Diamond as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Rodney Sinclair (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. Clarify the color differences between white and yellow in their triple staining of immunofluorescent photo data in Figure 1A-C, either in the figure legend or the Materials and methods section.</p><p>2. Please provide the data for the effect of non-autologous ILC1lc on AA patients ex vivo with co-culture or in vivo with injection are available as references.</p><p>3) The reviewers should discuss whether 5% Minoxidil is required for hair regrowth in this system given that the efficacy of Minoxidil has not been convincing to all subjects even for the human species in the previous clinical studies.</p><p>4. The authors should update their phenotyping data and subsequent sorting strategy to provide more definitive evidence for the involvement in an ILC1 or tissue-resident NK cell population in AA.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The authors provide useful data implicating a subset of type 1 innate lymphocytes in the pathogenesis of human AA. Strengths include mini organ models and humanized mouse models, and weaknesses involve inadequate characterization of ILC1-like populations to confidently conclude that the observed cell type is not of the NK cell lineage. This weakness restricts the impact of the manuscript given the author's previous findings on NK cells and AA pathogenesis. The authors need to provide definitive evidence that the reported &quot;ILC1-like&quot; cells are not an activation state of NK cells to support the conclusions and novelty claims written in the manuscript.</p><p>– Although previous literature has associated CD49a expression with the ILC1 lineage in mice and humans, CD49a is upregulated on activated NK cells (EOMES+), and EOMEShi TBETlo liver-resident NK cells have been described in humans. Recent single-cell RNAseq studies in mice and human tissues support the conclusion that EOMES+ ILCs represent the NK cell lineage. These findings are directly at odds with the author's main conclusions and are not discussed in the manuscript. The author's phenotype more closely resembles a tissue-resident or activated NK cell rather than an ILC1. Without further evidence of ILC1 lineage-defining markers (CD200R, granzyme C, etc.) or single cell RNAseq validation, the presented phenotyping data is inadequate to support the authors' claims. If evidence is presented to suggest that &quot;ILC1-like cells&quot; closely resemble a tissue-resident NK cell, then there would be no loss of impact on the manuscript.</p><p>– It is not clear from Figure S5 whether the authors can conclude that only ILC1-like cells were sorted into this fraction Lin-CD127+NKp44+ cells could still contain ILC3s capable of producing IFNγ. The authors need to formally exclude the possibility that contamination from ILC3s during sorting can contribute to their observed results. This is a caveat of previous studies that the author cites as well.</p><p>– ILC1 phenotyping in humans is controversial, however, the addition of more surface markers and single-cell RNAseq data will significantly improve the interpretation of the study. CXCR6, CD200R (ILC1) and Perforin, NKp80, CD16 (NK cells) staining can all be used to further support the author's conclusions. Lack of IRF8 and Eomes expression would signify strong evidence that ILC-like cells are not of the NK cell lineage. ILC1 gene signatures can be sourced from previously published studies in mice and humans to help with unbiased analysis of cell lineages.</p><p>– It is suggested that the authors update their phenotyping data and subsequent sorting strategy to provide more definitive evidence for the involvement in an ILC1 or tissue-resident NK cell population in AA.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Recent major breakthroughs in our understanding of the pathogenesis of AA have led to highly effective FDA-approved treatments for this potentially disfiguring disease. As these treatments require maintenance dosing to prevent relapse, further studies are required to identify the initiating events for hair follicle auto-immunity leading to AA. Natural killer cells expressing cell surface NKG2D transmembrane proteins are already implicated in the pathogenesis of AA. The authors identified and isolated a novel population of NKG2D+ cells – the ILC1-like lymphocytes – that are strategically localized around hair bulbs, that respond to hair follicle distress signals, that play a very early role in the pathogenesis of AA through robust secretion of IFN-γ, leading to loss of hair follicle immune privilege and also a later ole in AA pathogenesis through induction of hair fibre dystrophy and induction of catagen. in vivo studies using mouse xenograft models confirmed that ILCS-a-like cells can induce the AA hair loss phenotype.</p><p>This manuscript makes a very important contribution to our understanding of the molecular biology of AA and suggests novel therapeutic targets for future investigation.</p><p>A great body of work summarized in a single paper.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>This manuscript intensively studied the direct involvement of ILC1 cells on the onset of AA., cells which seem to be very difficult, characterized by no existence of a single clear marker, and its relatively few populations in the HF even in the lesion of AA patients. To overcome this situation, the authors nicely used a combination of multiple reliable markers such as Enomes, NKG2D, CD49a, and confirmed its location and existence very convincingly.</p><p>Authors also carefully define the ILC1 cells as &quot;ILC1-like cells (ILC1-lc), which is also a sincere attitude by the authors on scientific accuracy.</p><p>This is excellent work and a comprehensive set of various experiments to confirm the involvement of ILC1-lc on the onset of AA.</p><p>Although ex vivo and in vivo models in this manuscript each still have their limitations, such as no systemic system involved or host species difference, nevertheless, they seem to be highly valued as studies using the best model systems currently conceived for AA disease.</p><p>In the future, it is expected that clinical data indicating the direct involvement of ILC-1 in AA obtained from the results of this study will be accumulated, and the treatment of current AA patients will be further improved by this finding.</p><p>This manuscript is very comprehensive, and all necessary experiments to prove the involvement of ILC1lc for AA disease seem to be performed including both positive and negative controls. It is a very impressive and intensive study for me.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80768.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. Clarify the color differences between white and yellow in their triple staining of immunofluorescent photo data in Figure 1A-C, either in the figure legend or the Materials and methods section.</p></disp-quote><p>Thanks. We have now clarified the color differences between white and yellow in our triple staining of immunofluorescent photo data in Figure 1A-C and Figure 8A-C, as follows:</p><p>“For each panel yellow staining indicates double staining (A-EOMES+, NKG2D+; B- EOMES+,CD49a+ ; C- NKp44+,CD103+).”</p><disp-quote content-type="editor-comment"><p>2. Please provide the data for the effect of non-autologous ILC1lc on AA patients ex vivo with co-culture or in vivo with injection are available as references.</p></disp-quote><p>We respectfully propose that this is a questionable and dispensable request. In this study, only the effect of autologous ILC1lc on healthy scalp skin xenotransplants is clinically relevant in the context of alopecia areata (AA), since heterologous ILC1lc cells might induce an (entirely irrelevant and likely misleading) graft-versus-host scenario. This would cause a pathobiologically completely different, scarring type of folliculitis – which is exactly what one must avoid in AA in vivo models (for detailed discussion: see Gilhar et al. Autoimmun Rev 2016).</p><p>Using allogeneic ILC1lc would also be physiologically and clinically irrelevant, as this constellation almost never occurs in AA (except in the vanishly rare number of cases of AA after an allogeneic bone marrow transplantation). Moreover, the suggested control experiment could also be criticized for being wasteful, as it violates the widely accepted animal experimentation principle to only use the number of animals that is indispensable for answering the relevant research question(s) at hand.</p><p>While we agree that studying this would, nevertheless, be academically interesting, this clearly lies outside of our study scope and would cause major unjustifiable additional costs and loss of time.</p><disp-quote content-type="editor-comment"><p>3) The reviewers should discuss whether 5% Minoxidil is required for hair regrowth in this system given that the efficacy of Minoxidil has not been convincing to all subjects even for the human species in the previous clinical studies.</p></disp-quote><p>Thanks for raising this excellent point. We now explain in the revised Materials and methods section that topical minoxidil application is not required for hair regrowth induction after the initial post-transplantation hair shaft shedding, but only accelerates it, and that this application is discontinued before the ILC1lc injection (Gilhar et al. JID 2013). Since the immune cell infiltrate in AA attacks only hair follicles in anagen (Gilhar et al. NEJM 2012), it is critical that the majority of xenotransplanted HFs are in anagen at the time the immune cells are injected. Topical minoxidil pretreatment increases the likelihood that this is the case (Price, NEJM 1999; Suchonwanit et al. Drug Des Devel Ther 2019).</p><p>Moreover, we have recently demonstrated that 5% minoxidil does indeed significantly stimulate hair regrowth in human androgenetic alopecia scalp skin transplanted onto SCID/beige mice (Gilhar et al. Exp Dermatol 2022). It also deserves mentioning that topical minoxdil reduces the degranulation of – hair growth-modulatory! (Paus et al. Dev Biol 1994) – perifollicular mast cells in the skin of mice, namely under conditions of perceived stress (Arck et al. Exp Dermatol 2003), while excessive degranulation of perifollicular mast cells is an important feature of lesional human AA skin (Bertolini et al. PLoS One 2014). Therefore, this pretreatment likely also helps to reestablish perifollicular mast cell homeostasis after the stress of xenotransplantation.</p><p>These explanations are now given on pages 34 and 35:</p><p>“The topical minoxidil application is not required for hair regrowth induction after the initial post-transplantation hair shaft shedding, but only accelerates it. This application is discontinued before the ILC1lc injection (Gilhar et al., 2013).Since the immune cell infiltrate in AA attacks only hair follicles in anagen (Gilhar et al., 2012), it is critical that the majority of xenotransplant HFs are in anagen at the time the immune cells are injected. Topical minoxidil pretreatment increases the likelihood that this is the case (Price, 1999; Suchonwanit et al., 2019). Moreover, we have recently demonstrated that 5% minoxidil does indeed significantly stimulate hair regrowth in human androgenetic alopecia scalp skin transplanted onto SCID/beige mice (Gilhar et al., 2022). It also deserves mentioning that topical minoxdil reduces the degranulation of – hair growth-modulatory! (Paus et al., 1994) – perifollicular mast cells in the skin of mice, namely under conditions of perceived stress (Arck et al., 2003), while excessive degranulation of perifollicular mast cells is an important feature of lesional human AA skin (Bertolini et al., 2014). Therefore, this pretreatment likely also helps to reestablish perifollicular mast cell homeostasis after the stress of xenotransplantation.”</p><disp-quote content-type="editor-comment"><p>4. The authors should update their phenotyping data and subsequent sorting strategy to provide more definitive evidence for the involvement in an ILC1 or tissue-resident NK cell population in AA.</p></disp-quote><p>Thank you for this important suggestion. In order to provide more definitive evidence for the involvement in an ILC1 or tissue-resident NK cell population in AA, we now have re-analyzed the sorted ILC1lc by FACS analysis, using the additional ILC1lc markers CXCR6, CD200R (Curio et al. Cell Mol Immunol 2022) and the classical NK markers IRF8, perforin, NKp80, and CD16 (Brownlie et al. PNAS 2021; Krämer et al. Cell Rep 2023; Gilhar et al. JID 2013). Granzyme C is expressed by murine and not human NK cells and therefore has not been used in the current study (Susanto et al. Tissue Antigens 2012; Cai et al. J Immunol 2009). This shows more definitive evidence for the involvement of ILC1 cell population in AA. These novel data are now reported in the results (page 10) and in a new Figure 2—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The authors provide useful data implicating a subset of type 1 innate lymphocytes in the pathogenesis of human AA. Strengths include mini organ models and humanized mouse models, and weaknesses involve inadequate characterization of ILC1-like populations to confidently conclude that the observed cell type is not of the NK cell lineage. This weakness restricts the impact of the manuscript given the author's previous findings on NK cells and AA pathogenesis. The authors need to provide definitive evidence that the reported &quot;ILC1-like&quot; cells are not an activation state of NK cells to support the conclusions and novelty claims written in the manuscript.</p></disp-quote><p>We fully agree with this expert reviewer in principle, but must reemphasize how challenging it is to “definitively” distinguish between ILC1 and NK cells (even all experts on this do not seem to be able to fully agree on how to best do so…).</p><p>In fact, how to reliably discriminate between NK cells and ILC1s and unravelling the shared and distinct functions of these cell populations remains an important open quest (Seillet et al. Curr Opin Immunol 2021; Lopes et al. Semin Immunol 2023; Cheng et al. Cell Mol Gastroenterol Hepatol 2023; Taggenbrock et al. Eur J Immunol 2022). Therefore, distinction between NK cells and ILC1s remains provisional – which is exactly why we have cautiously labeled the latter as “ILC1lc”.</p><p>We have now further underscored this in the revised Introduction, pages 5 and 6.</p><p>&quot;In fact, how to reliably discriminate between NK cells and ILC1s and unravelling the shared and distinct functions of these cell populations remains an important open quest (Seillet et al., 2021; Lopes et al., 2023; Cheng et al., 2023; Taggenbrock and van Gisbergen, 2022). For example, Eomes<sup>hi</sup> T-bet<sup>lo</sup> liver-resident NK cells have been described in humans and mice (Park et al., 2019; Harmon et al., 2016), while ILC1s from human tonsil and blood were also found to be Eomes+ (Cella et al., 2019). Therefore, distinction between NK cells and ILC1s remains provisional – which is exactly why we have cautiously labeled the latter as “ILC1lc.&quot;</p><p>In order to provide even more persuasive evidence than before that the reported &quot;ILC1-like&quot; cells (ILC1lc) are not just activated NK cells, and to support the conclusions and novelty claims contained in our study, we have performed additional FACS analyses with multiple established key markers of NK versus ILC1lc (details: see above). These new data clearly support our claims (new Figure 2—figure supplement 1 A-C).</p><disp-quote content-type="editor-comment"><p>– Although previous literature has associated CD49a expression with the ILC1 lineage in mice and humans, CD49a is upregulated on activated NK cells</p></disp-quote><p>Thank you for pointing this out. An upregulation of CD49a on activated human and murine NK cells has indeed been reported (Albini et al. Cancers (Basel) 2021; Zheng et al. J Immunol 2016). To correctly reflect this, we have reworded the corresponding text in the revised Introduction (page 6):</p><p>“However, although integrin α1 (CD49a) is upregulated on activated NK cells (Albini et al., 2021; Zheng et al., 2016), CD49a and integrin α2 (CD49b) are used as two mutually exclusive markers for distinguishing between NK and ILC1 cells, with NK cells being defined as CD49b+CD49a- and ILC1 as CD49b-CD49a+ (Gao et al., 2017; Vienne et al., 2021; Flommersfeld et al., 2021; Krzywinska et al., 2022) In the current study, we have accepted and employed this consensus.&quot;</p><disp-quote content-type="editor-comment"><p>(EOMES+), and EOMEShi TBETlo liver-resident NK cells have been described in humans.</p></disp-quote><p>Thanks again for raising this important point. Indeed, Eomes<sup>hi</sup> T-bet<sup>lo</sup> liver-resident NK cells have been described in humans and mice (Park et al. <italic>eLife</italic> 2019; Harmon et al. Eur J Immunol 2016). However ILC1s from human tonsil and blood were also found to be Eomes+ (Cella et al. Nat Immunol 2019; Mazzurana et al. Cell Res 2021), further indicating the importance to compare the expression levels of additional key NK and ILC1 cell markers on both cell populations (see introduction, pages 5 and 6 and above). This has now been done by the new FACS analysis we have integrated into the R.1 manuscript (new Figure 2—figure supplement 1 A-C and Results section, page 10):</p><p>&quot;This immune phenotype suggests that the immune cells used in our study are best classified as ILC1lc (Nabekura et al., 2021a), and documents that all experiments reported below were indeed performed with autologous ILC1lc rather than with NK cell subpopulations. Indeed, the FACS analysis (Figure 2 – figure supplement 1A,B and C) revealed that ILC1lc demonstrate the ILC1 phenotype (CD200R, CD127, CXCR6) (Lopes et al., 2023; Curio and Belz, 2022) but not of the classical NK cell lineage (IRF8, Perforin, NKp80, CD16) (<xref ref-type="bibr" rid="bib12">Brownlie et al., 2021</xref>; <xref ref-type="bibr" rid="bib70">Krämer et al., 2023</xref>; <xref ref-type="bibr" rid="bib111">Sagebiel et al., 2019</xref>), thus further serving as an evidence that EOMES+ ILCs represent distinct ILC1 lineage-defining markers&quot;</p><disp-quote content-type="editor-comment"><p>Recent single-cell RNAseq studies in mice and human tissues support the conclusion that EOMES+ ILCs represent the NK cell lineage. These findings are directly at odds with the author's main conclusions and are not discussed in the manuscript.</p></disp-quote><p>Once again, the reviewer raises an excellent point. However, the ILC1lc analyzed in our study are highly unlikely to represent the NK cell lineage because our new data demonstrate that ILC1lc are positive for, CD200R, CD127, CXCR6 but negative for IRF8, Perforin, NKp80, CD16 (new Figure 2—figure supplement 1 A-C). We could not use granzyme C as NK marker, since it is expressed only in mice and not in human (Susanto et al. Tissue Antigens 2012; Cai et al. J Immunol 2009).</p><disp-quote content-type="editor-comment"><p>The author's phenotype more closely resembles a tissue-resident or activated NK cell rather than an ILC1. Without further evidence of ILC1 lineage-defining markers (CD200R, granzyme C, etc.) or single cell RNAseq validation, the presented phenotyping data is inadequate to support the authors' claims. If evidence is presented to suggest that &quot;ILC1-like cells&quot; closely resemble a tissue-resident NK cell, then there would be no loss of impact on the manuscript.</p></disp-quote><p>For the reasons delineated above, we respectfully disagree with this expert referee’s verdict. The following additional data and arguments further support our claim that the ILC1lc analyzed here indeed have much more in common ILC1 than NK characteristics:</p><p>1. EOMES expression by ILCs was observed differently dependent on tissue localization (McFarland et al. Immunity 2021).</p><p>2. Recent single-cell RNA-sequencing study reveals that ILC1lc both in blood and tonsil are Eomes positive (Mazzurana et al. Cell Res 2021).</p><p>3. Other study demonstrated that intraepithelial ILC1s from human tonsil were found to be heterogeneous, encompassing Eomes− and Eomes+ subsets (Cella, et al. Nat Immunol 2019).</p><p>Therefore, it is our carefully considered opinion that it would be unreasonable to demand additional data in support of the ILC1-like nature of “our” cells. However, in the revised Discussion, we have now openly acknowledged and cautiously highlighted that “…This claim remains limited by the set of biomarkers that is currently available (and can reasonably be expected to be applied) to “definitively” distinguish between ILC1 and NK lineages, namely in human skin, and that our data may eventually have to be re-evaluated in the context of research progress in this fast-moving field.” (page 19).</p><p>This is now stated clearly in the revised manuscript as follows in the M and M (page 32):</p><p>“Cells were incubated for 25 minutes at room temperature in the dark. All tubes were washed once with 1 ml staining buffer, then Fixation/Permeabilization solution (250 μl) was added and cells were incubated for 20 minutes at 4<sup>o</sup>C. Cell permeability was performed using 1xBD Perm/Wash buffer, intra-cellular antibody mixtures 50 μl/Brilliant Violet 605TM anti-T-bet (BLG 644817), Eomes-conjugated-PerCP-eFluor 710 (Dan11mag), IRF8 (sc-365042), Perforin (BLG-308119) and INF-γ-conjugated- PE/VIO-770 (Miltenyi Biotec 130-109-313), CD49a-APC-Vio770 (Miltenyi Biotec 130-101-324) ,FITC anti-human CD49b (BLG 359305), APC anti-human NKp80 (BLG 346707), BV421 anti-human CXCR6 (BLG 356013) and APC/Fire 810 anti-human CD16 (BLG 302073) and BV421 anti-human RORγt were added and incubated for 30 minutes at room temperature in the dark, cells were then washed twice with 1xBD Perm/Wash buffer (BD Cytofix/CytopermTM Fixation/Permeabilization Kit).</p><p>All cell samples were detected by FACS Calibur Flow Cytometer (Benton Dickinson) using Cell Quest software, and the acquired data were further analyzed using FlowJo 5.7.2 (Tree Star).”</p><p>In the abstract</p><p>“This provides the first evidence that ILC1lc, which are positive for the ILC1 phenotype and negative for the classical NK markers, suffice to induce AA in previously healthy human HFs ex vivo and in vivo, and further questions the conventional wisdom that AA is always an autoantigen-dependent, CD8<sup>+</sup> T cell-driven autoimmune disease.&quot;</p><p>Results (see above and page 10).</p><p>Discussion (pages 18 and 19):</p><p>&quot;The current study is the first to phenotypically and functionally explore the role of Eomes+ ILC1lc in human AA in vivo and ex vivo. Eomes+ ILCs may represent the NK cell lineage and therefore the ILC1 phenotype in our study, more closely resembles a tissue-resident or activated NK cell rather than an ILC1, based on recent single-cell RNAseq studies in mice and human tissues (Lopes et al., 2023). However, Eomes expression by ILCs was observed differently depending on the tissue localization (McFarland et al., 2021). For example, recent single-cell RNA-sequencing study reveals that ILC1lc both in blood and tonsil are Eomes positive (Mazzurana et al., 2021). Other study demonstrated that intraepithelial ILC1s from human tonsil were found to be heterogeneous, encompassing Eomes− and Eomes+ subsets (Cella et al., 2019). It is indeed very important to obtain greater clarity on how ILC1lc and NKs differ from each other, namely in the context of human AA. Our new data, which demonstrate that ILC1lc are positive for CD49a, CD200R, CD127, CXCR6 (Lopes et al., 2023) but negative for IRF8, Perforin, NKp80, CD16 (Sagebiel et al., 2019) (Figure 2 – figure supplement 1A,B and C), strongly support that ILC1lc and NK cells have distinct lineages. This claim remains limited by the set of biomarkers that is currently available (and can reasonably be expected to be applied) to “definitively” distinguish between ILC1 and NK lineages, namely in human skin, and that our data may eventually have to be re-evaluated in the context of research progress in this fast-moving field. It would be desirable to further complement these results in future studies with unbiased scRNAseq data, which can then be compared with published human ILC1 and NK cell gene signatures so as to gain deeper insights into the – still controversial and unclear – transcriptional similarities and differences between ILC1lc and NK cells and their lineage relationship to each other.&quot;</p><disp-quote content-type="editor-comment"><p>– It is not clear from Figure S5 whether the authors can conclude that only ILC1-like cells were sorted into this fraction Lin-CD127+NKp44+ cells could still contain ILC3s capable of producing IFNγ. The authors need to formally exclude the possibility that contamination from ILC3s during sorting can contribute to their observed results. This is a caveat of previous studies that the author cites as well.</p></disp-quote><p>We fully agree with the reviewer's comment and therefore have now formally excluded the possibility that contamination from ILC3s during sorting may have contributed to our results by generating a new set of FACS data on sorted ILC1lc. Given that ILC1 cells are RORγt negative while ILC3 cells are RORγt positive (Peng et al. PNAS 2022; Fiancette et al. Nat Immunol 2021), these novel data render the contamination hypothesis highly unlikely (see Figure 2—figure supplement 1 D). This is now stated clearly in the revised Materials and methods and Results sections.</p><p>Materials and methods (page 32)</p><p>“Cells were incubated for 25 minutes at room temperature in the dark. All tubes were washed once with 1 ml staining buffer, then Fixation/Permeabilization solution (250 μl) was added and cells were incubated for 20 minutes at 4<sup>o</sup>C. Cell permeability was performed using 1xBD Perm/Wash buffer, intra-cellular antibody mixtures (50 μl/Brilliant Violet 605TM anti-T-bet (BLG 644817)), Eomes-conjugated-PerCP-eFluor 710 (Dan11mag), IRF8 (sc-365042), Perforin (BLG-308119) and INF-γ-conjugated- PE/VIO-770 (Miltenyi Biotec 130-109-313), CD49a-APC-Vio770 (Miltenyi Biotec 130-101-324) ,FITC anti-human CD49b (BLG 359305), APC anti-human NKp80 (BLG 346707), BV421 anti-human CXCR6 (BLG 356013) and APC/Fire 810 anti-human CD16 (BLG 302073) and BV421 anti-human RORγt were added and incubated for 30 minutes at room temperature in the dark, cells were then washed twice with 1xBD Perm/Wash buffer (BD Cytofix/CytopermTM Fixation/Permeabilization Kit)..</p><p>All cell samples were detected by FACS Calibur Flow Cytometer (Benton Dickinson) using Cell Quest software, and the acquired data were further analyzed using FlowJo 5.7.2 (Tree Star).”</p><p>Result section (page 11):</p><p>“In order to exclude the possibility that contamination from ILC3s during sorting the ILC1lc and thus contributing to the observed results, we generated a new set of FACS data on sorted ILC1lc. Given that ILC1 cells are RORγt negative while ILC3 cells are RORγt positive (Peng et al., 2022; Fiancette et al., 2021), the data clearly demonstrate that the contamination hypothesis is highly unlikely (Figure 2 – figure supplement 1D).”</p><disp-quote content-type="editor-comment"><p>– ILC1 phenotyping in humans is controversial, however, the addition of more surface markers and single-cell RNAseq data will significantly improve the interpretation of the study. CXCR6, CD200R (ILC1) and Perforin, NKp80, CD16 (NK cells) staining can all be used to further support the author's conclusions. Lack of IRF8 and Eomes expression would signify strong evidence that ILC-like cells are not of the NK cell lineage. ILC1 gene signatures can be sourced from previously published studies in mice and humans to help with unbiased analysis of cell lineages.</p></disp-quote><p>Again, we fully agree with the reviewer's comment and have therefore engaged in more rigorous ILC1 phenotyping, including by investigating whether “our” ILC1lc lack IRF8 and Eomes surface marker expression. Our new data show that this is indeed the case (see new Figure 2—figure supplement 1 A-C), thus further supporting our previous claim that ILC-like cells are not of the NK cell lineage. This is now stated clearly in the revised Abstract and Results (page 10) and is explained in the revised Discussion (pages 18 and 19).</p><p>We also accept that single-cell RNAseq analysis and comparison with published data may help with unbiased analysis of cell lineages. However, this time-consuming and costly analysis far exceeds our available budget for this study and, in view of new, more relevant data (new Figure 2—figure supplement 1 A-C), also appears dispensable to support our claims. Moreover the costs for the ILC1 antibodies are extremely high and we simply do not have the funds for this, and that we therefore had to go for the FACS approach.</p><p>Yet, we now explicitly acknowledge in the revised Discussion (Page 19) that:</p><p>“It would be desirable to further complement these results in future studies with unbiased scRNAseq data, which can then be compared with published human ILC1 and NK cell gene signatures so as to gain deeper insights into the – still controversial and unclear – transcriptional similarities and differences between ILC1lc and NK cells and their lineage relationship to each other.”</p><disp-quote content-type="editor-comment"><p>– It is suggested that the authors update their phenotyping data and subsequent sorting strategy to provide more definitive evidence for the involvement in an ILC1 or tissue-resident NK cell population in AA.</p></disp-quote><p>Thanks again so much for these very helpful, important, and constructive suggestions!</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Recent major breakthroughs in our understanding of the pathogenesis of AA have led to highly effective FDA-approved treatments for this potentially disfiguring disease. As these treatments require maintenance dosing to prevent relapse, further studies are required to identify the initiating events for hair follicle auto-immunity leading to AA. Natural killer cells expressing cell surface NKG2D transmembrane proteins are already implicated in the pathogenesis of AA. The authors identified and isolated a novel population of NKG2D+ cells – the ILC1-like lymphocytes – that are strategically localized around hair bulbs, that respond to hair follicle distress signals, that play a very early role in the pathogenesis of AA through robust secretion of IFN-γ, leading to loss of hair follicle immune privilege and also a later ole in AA pathogenesis through induction of hair fibre dystrophy and induction of catagen. in vivo studies using mouse xenograft models confirmed that ILCS-a-like cells can induce the AA hair loss phenotype.</p><p>This manuscript makes a very important contribution to our understanding of the molecular biology of AA and suggests novel therapeutic targets for future investigation.</p><p>A great body of work summarized in a single paper.</p></disp-quote><p>Thank you kindly for this most encouraging verdict.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>This manuscript intensively studied the direct involvement of ILC1 cells on the onset of AA., cells which seem to be very difficult, characterized by no existence of a single clear marker, and its relatively few populations in the HF even in the lesion of AA patients. To overcome this situation, the authors nicely used a combination of multiple reliable markers such as Enomes, NKG2D, CD49a, and confirmed its location and existence very convincingly.</p><p>Authors also carefully define the ILC1 cells as &quot;ILC1-like cells (ILC1-lc), which is also a sincere attitude by the authors on scientific accuracy.</p><p>This is excellent work and a comprehensive set of various experiments to confirm the involvement of ILC1-lc on the onset of AA.</p></disp-quote><p>We are most grateful for this assessment.</p></body></sub-article></article>